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1.0 SUMMARY OF THE STUDY 
The primary aims of this Phase III study are to determine whether adding capecitabine or 
gemcitabine to docetaxel followed by AC will increase the pathologic complete response (pCR) 
rates in patients with palpable and operable HER2-negative breast cancer and to determine 
whether the addition of bevacizumab to three docetaxel-based regimens followed by AC will 
increase pCR rates.  Secondary aims include determination of whether pCR in the breast and 
axillary nodes, clinical overall response rates (cOR), and clinical complete response rates (cCR) 
can be increased by the additional therapies summarized above.  Other secondary aims include 
determination of whether the addition of bevacizumab to the chemotherapy regimens will 
improve disease-free survival and/or increase surgical complication rates, toxicity, and adverse 
effects on cardiac function. 
Patients will initially receive one of the following docetaxel-based regimens: 
 docetaxel (100 mg/m2) with or without bevacizumab 15 mg/kg every 3 weeks for 4 cycles 
 docetaxel (75 mg/m2 Day 1) + capecitabine (825 mg/m2 po BID Days 1-14) with or without 
bevacizumab 15 mg/kg every 3 weeks for 4 cycles 
 docetaxel (75 mg/m2 Day 1) + gemcitabine (1000 mg/m2 IV Days 1 and 8) with or without 
bevacizumab 15 mg/kg every 3 weeks for 4 cycles 
The docetaxel-based regimens will be followed by doxorubicin 60 mg/m2 and cyclophosphamide 
600 mg/m2 (AC) every 3 weeks for 4 cycles with or without bevacizumab 15 mg/kg given only 
with the initial 2 cycles of AC.  Treatment groups randomized to receive bevacizumab will 
resume bevacizumab postoperatively at 15 mg/kg every 3 weeks for an additional 10 doses. 
Following completion of neoadjuvant therapy, patients will undergo lumpectomy or mastectomy.  
Post-neoadjuvant chemotherapy axillary staging will be required, but the choice of the procedure 
will be at the physician's discretion.  Postoperative radiation therapy will be given at the 
physician's discretion except for prohibiting the use of partial breast irradiation techniques 
utilizing brachytherapy.  The choice of hormonal therapy for patients with hormone receptor-
positive tumors will also be at the physician’s discretion. 
Pathology specimens will be collected and used to identify gene expression profiles that can 
predict pCR and to test a chemoresponse assay as a predictor of pCR.  Attempted collection of 4 
core needle biopsy specimens, submitted in RNAlater® (a solution that preserves RNA), formalin, 
and shipping medium for Precision Therapeutics, Inc. is required for participation in B-40.  A 
tumor block from any gross residual disease  1 cm at time of surgery is also required for all 
patients.  For patients who have agreed, blood and serum specimens will be collected at baseline.  
Serum will also be collected before the 3rd cycle of the docetaxel-based regimen and at least  
3 weeks after completion of chemotherapy, but prior to surgery.  In addition, histopathology 
findings must be provided for all patients enrolled after local IRB approval of Amendment #2 for 
use by the NSABP Biostatistical Center in calculating Residual Cancer Burden index. 
Tumor assessments by palpation to determine clinical response will be reported between 
chemotherapy regimens and will be used to test the accuracy of a chemoresponse assay as a 
predictor of cOR with each of the docetaxel-based regimens administered without bevacizumab.  
Following the last chemotherapy cycle prior to surgery, cOR will be assessed for the sequential 
regimens (with and without bevacizumab). 
To determine the impact of bevacizumab on cardiac function, all patients will have evaluation of 
left ventricular ejection fraction (LVEF) by MUGA scans or echocardiograms performed at 
baseline and following preoperative chemotherapy (before surgery).  A third LVEF assessment at 
18 months after study entry is required for patients randomized to receive bevacizumab. 
The sample size for B-40 will be 1200 patients accrued over a period of 2 years.  Definitive 
analysis of the primary endpoints is expected at year 3. 
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HER2-Negative Invasive Breast Cancer Diagnosed by Core Needle Biopsy with a Palpable Breast Mass  2.0 cm 
REQUIRED TISSUE COLLECTION 
Four core needle biopsy tissue samples must be collected for submission prior to randomization. 
Randomization to 1 of the 6 Preoperative Therapy Regimens Below 
STRATIFICATION 
 Clinical Tumor Size (2.0 - 4.0 cm,  4.0 cm) 
 Clinical Nodal Status (negative, positive) 
 Hormone Receptor Status (ER-positive and/or PgR-positive, ER- and PgR-negative) 
 Age ( 50,  50) 
Group 1A 
Docetaxel 100 mg/m2 IV 
q 3 weeks x 4 cycles 
↓ 
AC* q 3 weeks x 4 cycles 
Group 1B 
Docetaxel 100 mg/m2 IV 
q 3 weeks x 4 cycles 
+ 
Bevacizumab 15 mg/kg IV 
q 3 weeks x 4 cycles 
 ↓ 
AC* q 3 weeks x 4 cycles 
+ 
Bevacizumab 15 mg/kg IV 
q 3 weeks x 2 cycles 
Group 3A 
Docetaxel 75 mg/m2 IV 
q 3 weeks x 4 cycles 
+ 
Gemcitabine 1000 mg/m2 
days 1 and 8 
q 3 weeks x 4 cycles 
↓ 
AC* q 3 weeks x 4 cycles 
Group 2A 
Docetaxel 75 mg/m2 IV 
q 3 weeks x 4 cycles 
+ 
Capecitabine 825 mg/m2  
PO BID days 1-14 
q 3 weeks x 4 cycles 
↓ 
AC* q 3 weeks x 4 cycles 
Group 2B 
Docetaxel 75 mg/m2 IV 
q 3 weeks x 4 cycles 
+ 
Capecitabine 825 mg/m2  
PO BID days 1-14 
q 3 weeks x 4 cycles 
+ 
Bevacizumab 15 mg/kg IV 
q 3 weeks x 4 cycles 
 ↓ 
AC* q 3 weeks x 4 cycles 
+ 
Bevacizumab 15 mg/kg IV 
q 3 weeks x 2 cycles 
Group 3B 
Docetaxel 75 mg/m2 IV 
q 3 weeks x 4 cycles 
+ 
Gemcitabine 1000 mg/m2 
days 1 and 8 
q 3 weeks x 4 cycles 
+ 
Bevacizumab 15 mg/kg IV 
q 3 weeks x 4 cycles 
 ↓ 
AC* q 3 weeks x 4 cycles 
+ 
Bevacizumab 15 mg/kg IV 
q 3 weeks x 2 cycles 
Surgery (Lumpectomy or mastectomy; evaluation of axilla)** 
Postoperative Therapy for Groups 1B, 2B, and 3B ONLY 
Bevacizumab 15 mg/kg IV q 3 weeks x 10 doses beginning no sooner than 28 days after surgery 
* 60/600 mg/m2 IV of doxorubicin/cyclophosphamide (AC) 
** See Section 9.9 for surgery-related instructions and Section 9.10 for radiation therapy instructions.  Hormonal 
 therapy is at the discretion of the investigator.  Patients with ER-positive and/or PgR-positive tumors should 
 receive a minimum of 5 years of hormonal therapy.
Figure 1 
B-40 SCHEMA 
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2.0 BACKGROUND  
2.1 Introduction 
The American Cancer Society projects 211,000 new cases of cancer of the female breast 
will be diagnosed in 2005, with the disease confined to the breast in 63% and regional 
lymph nodes in 29%.1  With early detection and routine use of appropriate systemic 
therapies, 75 to 80% of these women will enjoy long-term freedom from recurrence.  
While these improved outcomes are welcome, they have come at a cost of treating many 
women with therapy that is in reality, either unnecessary or ineffective.  This is in part 
due to the fact that accurate prognostic factors for outcome and predictive factors for 
response to treatment of individuals are lacking.  Neoadjuvant chemotherapy is an 
established approach for managing patients with larger early stage breast cancers, which 
provides an opportunity for collection of specimens for correlative science studies to 
identify predictive markers for response to specific agents.  Gene expression profiling has 
shown promise in neoadjuvant trials as a tool for defining patterns predictive of 
pathologic complete response to specific agent(s).2-4  Similarly, in vitro chemoresponse 
assays have the potential to predict response to therapy,5-7 but need validation in large, 
well-controlled trials.8  A primary goal of B-40 will be to expand this promising avenue 
of research into a large scale multi-institutional setting. 
2.2 Rationale for conduct of the study   
The rationale for evaluating preoperative chemotherapy in patients with operable breast 
cancer was provided by hypotheses formulated from findings obtained in laboratory 
investigations,9-12 from results of preoperative chemotherapy for locally advanced 
cancers,13-21 and by the establishment of lumpectomy as the surgical treatment of choice 
in patients with operable breast cancer.22,23 
2.2.1 Neoadjuvant chemotherapy in locally advanced breast cancer 
Initial trials of neoadjuvant chemotherapy administered for locally advanced 
tumors, including those in breast cancer, demonstrated that chemotherapy could 
induce sufficient tumor regression to allow for the resection of otherwise 
unresectable tumors.13-18  Subsequent demonstration of the equivalence of 
lumpectomy to mastectomy in patients with operable breast cancer,22,23 
stimulated interest in the concept of using preoperative chemotherapy to reduce 
large, but operable primary tumors, to allow for lumpectomy in these women 
who would otherwise require a mastectomy.19-21  Findings from a number of 
non-randomized trials demonstrated that chemotherapy administered 
preoperatively resulted in high rates of clinical response (47% to 85%) but low 
rates of pathologic complete response (4% to 7%).19,21,24,25  Some of these 
studies confirmed that reduction in tumor size allowed for more breast-
conserving procedures.  These results provided justification for Phase III trials 
comparing neoadjuvant chemotherapy with postoperative chemotherapy in 
women with operable breast cancer. 
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2.2.2 Phase III trials of neoadjuvant chemotherapy in women with operable breast 
cancer 
NSABP B-18 was a landmark Phase III trial that compared preoperative with 
postoperative chemotherapy in women with operable breast cancer.  In this study, 
1523 patients were treated with 4 cycles of doxorubicin/cyclophosphamide (AC) 
either before or after surgery.  In the group randomized to neoadjuvant 
chemotherapy, the overall clinical response rate was 79%, with a clinical 
complete response (cCR) of 36%.  Pathologic evaluation of surgical specimens 
demonstrated 13% of patients had a pathologic complete response (pCR) in the 
breast.  The incidence of pathologically positive axillary nodes in the 
preoperative group was 41% compared to 57% in the postoperative group, 
representing a 37% relative reduction in the rate of positive nodes with 
chemotherapy.26  In addition, significantly more women in the neoadjuvant 
group underwent lumpectomies compared to those in the adjuvant group (68% 
vs. 60%, p=.002).27  When the two groups were compared in terms of outcome, 
there were no significant differences in disease-free survival (p=.99), distant 
disease-free survival (p=.70) or overall survival (p=.83).  However, a significant 
correlation between complete pathologic tumor response following neoadjuvant 
chemotherapy and patient outcome was noted.  Patients achieving a pCR had 
superior disease-free survival (DFS) (p=.0001) and a strong trend for overall 
survival (OS) (p=.06) when compared to the other patient cohorts (cCR but with 
residual invasive carcinoma in the breast specimen [pINV], clinical partial 
response [cPR] or a clinical non-response [cNR]).  When the prognostic effect of 
pCR was examined after adjusting for known clinical prognostic factors such as 
clinical nodal status, clinical tumor size and age, pCR remained a significant 
independent predictor of disease-free survival (p=.0005).26  Through 9 years of 
follow-up, results continue to demonstrate equivalence in outcome between 
neoadjuvant and adjuvant chemotherapy, and the significant correlation between 
pCR and outcome remains.  At 9 years, the disease-free survival rate for patients 
achieving a pCR was 75% compared with 58% for patients with pINV.  For 
overall survival, the respective rates were 85% for patients with a pCR and 73% 
for patients with pINV.  Overall primary tumor response classified as pCR, 
pINV, cPR, or cNR remained strongly associated with outcome measures (DFS: 
p=.00005; OS: p=.0008).28 
EORTC 10902 was similar in design to the NSABP B-18 trial, but employed 4 
cycles of FEC (fluorouracil, epirubicin, cyclophosphamide) rather than 4 cycles 
of AC.  A total of 698 patients with T1c - T4b, N0-1, M0 breast cancers were 
entered.  The overall clinical response was 49% in the patients randomized to the 
neoadjuvant chemotherapy regimen (7% complete and 42% partial), with a pCR 
rate of only 2%.  There was evidence of axillary nodal down-staging with 
neoadjuvant chemotherapy, as 38% of these patients were found to have negative 
nodes compared to 32% in the postoperative chemotherapy group.  With a 
median follow up of 56 months, there was no significant difference between the 
two groups in terms of overall survival, progression-free survival or time to loco-
regional recurrence.29 
02/15/08 
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2.2.3 Potential advantages of neoadjuvant chemotherapy 
These results demonstrate that equivalent disease-free and overall survival in 
patients with operable breast cancer can be achieved with the two approaches.  
However, neoadjuvant therapy has several advantages as well as some minor 
limitations.  From the clinical perspective, a major advantage of neoadjuvant 
chemotherapy is the ability to increase the rate of breast conserving surgery.  
Additionally, by reducing the size of primary tumors, better cosmetic results with 
lumpectomies may be obtained in patients with larger tumors who were 
technically lumpectomy candidates before neoadjuvant chemotherapy.  Recently, 
a body of evidence supporting the feasibility and accuracy of sentinel node 
biopsy following neoadjuvant chemotherapy has evolved.30-37  Since the 
accuracy of negative sentinel nodes in predicting pathologic status of axillary 
nodes is similar whether the procedure is performed before or after systemic 
chemotherapy, neoadjuvant treatment should reduce the rates of axillary 
dissection by clearing involved axillary nodes.   
The presence of clinically and pathologically assessable disease allows for 
observation of the response to neoadjuvant therapy, and provides opportunity to 
evaluate pretherapy specimens for predictive biomarkers.  The importance of 
tumor sensitivity to systemic therapy is supported by the results from B-18 which 
showed disease-free survival and survival correlate with primary tumor complete 
response assessed either clinically or pathologically.26  Early identification of 
tumor resistance makes it possible to avoid further administration of ineffective 
therapy with the attendent unnecessary adverse events, and to allow change to a 
more potentially effective regimen.  Furthermore, it is possible that, by assessing 
changes in tumor biomarkers as the tumor undergoes neoadjuvant chemotherapy, 
patients could be categorized into more refined prognostic and predictive groups 
than is possible with clinical or histologic evaluation. 
Potential disadvantages to preoperative chemotherapy include the lack of pre-
chemotherapy, pathologic axillary node assessment and the relatively small 
amount of tumor tissue obtained by biopsy techniques such as fine needle 
aspiration.  The latter problem has been addressed by the availability of core 
needle biopsy for diagnosis and assessment of biomarkers.  Additionally, lack of 
knowledge of pathologic nodal status before neoadjuvant chemotherapy is not of 
major concern, since clinical decisions regarding systemic therapy, as well as 
adjuvant radiotherapy can be based on the initial clinical stage, and the 
pathologic information at the time of surgery.  Furthermore, nodal status 
following chemotherapy, which is reflective of both initial node status and 
chemoresponse, has at least equal, if not greater, prognostic power than pre-
treatment nodal pathology. 
2.2.4 Phase III trials evaluating the addition of taxanes to anthracycline-based 
neoadjuvant chemotherapy regimens 
Results from initial randomized trials of neoadjuvant chemotherapy strengthened 
the biologic and clinical rationale for continuing to evaluate its role in patients 
with operable breast cancer.  Since response to neoadjuvant chemotherapy 
correlated with patient outcome, it was hypothesized that more active 
neoadjuvant chemotherapy regimens should increase the pCR rates and improve 
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disease-free and overall survival.  More active chemotherapy regimens could also 
further reduce the extent of surgery in the breast and the axilla.  If higher pCR 
rates achieved with more effective regimens continued to predict for improved 
outcome, then pCR could be used as an intermediate endpoint in testing new 
chemotherapy regimens as well as newer targeted therapies.38 
The demonstration of significant antitumor activity of taxanes in advanced breast 
cancer provided the opportunity to test these hypotheses in the neoadjuvant 
setting.  Several randomized trials were designed to evaluate neoadjuvant 
chemotherapy regimens that employed anthracyclines and taxanes.36,39-45  As 
shown in Table 1, rates of pCR (22%-31%) have essentially been doubled with 
the addition of a sequential taxane to the anthracycline/cyclophosphamide 
combinations. 
TABLE 1. Randomized trials comparing anthracyclinetaxane vs. anthracycline-based neoadjuvant 
  chemotherapy regimens in patients with operable breast cancer 
Clinical Trial # of Patients 
Tumor 
Stage/Size 
Chemotherapy 
Regimen 
pCR 
% 
DFS 
Benefit 
OS 
Benefit 
Smith IC, et al43 
Hutcheon AW, et al44 145 
Operable 
T1c-T3 N0 
T1-3 N1 
CVAP x 4 
vs. 
CVAP TXT x 4 
15 
 
31 
CVAP-
TXT 
> CVAP
CVAP-
TXT 
> CVAP 
Bear H, et al36,45,46 
(NSABP) 2411 
Operable 
T1c-T3N0 
T1-3 N1 
AC x 4 
vs. 
AC x 4  TXT x 4 
13.7 
 
25.6 
No No 
Green MC, et al39 258 Operable 
Q 3 W TXL x 4  FAC x 
4 
vs. 
Q W TXL x 12  FAC x 4
13.6 
 
28.8 
NR NR 
Untch M, et al40 631 
Primary BC 
T > 3 cm or 
inflammatory 
Q 2 W E x 3  TXL x 3 
(dose-dense) 
vs. 
ETXL x 4 
18 
 
10 
NR NR 
Von Minckwitz G, et al41 913 Operable 
AC x 4  TXT x 4 
vs. 
ATXT x 4 q 2 W 
(dose-dense) 
22.4 
 
11.5 
NR NR 
Evans T, et al42 362 
Locally 
advanced, 
operable 
AC x 6 
vs. 
ATXT x 6 
12 
 
8 
NR NR 
CVAP:  cyclophosphamide, vincristine, doxorubicin, prednisone; TXT: docetaxel; AC: doxorubicin, 
cyclophosphamide; TXL: paclitaxel; FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; E: epirubicin 
PCR: pathologic complete response; DFS: disease-free survival; OS: overall survival; NR: not reported 
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The largest of these trials, NSABP B-27, was a three-arm study to determine if  
4 cycles of post-AC docetaxel administered before surgery would improve pCR 
rates, and if post-AC docetaxel administered before or after surgery would 
improve OS and DFS when compared to preoperative AC alone.  Comparisons of 
the clinical and pathologic response rates in patients receiving 4 cycles of AC  
(n = 1534) to those receiving 4 cycles of AC followed by 4 cycles of docetaxel  
(n = 752) are available.  A significant benefit in favor of the docetaxel group was 
seen both for cCR (63.6% vs. 40.1%, p  .001), and pCR (26.1% vs. 13.7%,  
p  .001).36  In addition, there was significant nodal down-staging for the group 
randomized to AC followed by docetaxel when compared to the group 
randomized to AC alone (negative nodes 58.2% vs. 50.8%, p  .001). 
However, the addition of docetaxel, either preoperatively or postoperatively, did 
not significantly increase OS.  Preoperative docetaxel increased DFS by 5%, with 
a hazard ratio of 0.86, but this was not statistically significant.  The impact on 
DFS was decreased by an unexpected increase in second primaries of the 
contralateral breast and other sites, as well as the inclusion of low-risk patients 
which decreased the rate of events.  Examining relapse-free survival (RFS), 
which was similar to DFS as defined in the CALGB’s 9344 trial, preoperative 
docetaxel improved outcomes significantly, with a HR of 0.81 (p=0.03).  Most of 
the effect of adding docetaxel so far has resulted from significant decreases (by 
nearly half) in local recurrences.  At the time of this analysis, with a median 
follow-up of 68.8 months, the magnitude of effects and hazard ratios were 
comparable to the effects of adding taxanes to the adjuvant therapy of node-
positive patients in NSABP B-28 and CALGB 9344.46  Patients whose tumors 
had a clinical partial response at the end of 4 cycles of AC derived the greatest 
benefit from the addition of preoperative docetaxel, with a significant increase in 
DFS (HR=0.68, p=0.003).  Interestingly, postoperative docetaxel did not produce 
a significant benefit in this subset of patients. Furthermore, as in B-18, complete 
pathologic response in the breast remained a powerful predictor of DFS and OS 
in all treatment groups. 
In contrast, the Aberdeen trial demonstrated significant improvement in DFS 
(p=0.004) and OS (p=0.04) with crossover to docetaxel in patients who had an 
objective clinical response to CVAP.44  Both CALGB 9344 and NSABP B-28 
compared 4 cycles of AC followed by 4 cycles of paclitaxel with 4 cycles of AC 
alone, and have shown significant improvements in DFS in the groups receiving 
paclitaxel (9344: p=0.0023; B-28: p=0.008).47,48  One of the studies, CALGB 
9344,  has also shown a statistically significant improvement in OS (p=0.0064).47  
An additional adjuvant trial, PACS 01, reported at San Antonio in 2004, also 
demonstrated significant improvement in DFS and OS for node-positive patients 
who received 3 cycles of anthracycline-based therapy followed by 3 cycles of 
docetaxel compared to 6 cycles of anthracycline-based therapy alone.49   
Reversal of the sequence of the regimens does not appear to reduce the activity.  
A neoadjuvant trial reported by MD Anderson evaluated 2 schedules of 
paclitaxel followed by 4 cycles of fluorouracil/doxorubicin/cyclophosphamide 
(FAC) in standard doses every three weeks.  A total of 258 patients were 
randomized to receive paclitaxel either weekly (for a total of 12 doses) or every 
three weeks (4 cycles), followed by FAC.  Patients receiving weekly paclitaxel 
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followed by FAC had a pCR rate of 28.2%50 which is similar to the pCR rate 
reported in NSABP B-27. 
Final results of a neoadjuvant Phase III trial of docetaxel and capecitabine (TX) 
versus doxorubicin and cyclophosphamide (AC) as primary therapy in early stage 
breast cancer was reported at San Antonio in 2005.  A total of 209 patients were 
randomized to receive docetaxel and capecitabine (four cycles) or doxorubicin 
and cyclophosphamide (four cycles) in the preoperative setting.  Patients then 
proceeded to surgery.  Patients who received TX in the preoperative setting, 
received AC in the postoperative setting.  Patients who received AC in the 
preoperative setting, received TX in the postoperative setting.  Patients receiving 
TX had an increased clinical response rate (84% vs 67%; p=0.0047) and an 
increased pCR rate (23% versus 10%) compared to patients receiving AC.51 
With the above results, it is appropriate to continue development of sequential 
chemotherapy regimens to improve on clinical and pathologic response rates.  
We propose to use preoperative sequential docetaxel followed by AC as the 
control arm for B-40 and to compare the docetaxel/AC regimen with 2 different 
docetaxel doublets, which have shown significant activity in metastatic and 
locally advanced breast cancer, followed by AC. 
2.2.5 Justification for use of pCR as primary endpoint 
Since achievement of pCR with neoadjuvant therapy has been shown to predict 
favorable long-term outcome, we will use pCR rate in the breast as the primary 
endpoint for this trial.  Use of traditional adjuvant endpoints such as DFS and OS 
require a large number of patients which limits the choice of investigational 
arms, and require lengthy follow-up for determination of outcome.  Additionally, 
use of these endpoints in neoadjuvant trials requires that post surgical therapy be 
applied uniformly in women receiving therapy on these trials to avoid 
introducing bias.  Since pCR identifies a small group with a favorable outcome 
and a larger group with a poorer outcome, it is difficult to justify a uniform 
approach to clinical management or clinical investigation in these dichotomous 
patient groups.  Current standard therapies following neoadjuvant chemotherapy 
and surgery include hormonal therapy, if the tumor was hormone receptor-
positive, and consideration for radiation therapy.  There is no evidence that 
additional chemotherapy provides benefit to either group, though consideration 
for additional chemotherapy is sometimes given for patients with significant 
residual disease.  Patients with residual disease following taxane/anthracycline-
based sequential neoadjuvant chemotherapy regimens have sufficient risk to 
warrant investigation of additional systemic treatments such as novel targeted 
agents.  Availability of residual tumor for gene expression profiling and 
identification of putative targets for new investigational agents provides an 
important opportunity for evaluation of these therapies.  Exclusion of patients 
with residual disease following treatment with chemotherapy regimens on 
neoadjuvant trials from participating in trials evaluating novel agents simply to 
obtain long-term endpoints on the initial study is not appropriate based on the 
prognostic information already provided by the failure to achieve pCR status. 
The efficient use of precious patient resources, which can be achieved by using 
pCR as the primary endpoint in neoadjuvant trials, has become critical with the 
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large number of promising therapies entering clinical development.  Thorough, 
but efficient evaluation of new agents in the neoadjuvant setting can reduce the 
risks of further development of ineffective therapies or incorrectly terminating a 
potentially effective therapy.  Importantly, the development time of effective 
therapies can also be substantially reduced. 
Finally, recent findings from small single institution trials have demonstrated the 
potential of using molecular markers, particularly gene expression profiles, for 
predicting pCR of breast cancers to neoadjuvant chemotherapy.  A report from 
MD Anderson demonstrated the potential power of genomic signatures to predict 
pCR of primary breast cancers to 4 cycles of paclitaxel followed by 4 cycles of 
FAC.2  Similarly, a group from Baylor reported gene expression profiles could 
be constructed to identify those breast cancers that were most likely to respond to 
single agent docetaxel therapy.3  These reports, along with others that have 
demonstrated the predictive power of similar techniques, suggest the neoadjuvant 
setting could be most valuable for validating genomic profiles in large patient 
populations.4  Therefore, this trial will evaluate baseline gene expression profiles 
and other molecular markers as potential predictors for pCR to the chemotherapy 
regimens evaluated in this study.  Following completion of the first part of the 
regimen, activity of the first portion of the sequential regimen will be assessed by 
clinical evaluation.  Following completion of the second part of the regimen, 
activity will be assessed by clinical evaluation and pathologic evaluation of the 
surgical specimens. 
2.3 Rationale for docetaxel doublets to be compared to docetaxel alone 
2.3.1 Capecitabine + docetaxel 
The oral fluoropyrimidine capecitabine (Xeloda®, Roche Laboratories, Inc.) was 
rationally designed to provide prolonged exposure to 5-FU and to generate 5-FU 
preferentially in tumor tissue.  Capecitabine52-58 is a rapidly absorbed oral 
compound, which is converted to 5-FU by a three-enzyme pathway.  A 
carboxylesterase cleaves the drug to make 5'-deoxy-5-fluorocytidine, which is 
then further metabolized to 5'-deoxy-5-fluorouridine (5'DFUR) by cytidine 
deaminase.  The final enzyme, thymidine phosphorylase (TP), converts 5'DFUR 
to 5-FU.  Capecitabine59-61 is rapidly absorbed with a tmax of 1-2 hours and 70% 
of it can be recovered as parent compound or metabolites in urine.  
Approximately 40% is detected as 5'DFUR in urine.  It has a t½ of 0.85 hours.  
Capecitabine Cmax and AUC increase in a dose proportional manner over the 
dose range of 666 – 1255 mg/m2.  The enzyme TP is present in tumor tissue in 
much higher concentrations than in normal tissues.  Exploitation of this higher 
level of thymidine phosphorylase (TP) in many human tumor tissues relative to 
healthy tissue provides a degree of tumor selectivity.62,63 
Preclinical studies in human cancer xenograft models demonstrated that 
administration of docetaxel or paclitaxel results in further upregulation of TP in 
tumor tissue.64  This has been confirmed in women with primary breast cancer 
who were treated with pre-operative docetaxel.65  Co-administration of 
capecitabine and either docetaxel or paclitaxel in xenograft models resulted in 
synergistic antitumor activity, whereas, taxanes in combination with either 5-FU 
or UFT (uracil plus tegafur) demonstrated only additive efficacy.64 
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Capecitabine has been approved in the U.S. for patients with previously treated 
metastatic breast cancer and is being evaluated in the adjuvant setting.  The Phase 
II pivotal trial which resulted in expedited approval of capecitabine showed an 
overall response rate of 20% in a population of patients who had previously 
received treatment with anthracyclines and taxanes.66  These results were later 
confirmed in a second multicenter trial.67  Capecitabine has also been shown to 
produce a higher response rate and a better median survival than CMF in women 
over 55 years of age.68 
A Phase III comparison of capecitabine plus docetaxel vs. docetaxel alone in 
patients with advanced or metastatic disease who either progressed while 
receiving anthracycline-containing therapy or relapsed after the completion of 
treatment showed an increase in objective response (32% vs. 23%, p = .025), as 
well as significant prolongation in median time to progression (6.1 months vs. 
4.2 months, p = .0001) and median survival (14.5 months vs. 11.5 months,  
p = .0126) for patients assigned to the combination.  At the initial doses used 
(docetaxel 75 mg/m2/D1/q3w and capecitabine 1250 mg/m2/D1-14/q3w), Grade 
3 hand foot syndrome (HFS) was 24%, Grade 3/4 diarrhea was 14.4%, and Grade 
3/4 stomatitis was 17.4%  The overall incidence of HFS, diarrhea, and stomatitis 
were each in excess of 60%.  Patient withdrawal due to treatment-related adverse 
events occurred in 26% of patients.69  Because of the high rate of HFS in the 
combination arm, dose modifications were frequently necessary.   
The U.S. Oncology Research Network (USON) is conducting an adjuvant trial of 
sequential AC/docetaxel vs. AC/docetaxel with capecitabine.  The trial was 
initiated employing the doses of docetaxel and capecitabine used in the Phase III 
metastatic trial.  However, the protocol has been modified to reduce the starting 
dose of capecitabine due to unacceptable rates and severity of toxicity which 
initially occurred.  With reduction in the starting dose, the tolerability of the 
regimen has substantially improved.70  Based on discussions with  
Dr. O’Shaughnessy and reports from the Data Monitoring Committee for the 
study, the manufacturer of capecitabine now recommends use of the modified 
starting dose of capecitabine when using the regimen either in research or routine 
clinical practice.71  We will therefore use this schedule in B-40. 
Dr. O’Shaughnessy has also shared the current dose modification program for the 
regimen being employed in the USON adjuvant trial.  A key aspect of the schema 
is use of filgrastim as secondary prophylaxis following neutropenia related 
toxicities.  When filgrastim has been administered concurrently with 
capecitabine, it has been effective without apparent increase in side effects.70  
Based on this experience, we will also administer filgrastim concurrently with 
capecitabine when needed for secondary prophylaxis. 
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2.3.2 Rationale for gemcitabine + docetaxel doublet  
Gemcitabine (Gemzar®) is a nucleoside analog antimetabolite, which exhibits 
cell phase specificity, primarily killing cells undergoing DNA synthesis (S phase) 
and also blocking the progression of cells through the G1/S phase boundary.  
Gemcitabine is metabolized intracellularly by nucleoside kinases to active 
diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides.  The cytotoxic 
effect of gemcitabine is attributed to a combination of two actions of the 
diphosphate and the triphosphate nucleosides, which lead to inhibition of DNA 
synthesis. First, gemcitabine diphosphate inhibits ribonucleotide reductase, which 
is responsible for catalyzing the reactions that generate the deoxynucleoside 
triphosphates for DNA synthesis. Inhibition of this enzyme by the diphosphate 
nucleotide causes reduction in the concentrations of deoxynucleotides, including 
dCTP.  Second, gemcitabine triphosphate competes with dCTP for incorporation 
into DNA, which allows only one additional nucleotide to be added to the 
growing DNA strands.  This results in inhibition of further DNA synthesis.  DNA 
polymerase epsilon is unable to remove the gemcitabine nucleotide and repair the 
growing DNA strands (masked chain termination).  In CEM T lymphoblastoid 
cells, gemcitabine induces internucleosomal fragmentation, one of the 
characteristics of programmed cell death. 
Gemcitabine possesses a broad range of antitumor activity against solid tumors 
and leukemias in vitro and in vivo.72,73  It is active in several tumor cell lines and 
human tumor xenografts.  Gemcitabine has undergone considerable testing for 
various malignancies and exhibited activity in non-small cell lung cancer 
(NSCLC), pancreatic cancer, bladder cancer, advanced breast carcinoma, and 
cisplatin-refractory ovarian carcinoma.74-78 
Multiple studies have established the activity of single agent gemcitabine in 
patients with metastatic breast cancer.  Response rates of 37% to 42% have been 
seen in less heavily pretreated patients.79-82  Activity of gemcitabine has also 
been shown in patients previously treated with up to three prior regimens in the 
metastatic setting, as well as in patients resistant to both an anthracycline and a 
taxane (see Table 2).83-85  The weekly dose of gemcitabine has ranged from 800-
1250 mg/m2 administered every week for 3 out of 4 weeks.  The toxicities seen 
have typically been mild and included neutropenia, thrombocytopenia, fatigue, 
flu-like syndrome and anemia.79-85 
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TABLE 2.  Activity of gemcitabine in advanced breast cancer 
Author Weekly Dosing (mg/m2) 
Prior Chemo 
Regimens MBC # Pts 
Percent 
CR/PR/OR Major Toxicities (> 5% grade 3 or 4) 
Blackstein79 1200 0 35 11/26/37 WBC, nausea 
Carmichael80 800 0-1 40  8/17/25 WBC, nausea 
Possinger81 1000 0-1 42  0/14/14 WBC, LFTs 
Gerson82 1250 NA 19  11/31/42 Anemia, plts 
Valerio83 1000 
Resistant 
A and T 
22 5/18/23 
WBC, fatigue, flu-like 
syndrome 
2nd 9 0/22/22 
Brodowicz84 1250 
3rd 16 6/6/12 
WBC 
Spielmann85 1200 0-1 prior A 43 9/19/28 WBC, anemia, asthenia 
MBC: Metastatic breast cancer; CR: complete response; PR: partial response; OR: overall response; LFTs: liver 
function tests; A: anthracycline; T: taxane 
 
Gemcitabine in combination with taxanes has been evaluated in both pre-clinical 
and clinical studies.  Additive, but not synergistic, effects have been observed in 
vitro and in vivo when paclitaxel and gemcitabine have been combined.86,87  
When paclitaxel was administered prior to gemcitabine, increased accumulation 
of the active metabolite dFdCTP was observed, contributing to the additive 
effect.88 
Recently, results from a Phase III randomized trial comparing paclitaxel alone to 
paclitaxel with gemcitabine in patients with metastatic breast cancer have been 
reported.88  All patients (529 subjects in both arms) included in the study had 
received anthracycline in the adjuvant setting and no prior treatment for 
metastatic disease. This study demonstrated significant improvement in response 
rates (40.8% vs. 22.1%, p<0.0001), median time to progression (5.2 vs. 2.9 mos., 
p<0.0001) and median overall survival (18.5 vs. 15.8 months, p=0.018) with the 
addition of gemcitabine to paclitaxel. 
While these results are impressive, we propose to evaluate docetaxel/gemcitabine 
rather than paclitaxel/gemcitabine for several reasons.  First of all, the superiority 
of the combination of gemcitabine with a taxane relative to the taxane alone 
justifies evaluation of a gemcitabine/taxane combination in the neoadjuvant 
setting.  Second, when docetaxel has been administered prior to gemcitabine in 
multiple adenocarcinoma cell lines, synergistic effects were observed.  
Additionally, the combination of gemcitabine and docetaxel has been evaluated 
in ten Phase II trials conducted in a total of 408 evaluable patients with metastatic 
breast cancer.90-99  Studies have shown activity in patients with multiple lines of 
previous therapy, including patients treated with prior taxanes.  Overall responses 
have ranged from 36% to 79%.  The major side effects of the combination have 
been neutropenia, anemia, asthenia, neuropathy, nausea, mucositis, and 
neutropenic fevers (see Table 3). 
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TABLE 3.  Data for docetaxel and gemcitabine combinations in Phase II studies 
Author 
Weekly 
Gemcitabine 
Dosing (mg/m2) 
Docetaxel 
Dosing (mg/m2) 
Prior Chemo 
Regimens 
MBC 
# Pts 
Eval 
Percent 
CR/PR/ORR 
Major Toxicities 
 5% grade 3 or 4 
Fountzilas90 1000 D 1, 8 
75 
D 1 q 3 wks 
Prior adj (19 pts) 
Prior A (36 pts) 40 8/28/36 
Neutropenia, anemia, 
fatigue, N/V, asthenia, 
infection 
900 
D 1, 8 
100 
D 8 q 3 wks Mavroudis91 
G-CSF 150 mcg/m2 
D 9-16 
Prior T 
(25 pts) 
A resistant 
(all pts) 
52 14/40/54 Infection with neutropenia, anemia, platelets 
Laufman92 800 D 1, 8, 15 
100 
D 1 q 4 wks 
Prior A (33 pts) 
Prior C (37 pts) 39 5/74/79 
Neutropenia, F/N, anemia, 
nausea, asthenia, infection, 
edema 
Brandi93 1000 D 1, 8 
80 
D 8 q 3 wks 
 2 prior 
regimens (17 pts) 
1 prior regimen 
(13 pts) 
Prior A (26 pts) 
Prior T (4 pts) 
30 7/53/60 Neutropenia, anemia, nausea, LFTs, mucositis 
Kornek94 1500 D 1, 15 
50 
D 1, 15 q 4 wks 
1 prior regimen 
(14 pts) 
Refractory to A 
(10 pts) 
51 11/50/61 
Neutropenia, N/V, 
infection, neuropathy, use 
of G-CSF based on counts 
Alexopoulos95 
900 
D 1, 8 
If pt had SD or PD 
while on docetaxel 
100 
D 8 q 3 wks 
Prior A 1st line 
and prior T 2nd 
line (all pts) 
30 SD on Doc 
and 20 PD on 
Doc 
50 6/40/46 Neutropenia, platelets, asthenia 
Mavroudis96 1500 D 1 
65 
D 1 q 2 wks 
Prior adj chemo 
(24 pts) 37 14/62/76 
Neutropenia, F/N, anemia, 
platelets 
Slee97 1000 D 1, 8 
75 
D 8 q 3 wks 
Prior adj A 
therapy (10 pts) 
Prior therapy for 
MBC (16 pts) 
26 8/54/62 Not reported 
Garle98 2500 D 1 
65  
D 1 q 2 wks 
Prior adj chemo 
(45%) 
Prior A therapy 
(33%) 
48 17/54/71 Neutropenia, nausea  
Lenz99 800 D 1, 8, 15 
35 
D 1, 8, 15 q 4wks
Prior A adj or 
neoadj therapy 
(100%) 
35 ORR - 54 Neutropenia, platelets 
MBC: metastatic breast cancer; CR: complete response; PR: partial response; ORR: overall response rate; adj: adjuvant;  
A: anthracycline; N/V: nausea/vomiting; T: taxane; F/N: febrile neutropenia; C: cyclophosphamide; LFT: liver function tests; 
SD: stable disease; PD: progressive disease; DOC: docetaxel 
 
 
Finally, a Phase III trial in 305 patients with anthracycline pre-treated metastatic 
breast cancer has shown docetaxel/gemcitabine to have similar efficacy to 
docetaxel/capecitabine.  The study is comparing the regimen of docetaxel  
75 mg/m2 Day 1 and gemcitabine 1000 mg/m2 Days 1 and 8 every 21 days with 
docetaxel 75 mg/m2 Day 1 and capecitabine 1250 mg/m2 bid Days 1-14.  Both 
arms demonstrated an overall response rate of 32% and a median progression-
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free survival of 35 weeks.  Overall the gemcitabine combination was associated 
with less grade 3/4 diarrhea (7 vs. 18%), less grade 3/4 mucositis (4 vs. 17%) and 
fewer drug-related discontinuations due to toxicity (13 vs. 28%).  Grade 3 hand-
foot syndrome was not seen in the gemcitabine cohort.  Hematologic toxicity was 
greater with gemcitabine but only one patient developed grade 4 
thrombocytopenia, and the incidence of febrile neutropenia was actually less in 
the gemcitabine arm (12 vs. 19%).100   
2.4 Rationale for evaluating the addition of bevacizumab to neoadjuvant chemotherapy 
See Section 2.5 for additional bevacizumab information provided at the time of 
Amendment #3. 
Bevacizumab (rhuMAb VEGF), developed by Genentech, Inc., is a recombinant 
humanized monoclonal antibody against human VEGF.  Results of ECOG E2100 have 
demonstrated substantial activity of bevacizumab added to paclitaxel in the front-line 
treatment of metastatic breast cancer.  Similar benefits have been demonstrated with the 
addition of bevacizumab to combination chemotherapy in front-line treatment of 
metastatic colorectal cancer and lung cancer.  These results suggest bevacizumab may be 
the most broadly effective anti-cancer therapy to enter clinical trials to date.  It is 
imperative that the clinical research community evaluate this promising agent as quickly 
and efficiently as possible in adjuvant trials of these common malignancies since delays 
in demonstration of efficacy of a highly active agent in common malignancies would 
allow for a substantial number of potentially avoidable deaths to occur.  However 
toxicities and costs of adjuvant therapies require that correlative science studies be 
conducted to understand mechanisms of action and resistance, and ultimately to define 
predictive factors for benefit from specific agents.  Neoadjuvant trials provide a unique 
opportunity for early correlation between potential molecular predictive factors and 
outcomes such as overall clinical response and complete pathologic response.  Given the 
promise of bevacizumab it is important to evaluate the agent in a large Phase III 
neoadjuvant trial incorporating correlative science studies on tumor specimens. 
Recently, Miller et al reported results of ECOG E2100, a randomized Phase III trial 
comparing weekly paclitaxel with weekly paclitaxel and bevacizumab 10 mg/kg every  
2 weeks in the front-line treatment of metastatic breast cancer.  The large majority of the 
patients had HER-2 negative primary breast cancer.  Results demonstrated an 
improvement in progression-free survival (primary endpoint) from 6.11 months to  
11.4 months (HR=.51; 0.43-0.62, p<0.0001) an improvement in response rate from 
13.8% to 29.9% (p<0.0001) with the addition of bevacizumab.101 
Based on these results, we will evaluate the benefit of adding bevacizumab to the 
sequential docetaxel-based regimens being evaluated in NSABP B-40 by incorporating a 
3 X 2 factorial design.  Patients will be randomized to one of the 3 chemotherapy 
regimens with a secondary randomization to receive bevacizumab or no bevacizumab.  
Bevacizumab 15 mg/kg every 3 weeks will be administered with the first 6 cycles of 
chemotherapy in the neoadjuvant setting and for 10 doses in the postoperative setting. 
Since the definitive adjuvant trial of bevacizumab being developed by ECOG is 
evaluating 6 months versus 12 months of therapy, it is important to employ a treatment 
schedule of bevacizumab in B-40 that will be interpretable regardless of the duration 
outcome in the ECOG study.  If longer durations of bevacizumab appear to be more 
04/01/11 
 NSABP B-40 – Page 15 
effective than shorter durations, applicability of results from B-40 could be problematic if 
bevacizumab therapy was ended after 4 months, since safety data regarding post-
operative resumption of bevacizumab following neoadjuvant chemotherapy combined 
with bevacizumab would not be available.  Even if the ECOG study does not demonstrate 
a difference between 6 and 12 months of bevacizumab, uncertainty would remain about 
the efficacy of only 4 months of neoadjuvant bevacizumab on disease-free survival if 
bevacizumab is limited to the preoperative period in B-40.  By administering 10 doses of 
bevacizumab post-operatively, B-40 patients randomized to bevacizumab will receive a 
total exposure of 12 months, which will be comparable to the longest treatment duration 
being evaluated in the ECOG trial. 
Since E2100 evaluated bevacizumab with a taxane and bevacizumab will only be 
administered for the first half of the second regimen in the sequential program, reversal 
of the chemotherapy sequences will maximize the concurrent administration of 
bevacizumab with the docetaxel regimens in B-40.  Additionally, since the cardiac safety 
of prolonged co-administration of bevacizumab and anthracyclines is still being defined, 
reversing the sequence of chemotherapy regimens will limit exposure of concurrent 
bevacizumab to the AC combination. 
2.4.1 Mechanism of action of bevacizumab 
Vascular endothelial growth factor (VEGF) is a critical regulator of both normal 
and pathologic angiogenesis.102  It is a highly conserved homodimeric 
glycoprotein whose dominant isoform has a molecular weight of 45kD.  The 
biologic activity of VEGF is mediated by binding to two receptors on the surface 
of endothelial cells, namely Flt-1 and KDR.  Increased levels have been 
demonstrated in colon cancer and presumably represent an important factor 
needed to support the cancer through the growth of tumor vasculature.103  
Folkman and coworkers provide convincing evidence linking tumor growth and 
metastases with angiogenesis, and several investigators have demonstrated a 
correlation between vascular density in colorectal cancer and metastases, 
recurrence, and survival.104-111  Inhibition of VEGF, either alone or in 
combination with chemotherapy, results in growth inhibition of a number of 
human tumor xenografts in the nude mouse model, including colorectal cancer 
cell lines, LS174T, HM7, and LSLiM6.102,112 
2.4.2 Phase I clinical experience with bevacizumab  
The dose and toxicities associated with bevacizumab were investigated in two 
phase I trials.113,114  Study AVF0737g was an open-label dose-escalation study 
of single agent bevacizumab in patients with advanced cancers.  Three patients in 
this trial experienced tumor-related hemorrhagic events (2 cases were considered 
serious).  Linear pharmacokinetics were observed for doses of drug in excess of 1 
mg/kg.  The half-life of bevacizumab was found to be approximately 15 days.   
Study AVF0761g evaluated bevacizumab in combination with 3 cytotoxic 
regimens including 5-FU + LV, carboplatin + paclitaxel, and doxorubicin in 
patients with advanced cancers.  No patients in this study experienced serious 
hemorrhagic events, and the co-administration of bevacizumab with 
chemotherapy did not alter the pharmacokinetics of the cytotoxic agents.  Neither 
study detected antibodies to bevacizumab. 
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2.4.3 Bevacizumab improves tumor response rates in patients with breast cancer 
A Phase I/II study of bevacizumab monotherapy conducted in patients with 
previously treated metastatic breast cancer demonstrated an overall response rate 
of 9.3% with 16 % of the patients having stable disease or an ongoing response at 
22 weeks.  The data from this trial supported the initiation of trials combining 
bevacizumab with chemotherapy in metastatic breast cancer.115 
The preliminary results of a Phase II study comparing neoadjuvant docetaxel 
with or without bevacizumab in patients with locally advanced breast cancer has 
been reported.  Patients received neoadjuvant therapy with bevacizumab  
(10 mg/kg qo wk) and docetaxel (two 8-week cycles of 35 mg/m2 x 6 with a two-
week break) or docetaxel alone.  Patients with disease response underwent 
definitive surgery and radiation therapy, followed by 4 cycles of adjuvant 
conventional doxorubicin and cyclophosphamide and tamoxifen (if ER/PR+).  
Treatment converted 84% of tumors to being surgically resectable.  Statistically 
significant reduction in tumor volume and perfusion associated with the 
combination bevacizumab and docetaxel compared to docetaxel alone were also 
noted.  The combination of docetaxel and bevacizumab was safe and well 
tolerated.  At the time of the report, there had been no episodes of uncontrolled 
hypertension, proteinuria, thrombosis, or change in left ventricular function 
associated with bevacizumab or subsequent doxorubicin administration.116 
In a second trial for locally advanced or inflammatory breast cancer, patients 
were treated with bevacizumab, doxorubicin, and docetaxel.  The treatment 
program consisted of bevacizumab (15 mg/kg) alone for cycle one followed by  
6 cycles of bevacizumab (15 mg/kg) with doxorubicin (50 mg/m2) and docetaxel 
(75 mg/m2) every 3 weeks.  Following surgery and radiation therapy, 
bevacizumab was given for an additional 8 cycles with hormonal therapy in 
estrogen-positive patients.  In this trial, the overall response rate was 67% (95% 
CI; 43%-85.4%).  Grade 2 asymptomatic decrease in left ventricular ejection 
fraction (LVEF) was observed in 2 patients.  The LVEF dysfunction occurred in 
both after 7 cycles of neoadjuvant therapy (total 300 mg/m2 doxorubicin and  
450 mg/m2 docetaxel), surgery, and radiation therapy prior to starting cycle 8.  
One patient was taken off study therapy.  Her LVEF normalized 6 months after 
discontinuing therapy and receiving an ACE inhibitor.  The second patient had 
normalization of her LVEF within 3 weeks and remained on study.  Other than 
these 2 patients, no patient had >15% absolute decrease in LVEF or a decrease in 
LVEF below the lower limits of normal, and no segmental abnormalities were 
noted on echocardiogram.  Left ventricular dysfunction was asymptomatic and 
recovered in both cases.117 
2.4.4 Phase III trials with chemotherapy and bevacizumab in breast cancer 
A Phase III trial of capecitabine compared with bevacizumab plus capecitabine in 
patients with metastatic breast cancer previously treated with anthracyclines and 
taxanes has been reported.  This study revealed significantly higher response 
rates with the combination therapy (19.8% vs. 9.1%; p=0.001) but did not meet 
its primary endpoint (time to tumor progression).  Bevacizumab was well 
tolerated in this treatment population.  No significant differences were found in 
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the incidence of diarrhea, hand-foot syndrome, thromboembolic events, or 
serious bleeding episodes between treatment groups.118 
A subsequent Phase III trial led by the Eastern Cooperative Oncology Group 
(E2100) compared paclitaxel with or without bevacizumab as first line therapy 
for locally recurrent and metastatic breast cancer.  The large majority of patients 
enrolled had HER2-negative tumors since administration of trastuzumab was not 
allowed in the trial.  Women received paclitaxel (90 mg/m2) weekly for 3 out of 
4 weeks with or without bevacizumab at 10 mg/kg every 2 weeks.  The primary 
endpoint was progression-free survival which was improved from 6.11 months to 
11.4 months (p<0.0001).  The overall response rate was also improved with 
bevacizumab and paclitaxel versus paclitaxel alone (29.9 % versus 13.8 %: 
p<0.0001.101 
2.5 Updated bevacizumab information provided at the time of Amendment #3 
A meta-analysis of 16 published, randomized controlled trials was performed to 
determine the overall risk of fatal adverse events associated with bevacizumab and 
chemotherapy compared to chemotherapy alone.  A total of 10,217 patients with a variety 
of advanced solid tumors including colorectal, non-small cell lung, pancreatic, prostate, 
breast, and renal cell cancers were included in this analysis.  The addition of 
bevacizumab was associated with an increased risk of fatal adverse events compared with 
chemotherapy alone (2.5% vs. 1.7% with a RR=1.46; p=0.01).  The highest relative risk 
was observed in patients with prostate cancer (RR 3.85; 95% CI 1.58–9.37; incidence 
4.4% vs. 1.1%), and lung cancer (RR 2.12; 95% CI 0.78–5.78; incidence 5.3% vs. 2.5%).  
The lowest relative risk was in renal cell carcinoma (RR 1.11; 95% CI 0.29–4.20; 
incidence 0.9% vs. 0.8%) and breast cancer.  The incidence of fatal adverse events in the 
breast cancer trials was 0.9 in the chemotherapy plus bevacizumab cohorts and 1.3 in the 
chemotherapy control cohorts (RR=0.69) suggesting that different patient populations 
may be at different degrees of risk for fatal adverse events when bevacizumab is added to 
chemotherapy.119 
On December 16, 2010, the United States Food and Drug Administration (FDA) 
announced that the agency was initiating a process to remove the indication for 
bevacizumab in metastatic breast cancer from the approved label.  This decision was 
made following an updated review of the results of four randomized trials of 
bevacizumab (E2100, AVADO, RIBBON-1, RIBBON-2) in patients with metastatic 
breast cancer.  The FDA concluded that "the drug does not prolong overall survival in 
breast cancer patients or provide a sufficient benefit in slowing disease progression to 
outweigh the significant risks to patients".  The key efficacy data from the four trials in 
metastatic breast cancer are summarized in Table 4. 
04/01/11 
 NSABP B-40 – Page 18 
TABLE 4.  Efficacy data from four trials using bevacizumab therapy to treat metastatic breast cancer 
 Median 
PFS 
(months) 
Hazard Ratio 
(bevacizumab 
vs. nil) 
P-Value 
Response
Rate 
(%) 
P-Value Median OS (months) 
E2100 (first-line)120 
Weekly paclitaxel 5.9 -- -- 21.2 -- 25.2 
Weekly paclitaxel with bevacizumab 11.8 0.60  0.001 36.9  0.001 26.7 
AVADO (first-line)121 
Docetaxel with placebo 8.2 -- -- 46.4 -- 31.9 
Docetaxel with bevacizumab 7.5 mg/kg 9.0 0.86 0.12 55.2 0.07 30.8 
Docetaxel with bevacizumab 15 mg/kg 10.1 0.77 0.006 64.1  0.001 30.2 
RIBBON-1 (first-line)122 
Capecitabine with placebo 5.7 -- -- 23.6 -- 22.8 
Capecitabine with bevacizumab 8.6 0.69 0.0002 35.4 0.0097 25.7 
Anthra or taxane with placebo 8.0 -- -- 37.9 -- NR 
Anthra or taxane with bevacizumab 9.2 0.64  0.001 51.3 0.0054 27.5 
RIBBON-2 (second-line)123 
Chemotherapy with placebo 5.1 -- -- 29.6 -- 16.4 
Chemotherapy with bevacizumab 7.2 0.78 0.0072 39.5 0.019 18.0 
 
The first studies to evaluate the potential of bevacizumab to improve the efficacy of 
adjuvant chemotherapy, NSABP C-08 and AVANT, were conducted in patients with 
colon cancer.  NSABP C-08 was designed to evaluate the addition of bevacizumab to 
modified FOLFOX6 (infusional/bolus fluorouracil, leucovorin, and oxaliplatin) for the 
treatment of patients with stages II and III colon cancer.124  The addition of bevacizumab 
to mFOLFOX6 did not result in an overall significant increase in DFS (HR 0.89; 95%  
CI 0.76–1.04; p=0.15).  The point estimates for 3-year DFS were 74.4% for bevacizumab 
plus mFOLFOX6 and 75.5% for chemotherapy alone.  The AVANT study evaluated 
bevacizumab in combination with either capecitabine plus oxaliplatin (XELOX) or 
fluorouracil/leucovorin with oxaliplatin (FOLFOX4) versus FOLFOX4 alone in patients 
with high-risk stage II or III colon cancer.125  With a median follow-up of 48 months, 
bevacizumab did not prolong DFS or OS when added to FOLFOX or XELOX.  The  
3-year DFS rates were 73% for FOLFOX plus bevacizumab, 75% for XELOX plus 
bevacizumab, and 76% for chemotherapy alone.  FOLFOX with bevacizumab was 
associated with a hazard ratio of 1.17 compared to FOLFOX alone (95% CI 0.98–1.39), 
and XELOX with bevacizumab was associated with a hazard ratio of 1.07 (95%  
CI 0.90–1.28) compared to FOLFOX alone, neither of which was statistically different 
from chemotherapy alone.  The efficacy results numerically favored the  
chemotherapy-alone control arm.  No benefit was apparent from the addition of 
bevacizumab to oxaliplatin/fluoropyrimidine-based chemotherapy in either trial.  On the 
basis of these results, accrual to other adjuvant trials in colon cancer has been stopped. 
The AVANT results have renewed concerns about possible accelerated tumor growth and 
distant metastases following discontinuation of prolonged antiangiogenic agents.  
Updated survival results of C-08 with a median follow-up of 4 years continue to show no 
evidence to support this hypothesis.  Additionally, a pooled analysis of 5  
placebo-controlled trials of bevacizumab conducted in patients with metastatic breast, 
renal, colon, and pancreatic cancers did not show evidence of a decreased time to 
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progression, increased mortality, or altered disease progression patterns after 
discontinuation of bevacizumab.126  The median time from discontinuation as a result of 
adverse events to progression or death was 4 months (95% CI 3.4 to 4.6 months) in the 
bevacizumab group and 3.0 months (95% CI 2.6 to 3.8 months) in the placebo group  
(HR 0.93; 95% CI 0.79 to 1.10). 
The results of the 3 large trials in the first-line therapy of metastatic breast cancer, and the 
RIBBON-2 study in the second-line setting, justify the completion of this trial. 
2.6 Importance of this trial 
This trial will further develop the role of primary chemotherapy for patients with 
operable breast cancer.  Use of the neoadjuvant setting to test and compare new drug 
combinations correlating pCR with gene expression profiles and in vitro chemoresponse 
profiles represents a paradigm shift in the study of primary breast cancer.  At the present 
time, hormone-receptor status and HER-2 status are the only available predictive markers 
on which breast cancer treatments can be based.  By using genomics technology on 
samples of malignant tissue collected before treatment and assessing the in vitro response 
to chemotherapy on tumor biopsy material before treatment on neoadjuvant clinical trials, 
we hope to define genetic and in vitro chemoresponse profiles that ultimately can be used 
to tailor specific therapies for individual patients. 
Bevacizumab has been shown to have activity in combination with anthracyclines, 
taxanes and capecitabine.  It would be of clinical value to investigate the addition of 
bevacizumab to taxanes/anthracycline based regimens in patients with locally advanced 
breast cancer.  These regimens have the potential to provide anti-tumor activity with an 
increase in pCR rate. 
The NSABP has a long history of conducting clinical trials evaluating pre-operative or 
primary chemotherapy in the treatment of patients with operable breast cancer.  The 
proposed trial represents the next logical step in the evolution of this treatment approach 
and builds on the results of clinical trials and correlative science studies performed by the 
NSABP as well as by other investigators. 
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3.0 STUDY AIMS 
3.1 Primary aims 
 To determine whether the combination of docetaxel/capecitabineAC or 
docetaxel/gemcitabineAC, with or without bevacizumab, will increase the rate of 
pathologic complete response in the breast (pCR breast) relative to docetaxelAC 
with or without bevacizumab. 
 To determine whether the addition of bevacizumab to the docetaxel/anthracycline-
based regimens (docetaxelAC, docetaxel/capecitabineAC, and 
docetaxel/gemcitabineAC) will increase the rate of pCR breast relative to the same 
docetaxel/anthracycline-based regimens without bevacizumab. 
3.2 Secondary aims 
 To determine whether the combination of docetaxel/capecitabineAC or 
docetaxel/gemcitabineAC, with or without bevacizumab, will increase the rate of 
pathologic complete response in both the breast and all post-therapy lymph nodes 
evaluated histologically (pCR breast and nodes) relative to docetaxelAC with or 
without bevacizumab. 
 To determine whether the addition of bevacizumab to the docetaxel/anthracycline-
based regimens (docetaxelAC, docetaxel/capecitabineAC, and 
docetaxel/gemcitabineAC) will increase the rate of pCR breast and nodes relative 
to the same docetaxel/anthracycline-based regimens without bevacizumab. 
 To determine whether the addition of capecitabine or gemcitabine to docetaxel, with 
or without bevacizumab, will increase the rate of clinical overall response (cOR) of 
primary breast cancers relative to docetaxel alone with or without bevacizumab. 
 To determine whether the addition of bevacizumab to the docetaxel/anthracycline-
based regimens (docetaxelAC, docetaxel/capecitabineAC, and 
docetaxel/gemcitabineAC) will increase the rate of cOR of primary breast cancers 
relative to the same docetaxel/anthracycline-based regimens without bevacizumab. 
 To determine whether the addition of capecitabine or gemcitabine to docetaxel, with 
or without bevacizumab, will increase the rate of clinical complete response (cCR) of 
primary breast cancers relative to docetaxel alone with or without bevacizumab. 
 To determine whether the addition of bevacizumab to the docetaxel/anthracycline-
based regimens (docetaxelAC, docetaxel/capecitabineAC, and 
docetaxel/gemcitabineAC) will increase the rate of cCR of primary breast cancers 
relative to the same docetaxel/anthracycline-based regimens without bevacizumab. 
 
 To identify gene expression profiles that can predict pCR with each of the sequential 
docetaxel/anthracycline-based regimens with or without bevacizumab. 
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 To identify gene expression profiles that can predict cOR with docetaxel alone, 
docetaxel/capecitabine, and docetaxel/gemcitabine with or without bevacizumab. 
 
 To test the accuracy of an in vitro chemoresponse assay (ChemoFx®, Precision 
Therapeutics, Inc.) as a predictor of pCR with each of the sequential 
docetaxel/anthracycline-based regimens when administered without bevacizumab. 
 
 To test the accuracy of an in vitro chemoresponse assay (ChemoFx®, Precision 
Therapeutics, Inc.) as a predictor of cOR with docetaxel alone, 
docetaxel/capecitabine, and docetaxel/gemcitabine when administered without 
bevacizumab. 
 To determine the impact of preoperative bevacizumab and sequential chemotherapy 
regimens and postoperative bevacizumab therapy on cardiac function. 
 To determine the impact of bevacizumab on surgical complications. 
 To determine the toxicity of the preoperative regimens and the toxicity of 
postoperative bevacizumab employed in this trial. 
 To determine whether the addition of bevacizumab to the docetaxel/anthracycline-
based regimens (docetaxelAC, docetaxel/capecitabineAC and 
docetaxel/gemcitabineAC) will increase disease-free survival (DFS) relative to the 
same docetaxel/anthracycline-based regimens without bevacizumab. 
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4.0 STUDY ENDPOINTS 
4.1 Primary endpoint 
The primary endpoint is pathologic complete response of the primary tumor in the breast 
(pCR breast).  This is defined as no histologic evidence of invasive tumor cells in the 
breast specimen removed at surgery. 
4.2 Secondary endpoints 
 pCR breast and nodes defined as no histologic evidence of invasive tumor cells in the 
breast specimen or the regional lymph nodes removed at surgery.  Regional lymph 
nodes include axillary nodes (both sentinel and non-sentinel) and non-axillary 
sentinel nodes. 
 
 cOR following docetaxel alone, docetaxel/capecitabine, and docetaxel/gemcitabine, 
with or without bevacizumab, as assessed by physical exam at the completion of the 
docetaxel-based portion of the chemotherapy program. If either cCR or clinical 
partial response (cPR) is identified at that time, the patient would be considered to 
have cOR following the docetaxel-based therapy, with or without bevacizumab (see 
Section 12.1.4 for definitions of cCR and cPR). 
 cOR following the entire sequential chemotherapy program as assessed by physical 
exam at the completion of the sequential chemotherapy regimens.  If either cCR or 
cPR is identified at that time, the patient would be considered to have a cOR 
following docetaxel-based therapy followed by AC, with or without bevacizumab. 
 cCR following docetaxel alone, docetaxel/capecitabine, and docetaxel/gemcitabine, 
with or without bevacizumab, as assessed by physical exam at the completion of the 
sequential chemotherapy regimens. 
 
 cCR following completion of the sequential chemotherapy program as assessed by 
physical exam at the completion of the sequential chemotherapy regimens. 
 The percentage of cardiac events defined as NYHA Class III/IV congestive heart 
failure. 
 
 The percentage of surgical complications (from mastectomy, lumpectomy, and 
axillary staging procedures) defined as: 
 wound dehiscence 
 infection 
 seroma 
 hematoma 
 Toxicities, including cardiac events other than congestive heart failure, of 
chemotherapy alone, bevacizumab with chemotherapy, and bevacizumab alone. 
 Events for the DFS endpoint include local recurrence following mastectomy, local 
recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant 
recurrence, contralateral breast cancer, second primary cancer (other than squamous 
or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, 
colon carcinoma in situ, or lobular carcinoma in situ of the breast), and death from 
any cause prior to recurrence or second primary cancer. 
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5.0 PATIENT ELIGIBILITY AND INELIGIBILITY 
5.1 Patient selection guidelines 
The guidelines in Section 5.1 will not be considered exclusion criteria; however, in 
addition to the formal eligibility/ineligibility criteria in Sections 5.2 and 5.3, investigators 
should consider each of these factors when selecting patients for B-40.  Investigators 
should also consider all other relevant factors (medical and non-medical), as well as the 
risks and benefits of the study therapy when deciding if a patient is appropriate for B-40.  
These considerations should be weighed carefully, as they may make a patient an 
unsuitable candidate for B-40 and may increase risk to the patient. 
 Patients with a life expectancy less than 10 years, excluding her diagnosis of breast 
cancer.  (Comorbid conditions should be taken into consideration, but not the 
diagnosis of breast cancer.) 
 Any patient who intends to have a mastectomy with immediate breast reconstruction 
using tissue expanders, regardless of the clinical response to neoadjuvant therapy, 
must be in agreement with not having expansion performed for 2 weeks prior to the 
first postoperative bevacizumab dose, during bevacizumab, and for at least 6 weeks 
following the last dose of bevacizumab.  (See Section 9.9.2 for further details on 
breast reconstruction.) 
 Women of reproductive potential must agree to use an effective non-hormonal 
method of contraception during therapy and for at least 3 months after completion 
of bevacizumab. 
 Psychiatric or addictive disorders or other conditions that, in the opinion of the 
investigator, would preclude the patient from meeting the study requirements. 
5.2 Conditions for patient eligibility 
Patients who satisfy all of the following conditions are the only patients who will be 
considered eligible for the study: 
5.2.1 The patient must have consented to participate and must have signed and dated 
an appropriate IRB-approved consent form that conforms to federal and 
institutional guidelines for the study treatment and submission of pre-entry core 
biopsy material for correlative studies (see Section 16.1). 
5.2.2 Patients must be female. 
5.2.3 Patients must be 18 years of age or older. 
5.2.4 Patients must have an ECOG performance status of 0 or 1 (see Appendix A). 
5.2.5 The diagnosis of invasive adenocarcinoma of the breast must have been made by 
core needle biopsy. 
5.2.6 The primary breast tumor must be palpable and measure  2.0 cm on physical 
exam. 
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5.2.7 All patients must have their left ventricular ejection fraction (LVEF) assessed by 
MUGA scan or echocardiogram within 3 months prior to study entry.  The LVEF 
must be  the lower limit of normal (LLN) for the cardiac imaging facility 
performing the study.  Note: If the cardiac imaging facility cannot provide a 
LLN, use 50% as the LLN value. 
Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent 
LVEF assessments to determine if bevacizumab therapy can be continued, it is 
critical that this baseline study be an accurate assessment of the patient’s LVEF.  
If the baseline LVEF is  75%, the investigator should have the study reviewed 
for accuracy prior to study entry.  Following study entry, the LVEF 
determination may be reviewed up until the time of the post-chemotherapy 
(preoperative) evaluation.  Please note that if a more accurate value is obtained 
from the review of the baseline MUGA or echocardiogram, the correct value 
must be submitted to the NSABP before the post-chemotherapy (preoperative) 
MUGA or echocardiogram is performed or it cannot be used for managing 
postoperative bevacizumab. 
5.2.8 All patients must have an EKG within 3 months prior to study entry. 
5.2.9 At the time of randomization: 
 Absolute neutrophil count (ANC) must be ≥ 1200/mm3. 
 Platelet count must be ≥ 100,000/mm3. 
 Hemoglobin must be  10 g/dL. 
 There must be evidence of adequate hepatic function by these criteria: 
 Total bilirubin must be ≤ the ULN for the lab unless the patient has a 
grade 1 bilirubin elevation ( ULN to 1.5 x ULN) resulting from 
Gilbert’s disease or similar syndrome due to slow conjugation of 
bilirubin; and 
 Alkaline phosphatase must be ≤ 2.5 x ULN for the lab (refer to Sections 
5.2.10 and 5.2.11); and 
 AST must be  1.5 x ULN for the lab (refer to Section 5.2.11). 
 Alkaline phosphatase and AST may not both be > the ULN.  For 
example, if the alkaline phosphatase is > the ULN but ≤ 2.5 x ULN, then 
the AST must be ≤ the ULN.  If the AST is > the ULN but  1.5 x ULN, 
then the alkaline phosphatase must be ≤ ULN. 
5.2.10 Patients with either skeletal pain or alkaline phosphatase that is  ULN but  
 2.5 x ULN are eligible for inclusion in the study if bone scans do not 
demonstrate metastatic disease.  Suspicious findings on bone scan must be 
confirmed as benign by x-ray, MRI, or biopsy. 
5.2.11 Patients with AST or alkaline phosphatase  ULN are eligible for inclusion in the 
study if liver imaging does not demonstrate metastatic disease and the 
requirements in criterion 5.2.9 are met. 
5.2.12 The following criteria for evidence of adequate renal function must be met: 
 Serum creatinine  ULN for the lab. 
 Calculated creatinine clearance must be  50 mL/min (see Appendix C). 
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5.2.13 Urine protein/urine creatinine (UPC) ratio must be  1.0 (see Appendix B). 
5.2.14 Patient must be able to swallow oral medications. 
5.3 Conditions for patient ineligibility 
Patients with one or more of the following conditions will be ineligible for this study: 
5.3.1 Tumor determined to be strongly HER2-positive by immunohistochemistry (3+) 
or by fluorescent in situ hybridization (positive for gene amplification). 
5.3.2 Excisional or incisional biopsy for this primary breast tumor. 
5.3.3 Surgical axillary staging procedure prior to study entry.  Exceptions:  1) FNA or 
core biopsy of an axillary node is permitted for any patient, and 2) although not 
recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients 
with clinically negative axillary nodes is permitted.  (See Section 9.9.3 for post-
neoadjuvant therapy axillary staging requirements.) 
5.3.4 Tumors clinically staged as T4. 
5.3.5 Ipsilateral cN2b or cN3 disease.  (Patients with cN1 or cN2a disease are eligible.) 
5.3.6 Definitive clinical or radiologic evidence of metastatic disease. 
5.3.7 Synchronous bilateral breast cancer (invasive or DCIS). 
5.3.8 Treatment including radiation therapy, chemotherapy, biotherapy, and/or 
hormonal therapy for the currently diagnosed breast cancer prior to study entry 
(see Section 9.11). 
5.3.9 Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal 
replacement therapy, etc.  (These patients are eligible if this therapy is 
discontinued prior to randomization.  See Section 9.12.)   
5.3.10 Therapy with any hormonal agent such as raloxifene, tamoxifen, or other 
selective estrogen receptor modulator (SERM), either for osteoporosis or breast 
cancer prevention.  (Patients are eligible only if these medications are 
discontinued prior to randomization.) 
5.3.11 Prior history of breast cancer, including DCIS.  (Patients with a history of LCIS 
are eligible.) 
5.3.12 Prior therapy with anthracyclines, taxanes, capecitabine, 5-FU, gemcitabine, or 
bevacizumab for any malignancy. 
5.3.13 Other malignancies unless the patient is considered to be disease-free for 5 or 
more years prior to randomization and is deemed by her physician to be at low 
risk for recurrence.  Patients with the following cancers are eligible if diagnosed 
and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in 
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situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma 
of the skin. 
5.3.14 Cardiac disease that would preclude the use of anthracyclines.  This includes: 
 angina pectoris that requires the use of anti-anginal medication; 
 history of documented congestive heart failure; 
 serious cardiac arrhythmia requiring medication; 
 severe conduction abnormality; 
 valvular disease with documented cardiac function compromise; and  
 uncontrolled hypertension defined as BP  150/90 on antihypertensive 
therapy.  (Patients with hypertension that is well controlled on medication are 
eligible.) 
5.3.15 History of myocardial infarction documented by elevated cardiac enzymes or 
persistent regional wall abnormalities on assessment of LV function. 
5.3.16 History of TIA or CVA. 
5.3.17 History of other arterial thrombotic event within 12 months before study entry. 
5.3.18 Symptomatic peripheral vascular disease. 
5.3.19 Any significant non-traumatic bleeding within 6 months before study entry. 
5.3.20 Serious or non-healing wound, skin ulcers, or incompletely healed bone fracture. 
5.3.21 Gastroduodenal ulcer(s) determined by endoscopy to be active. 
5.3.22 Invasive procedures defined as follows: 
 Major surgical procedure, open biopsy, or significant traumatic injury within 
28 days prior to planned start of study therapy.  (Note: Placement of a 
vascular access device is not considered a major surgical procedure.  See 
Sections 9.2, 9.4, and 9.6 for instructions regarding initiation of therapy after 
device placement.) 
 Anticipation of need for major surgical procedures (other than the required 
breast surgery) during the course of the study. 
5.3.23 Known bleeding diathesis or coagulopathy.  (Patients on warfarin with an  
in-range INR [usually between 2 and 3] are eligible.) 
5.3.24 Sensory/motor neuropathy  grade 2, as defined by the NCI’s Common 
Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0). 
5.3.25 Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that 
would preclude treatment with any of the treatment regimens or would prevent 
required follow-up. 
5.3.26 Conditions that would prohibit administration of corticosteroids. 
5.3.27 History of severe hypersensitivity reaction to drugs formulated with  
polysorbate 80. 
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5.3.28 Administration of any investigational agents within 30 days before study entry. 
5.3.29 Pregnancy or lactation at the time of proposed randomization.   
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6.0 CARDIAC SAFETY MONITORING 
6.1 Timing of LVEF assessments 
LVEF assessments using the same method (MUGA scan or echocardiogram) are required 
as follows: 
 For all patients: 
 At baseline (prior to study entry) 
 3-4 weeks after the last chemotherapy cycle (before surgery) 
 For patients in Groups 1B, 2B, and 3B: 
 If the LVEF assessment performed following chemotherapy (before surgery) did 
not meet criteria to administer postoperative bevacizumab (see Section 11.2 
[Table 28]), the LVEF assessment must be repeated 3-5 weeks following 
surgery.  If the postoperative LVEF assessment met criteria to initiate 
bevacizumab, an additional LVEF assessment must be performed after  
4 postoperative doses of bevacizumab. 
 At 18 months following study entry for patients who received any bevacizumab 
(before or after surgery). 
6.2 Important LVEF assessment guidelines 
 All LVEF assessments must be performed by the same method, either MUGA 
scan or echocardiogram, that was performed at baseline (before study entry). 
 Investigators are strongly urged to schedule the LVEF assessment at the same cardiac 
imaging facility where the patient's baseline LVEF assessment was done.  Note: If the 
cardiac imaging facility cannot provide a LLN, use 50% as the LLN value. 
 Submission of the LVEF report form (Form LVA) with the LVEF assessment 
(MUGA scan or echocardiogram) report attached is required.  Please submit all 
LVEF evaluation forms within 4 weeks after the LVEF assessment to the NSABP 
Biostatistical Center (see the B-40 section of the NSABP Web site for submission 
instructions).  For all patients, regardless of treatment assignment, Form LVA must 
be submitted for every MUGA scan or echocardiogram done for any reason until  
2 years following study entry. 
 LVEF assessment and submission of Form LVA with the MUGA scan or 
echocardiogram report continue to be required even if the patient has had any of the 
following: 
 discontinuation of study therapy 
 congestive heart failure (CHF) 
 breast cancer recurrence 
 second primary cancer 
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6.3 Reporting cardiac events 
 Cardiac events will be graded utilizing CTCAE v3.0. 
 Left ventricular systolic dysfunction and left ventricular diastolic dysfunction  
 grade 3 requires expedited adverse event reporting via AdEERS (see  
Section 14.2.2).  Also submit Form LVA and the MUGA scan or echocardiogram 
report, if applicable.  (See Section 14.0 for additional adverse event reporting 
requirements.) 
 Other cardiac events will be reported according to routine and expedited reporting 
instructions in Section 14.0. 
6.4 Reporting cardiac history 
Cardiac history and risk factors will be collected for all patients at baseline. 
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7.0 REQUIRED ENTRY AND FOLLOW-UP STUDIES 
TABLE 5.  Studies required for study entry and during preoperative therapy 
Required studiesa Prior to study entry (within 4 wks unless indicated otherwise) 
Within 72 hrs of Day 1 of  
Each Pre-op Therapy Cycle 
(beginning with Cycle 2) 
Between 
chemotherapy
regimens 
Prior to surgery 
3-4 wks after last  
chemotherapy dose 
History & physical examb X (within 3 months) X  X 
Height (baseline only) and weight X X   
BP & anti-HTN meds assessment X X   
Cardiac history X    
Tumor assessment by physical examc X X (recommended) X X 
Measurement of target lesion(s) X    Xd      Xd,e 
Adverse event assessment  X  Xf 
CBC/differential/platelet count X X  X 
Serum creatinine X X (before cycles 3, 5, and 7)  X 
Calculated creatinine clearance X X (only Groups 2A and 2B)g   
Urine protein/creatinine (UPC) ratioh X X (before cycles 3 and 5; only Groups 1B, 2B, and 3B)i   
Bilirubin/AST/Alkaline phosphatase X X (before cycles 3, 5, and 7)  X 
Serum hCG (women of childbearing potential) X (within 2 weeks)    
Chest CT or chest x-ray (PA and lateral)j X (within 3 months)    
Liver imagingj   Xk    
Bone scanj   Xl    
MUGA or echocardiogramm X (within 3 months)n   X 
EKG X (within 3 months)    
Bilateral breast imaging   Xo,p   X (ipsilateral)o 
Ultrasound of ipsilateral axilla Xq    
Marking of primary tumor site Xr 
(before or after entry but before 
therapy begins)    
Core biopsy tissue for submission X (primary tumor)s    
Blood/serum collectiont X (after entry - before therapy begins) X (serum only; before cycle 3 of docetaxel-based regimen)  X (serum only) 
a H&P, bloodwork, x-rays, scans, and other testing may be performed more frequently at the discretion of the investigator. 
b Complete H&P including performance status (see Appendix A) prior to study entry; targeted assessment at remaining timepoints (physician or other healthcare professional). 
c Includes assessment of the primary breast tumor and palpable regional lymph nodes. 
d Required tumor measurement for evaluation of clinical response. 
e Surgery should be performed after recovery from chemotherapy, clinical tumor assessment, and preop LVEF assessment.  (See Section 9.9.2 regarding timing of surgery for Groups 1B, 2B, & 3B.) 
f Final AE assessment for preoperative therapy should be performed 3-4 weeks after completion of preoperative therapy (before surgery).  See Table 31 (footnote c) and Table 32 (footnote b) for 
expedited reporting requirements for AEs that occur  30 days. 
g Only if serum creatinine is  grade 2 at any time during treatment with capecitabine. 
h See Appendix B for calculation of UPC ratio. 
i For patients who permanently discontinue bevacizumab prior to surgery: If UPC ratio was  1.0 at last assessment during bevacizumab, repeat UPC ratio every 3 months for 12 months after the last 
dose of bevacizumab.  If the UPC ratio improves to  1.0 before 12 months, no additional UPC ratios are required. 
j PET scan is permitted as an alternative to CT scans of the chest and abdomen and bone scan to rule out metastatic disease.  Canadian investigators: Refer to Section 16.2 for regulatory requirements 
related to PET scan. 
k Liver imaging is required if alkaline phosphatase or AST is  ULN. 
l Bone scan is required if alkaline phosphatase is  ULN or if the patient has unexplained bone pain. 
m The same method of LVEF assessment (MUGA scan or echocardiogram) must be performed at each time point.  If possible, all LVEF assessments should be performed at the same facility. 
n If LVEF is  75%, the investigator should consider having the LVEF assessment result reviewed prior to study entry (see Section 5.2.7). 
o MRI is permitted as a substitute for mammogram (ultrasound is not) at baseline and before surgery; all other assessments must be performed by mammogram. 
p Ipsilateral within 6 months; contralateral within 12 months. 
q Strongly recommended to assist in planning the axillary staging procedure.  If abnormal, FNA is recommended (see Section 9.9.3). 
r Clip placement, tattoo, or other method of marking the primary tumor site should be done before therapy begins (see Section 9.9.1). 
s Study entry requirement for all patients; includes cores in formalin, RNAlater, and shipping medium for PTI; ship to Precision Therapeutics, Inc. (see Sections 8.1 and 8.6.) 
t For patients who have consented to blood/serum submission (see Section 8.8). 
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TABLE 6.  Studies required after surgery and during follow-up (all patients); during postoperative bevacizumab (Groups 1B, 2B, and 3B) 
Patients in Groups 1B, 2B, and 3B 
All patients If postop bevacizumab is 
anticipated 
If postop bevacizumab is 
re-initiatedb 
All patients 
Required studiesa 
3–5 weeks 
postop 
At 9 months 
following 
study entry 
At 12 months 
following 
study entry 
Before re-initiating 
bevacizumab 
During Postop 
Bevacizumab 
Every 6 weeks 
At 18 months 
following 
study entry 
Years 2 through 5 
Following study entry 
Years 6 through 10 
Following study 
entry 
Updated history & physical examc X   Xd X   Xe X   X (every 6 months) X (every 12 months) 
Weight    X X    
BP & anti-HTN meds assessment    X   Xf    
Adverse event assessment Xg     Xd,g   Xg    Xh    
CBC/differential/platelet count    X     
Urine protein/creatinine (UPC) ratioi    X   Xj  Xj  
Serum creatinine    X     
Bilirubin/AST/Alkaline phosphatase    X     
MUGA or echocardiogramk    X (3-5 weeks postop)l   Xm Xn   
Mammogramo   Xp      X (every 12 months) X (every 12 months) 
Tumor block collection Xq        
a H&P, bloodwork, x-rays, scans, and other testing may be performed more frequently at the discretion of the investigator. 
b For patients in Groups 1B, 2B, and 3B who will NOT re-initiate bevacizumab postoperatively, bevacizumab-related studies are not required. 
c Targeted/updated assessment by physician or other healthcare professional. 
d At this time point, it is preferred that patients have an exam that includes assessment of adverse events related to surgery.  However, if an exam is not possible, the AE assessment at 
this time point can be based on notes and other source documentation from other physicians (for example, surgeon, radiation oncologist, or primary care physician) and by telephone 
contact with the patient. 
e If initiation of postoperative bevacizumab is delayed  6 weeks after the most recent postoperative exam, a repeat assessment should be performed within 10 days of initiation of 
postoperative bevacizumab. 
f BP required every 3 weeks prior to each postoperative bevacizumab dose. 
g Assessment of adverse events related to surgery. 
h Final AE assessment 30 days after last bevacizumab dose; assessment may be based on office notes from other physician visits or telephone contact with the patient. 
i See Appendix B for UPC ratio instructions. 
j For Groups 1B, 2B, and 3B patients who had a UPC ratio  1.0 at the last assessment during bevacizumab, repeat every 3 months for 12 months after the last dose of 
bevacizumab.  If the UPC ratio improves to  1.0 before 12 months, no additional UPC ratios are required. 
k The same method of LVEF assessment (MUGA scan or echocardiogram) must be performed at each time point.  If possible, all LVEF assessments should be performed at the 
same facility. 
l LVEF assessment must be performed at this time point ONLY if the LVEF obtained after chemotherapy (before surgery) did not meet requirements for initiating postoperative 
bevacizumab (see Section 11.2 [Table 28]). 
m LVEF assessment must be performed after 4 postoperative doses of bevacizumab ONLY if an LVEF assessment was required at 3-5 weeks after surgery (because the assessment 
performed following chemotherapy [before surgery] did not meet criteria to administer postoperative bevacizumab) and the postop assessment met LVEF criteria to initiate 
postoperative bevacizumab (see Section 11.2 [Table 28]). 
n Required for all Group 1B, 2B, and 3B patients who have received any bevacizumab, even if the patient has not received any postoperative bevacizumab.  For patients whose last 
dose of bevacizumab was administered  4 weeks prior to 18 months following study entry, the 18-month LVEF assessment should be delayed until 4 weeks after the last dose. 
o MRI is not permitted as a substitute for mammogram. 
p Ipsilateral or contralateral mammogram is required every 12 months; specific timing of the first postoperative mammogram depends on the timing of the pre-entry and pre-op 
mammograms. 
q Blocks from tumor and positive node (if gross residual disease  1 cm) are required (see Section 8.7).  Reminder: Histopathology findings must be submitted on Form RCB for 
ALL B-40 patients enrolled after local IRB approval of Amendment #2 for use by the NSABP Biostatistical Center in calculating the RCB index (see Section 8.4). 
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8.0 PATHOLOGY AND CORRELATIVE STUDIES 
8.1 Summary of pathology-related requirements (also see Sections 8.4 and 8.6-8.8) 
NSABP B-40 requires the collection and submission of tumor and blood/serum samples 
and histopathology findings. 
 A total of 4 core biopsy samples will be collected from the primary tumor prior to 
randomization.  These tumor samples are required for B-40 study entry. 
 One core biopsy sample will be collected in RNAlater  
 One core biopsy sample will be collected in formalin  
 Two core biopsy samples will be collected in tissue culture transport medium for 
Precision Therapeutics, Inc. (referred to as shipping medium for PTI throughout 
the protocol) 
 Representative block(s) of gross residual disease  1 cm must be submitted to the 
NSABP following definitive surgery.  See Section 8.7 for specific requirements.  
These samples are required. 
 Histopathology findings to calculate residual cancer burden (RCB) must be provided 
by the pathologist who reviewed the case.  See Section 8.4. 
 Three serial blood/serum collections are required elements of the study, unless a 
patient refuses to have these specimens collected and submitted to the NSABP.  
Such patients may still participate in the trial.  Specimens are to be collected at the 
following times: 
 At baseline before chemotherapy (blood and serum) 
 Before the 3rd cycle of T (docetaxel), TCape (docetaxel/capecitabine), or TG 
(docetaxel/gemcitabine) (serum) 
 At the completion of chemotherapy but before surgery (serum) 
Non-submission of required tissue or blood/serum samples will be a protocol violation 
(unless, for the blood/serum collections, a patient has not consented to collection, use, 
and storage of her samples). 
NOTE: The tissue and blood/serum samples collected in this study will be used for B-40 
studies as described in Section 8.2. DNA extracted from blood specimens will be used 
specifically to examine the role of gene polymorphism on response to chemotherapy and 
toxicity.  The specimens procured, including DNA samples, will not be used for hereditary 
genetic studies involving genes conferring susceptibility to cancer or other diseases.  Central 
review of a patient’s tumor pathology and markers examined will not be reported to the 
patient or her physician and will not have any bearing on her treatment. 
All pretreatment core biopsy samples are to be submitted in a single shipping kit to 
Precision Therapeutics, Inc. (PTI) (refer to Information Resources, page v).  Tissue 
samples in RNAlater and formalin are subsequently forwarded to the NSABP Division of 
Pathology. All biopsy samples will be identified by the PTI Control Number (a unique 
coded number provided by the NSABP Biostatistical Center). 
Submitted slides and blocks from the definitive surgery are initially shipped to and 
logged into the database at the NSABP Biostatistical Center (refer to Information 
Resources, page v).  These samples are then stripped of patient identifiers except NSABP 
Patient ID numbers and forwarded to the NSABP Division of Pathology where they are 
assigned a code number for further processing and study.  Tissue microarrays of 1 mm 
cores will be constructed from collected blocks from residual tumors. 
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Blood/serum samples are to be submitted to the NSABP Serum Bank at Baylor where 
they are logged into the database and assigned a Serum Bank number.  Blood/serum 
samples are stripped of patient identifiers, except the NSABP Patient ID numbers, and 
are processed and stored. 
TABLE 7.  Summary of B-40 pathology-related requirements 
At the time of definitive surgery 
 
Pre-entry 
After study 
entry before 
therapy 
begins 
Prior to  
cycle 3 of  
T, TCape, or 
TG regimen 
At least 3 weeks 
following last 
chemotherapy 
dose 
(before surgery) 
No gross 
residual disease 
or gross residual 
disease  1 cm 
Gross residual 
disease  1 cm 
Core biopsy 
tissue in 
RNAlater 
1 corea No No No No No 
Core biopsy 
tissue in 
formalin 
1 corea No No No No No 
Core biopsy 
tissue in 
shipping 
medium for 
PTI 
2 coresa No No No No No 
Paraffin 
blocks No No No No No 
Representative 
blocks of 
residual tumor 
and the node 
with the largest 
focus of 
metastasisb 
Pathology 
information 
needed for 
RCB index 
No No No No Yesc Yesc 
Diagnostic  
H & E slides No No No No No No 
Blood/serum No Yesd Yesd,e Yesd,e No No 
a Biopsy tissue must be collected before study entry.  All cores must be from the primary tumor and will be 
 submitted in the same shipping kit.  (For core biopsy specimen procurement, follow instructions provided with 
 the Precision Therapeutics, Inc. specimen collection kit or the B-40 Pathology Instructions.*) 
b Alternative submission – 2 mm core sampling of an existing tumor block plus 20-30 unstained sections (mounted 
 on charged slides) from both tumor and positive node. 
c Histopathology findings must be submitted for ALL B-40 patients enrolled after local IRB approval of Amendment 
#2 for use by the NSABP Biostatistical Center in calculating RCB index.  See Section 8.4. 
d For patients who have consented to blood/serum collection. 
e Only serum. 
* PLEASE NOTE: Refer to the Members' Area of the NSABP Web site for the B-40 Pathology Instructions.  
 (CTSU investigators should refer to Section 3.0 in Appendix F and to the B-40 Web page located on the CTSU 
 Registered Member Web site for the B-40 Pathology Instructions.) 
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8.2 Scientific and clinical rationale for pathology and correlative science studies  
8.2.1 Predictive markers – needs and barriers to development 
In an ideal situation, physicians would base the treatment of patients on 
individual risk prediction using precise prognostic factors, and select specific 
treatments based on accurate predictive markers for therapeutic response.  
Results from NSABP Protocol B-18 and other published studies clearly suggest 
that only a subset of patients with early breast cancer derive benefit from a 
specific chemotherapy regimen. 
Data from NSABP B-11, B-15, and B-20 suggest that the response to 
chemotherapy may be determined by molecular changes in the tumor  
cells.128-130  Development of a panel of molecular markers that would predict 
complete response to specific chemotherapeutic agents would improve the 
overall effectiveness of adjuvant therapy by tailoring treatments for individuals 
based on responsiveness of their disease to specific regimens. 
While there have been advances in development of prognostic markers, little 
progress has been made in defining predictive markers for response to specific 
chemotherapy regimens, or response to chemotherapy in general.  There are two 
main reasons for this lack of progress in developing these markers.  First, 
discovery tools that could be applied to clinical specimens initially were limited 
or too expensive.  This problem has been largely resolved with the development 
of gene expression microarrays that allow interrogation of the entire human 
transcriptome at once.131  However, a more serious problem remains unresolved, 
which is the limitation in statistical power inherent in utilizing materials from 
adjuvant trials to study predictive markers.  For studies addressing predictive 
markers (marker-by-treatment interaction), as many as four times the event rate is 
required to have the same statistical power as is needed in addressing treatment 
effect.132  For example, in a hypothetical situation in which 1300 patients are 
randomized equally to two adjuvant treatment arms with the expected total 
number of events being 425, the power to detect a hazard ratio of 1.5 between the 
two treatments would be 99%.  With a hypothetical marker prevalence of 23% 
(similar to HER2), and assuming all tumor blocks would be available for assay, 
the power to detect a hazard ratio of 1.5 between marker-negative versus marker-
positive cohorts (thus, this marker being a prognostic factor) would be reduced to 
73%.  For detection of marker-by treatment interaction, the power to detect a 
hazard ratio of 1.5 would be decreased to 47%.  Therefore, studies utilizing 
specimens procured through Phase III adjuvant treatment trials are generally 
seriously underpowered to address marker-by-treatment interactions. 
8.2.2 Neoadjuvant setting provides solutions  
Neoadjuvant studies provide a unique setting in which molecular measurement in 
the tumor tissue before therapy can be correlated with in-situ response of tumor 
to chemotherapy.  The most objective measurement of tumor response in 
neoadjuvant trials is pathologic complete response (pCR).  Previous studies 
including NSABP Protocols B-18 and B-27 have demonstrated the value of pCR 
as a surrogate marker for clinical outcome measures.36,133 
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There are two major advantages in using pCR as a surrogate endpoint for marker 
analysis.  First, long-term clinical follow-up is not required.  The second reason, 
which is not widely recognized, is statistical.  When using materials collected 
from an adjuvant trial, marker-by-treatment analysis is usually severely 
underpowered as described above.  In the neoadjuvant setting, direct correlation 
with pCR rather than serial follow-up data, provides much greater statistical 
power for marker studies. 
8.2.3 Justification for not using a survival endpoint as primary endpoint 
In NSABP B-27, the doxorubicin/cyclophosphamide (AC) followed by docetaxel 
(T) arm had twice the rate of pCR compared to the AC arm.36  While this result 
is exciting, it does not appear to correlate well with the small absolute benefit 
demonstrated in adjuvant trials such as NSABP B-28 for similar sequential 
taxane regimens.  However, a simple mathematical calculation using survival 
estimates from cohorts in NSABP B-18 illustrates that doubling of the pCR rate 
may not translate into a large increase in the survival rate. 
Figure 2. B-18 data prediction for survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This dichotomy between adjuvant and neoadjuvant clinical trial data is most 
likely due to the fact that the average survival of non-pCR patients is still fairly 
good due to the contamination of this group with inherently good prognosis 
patients such as those with ER-positive tumors with a low proliferation rate 
which are known to have a low pCR rate.  More recently, in the retrospective 
analysis of NSABP B-20 cases, we found that low risk groups as defined by the 
OncotypeDx assay gain minimum benefit from chemotherapy in support of this 
notion.134  Ideally, patients with such a favorable prognosis who do not tend to 
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completely respond to chemotherapy should be left out of neoadjuvant studies.  
However, at present they do not confound our aim of evaluating predictive 
markers in this study even if they are included. 
In summary, continued pursuit of survival endpoints in neoadjuvant trials 
obviates the inherent advantages of this neoadjuvant clinical trial model now that 
correlation of pCR with favorable long-term outcome has been established.  For 
this reason, coupled with the clinical justifications outlined in Section 2.2.5, we 
will use pCR as the primary endpoint. 
8.2.4 Hypotheses to be tested 
 We hypothesize that we can use gene expression profiling techniques such as 
the Affymetrix GeneChip or RT-PCR assays to identify a set of genes that 
correlate with pCR to each treatment regimen used in this study. 
 
 We hypothesize that an in vitro chemoresponse assay (ChemoFx® assay) can 
be used to predict tumor response to each regimen. The dose-response curves 
produced by the ChemoFx® assay from core biopsies before treatment will 
enable the identification of patients who will achieve a clinical response after 
treatment with T, TCape, TG (without bevacizumab).  Further, for each arm 
of the trial, pCR can be predicted utilizing the dose-response curves; one for 
T, TCape, or TG treatment, and a second for AC (all without bevacizumab) 
depending on the patient’s regimen.  Further exploratory analysis will be 
conducted for subgroups with bevacizumab, for example, T and TBev, 
TCape and TCapeBev, TG and TGBev, and AC and ACBev to quantify how 
the prediction is or is not affected by addition of bevacizumab. 
 We hypothesize that there are serum proteins that can be used to predict pCR 
at earlier cycles of treatment.  A proteomics approach will be used to identify 
such markers. 
 
 We hypothesize that polymorphisms in specific genes may influence tumor 
response and toxicity.  We will perform a focused survey of candidate genes 
as well as a general survey of all genes in order to identify such polymorphic 
markers. 
 
8.2.5 Rationale for each marker, technical feasibility and preliminary data 
Response to chemotherapy is thought to be predicated on a combination of 
complex factors such as the anticancer effectiveness of the drug (drug factors), 
tumor cell sensitivity or resistance, which includes the tumor's expression of drug 
targets and other proteins such as p-glycoprotein drug (tumor factors), physical 
delivery of the drug to the tumor as well as the body's ability to effectively 
metabolize and clear the drug (host factors).135  Very few tools are available to 
the clinician to incorporate tumor factors or host factors into the choice of 
chemotherapy and dosage regimen, even though it is hypothesized that these 
factors dictate a major part of a patient's response to chemotherapy, future health, 
and survival.   
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In this study, we will examine tumor molecular characteristics, cellular response 
to chemotherapy in vitro, and host characteristics that may influence 
chemotherapy response.  The rationale for each study component and currently 
available data in support of such studies are described in this section.  Since there 
is rapid progress in the field of genomics, especially in methodological aspects, 
the actual conduct of many of the listed molecular studies will be based upon 
funding and available technologies at the conclusion of accrual.  Any unused 
materials will be stored permanently for future studies related to the study aims 
of the B-40 protocol – this will allow us to further develop/enhance predictive 
tests using improved technologies that will be developed in the future.  
 Gene expression analysis – available data from other published microarray 
studies in support of the proposed gene expression profiling study  
 
There are two studies that have used microarray-based gene expression 
analysis to identify predictive markers for pCR with pre-operative 
chemotherapy.  Both are small exploratory studies, but they suggest that the 
approach we are proposing may provide valuable information. 
The first study was by Chang et al from the Baylor College of Medicine 
Breast Center.136  Using the Affymetrix GeneChip, the investigators 
examined a handful of cases treated preoperatively with docetaxel.  Due to 
the small number of cases, they attempted to identify genes that correlated 
with the degree of pathologic response rather than pCR.  Differential patterns 
of expression of 92 genes correlated with docetaxel response (p=0.001).  In 
leave-one-out cross validation analysis, 10 of 11 sensitive tumors (90% 
specificity) and 11 of 13 resistant tumors (85% sensitivity) were correctly 
classified, with an accuracy of 88%.  This 92-gene predictor had positive and 
negative predictive values of 92% and 83%, respectively.  
Ayers et al from MD Anderson recently reported their analysis of 45 cases 
treated with pre-operative paclitaxel (+/- trastuzumab) plus the FAC 
regimen.2  Using FNA specimens procured in RNAlater, they were able to 
identify a set of genes that correlated with pCR in the initial training set of 24 
cases and were able to validate them using an additional 21 cases.  The 
predictive value of the gene expression pattern was 75% for all 21 patients 
and 100% when only those not getting trastuzumab were considered.  From 
this study, the investigators identified Tau protein as a candidate predictive 
marker for response to the paclitaxel-based regimen.  An 
immunohistochemistry assay was developed for tissue in paraffin blocks.137  
We will utilize specimens collected in the B-40 trial to validate Tau as a 
predictor of response to our taxane regimen.  These two studies, although 
having a small sample size, provide solid support for the proposed correlative 
science studies for this trial. 
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 NSABP experiences from the NSABP Foundation Research Program GET 
Trial (FB-GE-001) 
 
Two critical aspects need to be satisfied before launching a large scale 
clinical study such as this one.  First, a specimen procurement method to 
allow easy procurement at the multiple sites needs to be established.  
The ideal method of tissue procurement and long-term storage is snap-
freezing in liquid nitrogen.  However, the logistical limitations of a multi-
center trial require a more pragmatic approach for tissue procurement.  We 
have developed and tested a simple tissue procurement kit using RNAlater 
(Ambion).  RNAlater is a non-toxic, non-flammable, high-salt solution that 
allows procurement of tissue at room temperature.  It has been shown that 
RNA is stable without degradation for a week in RNAlater, even when tissue 
is stored at room temperature.138,139  Two studies have demonstrated the 
value of RNAlater in preserving good quality RNA in core biopsy and FNA 
specimens of breast cancer.140,141  The median yield of total RNA from 
RNAlater-fixed single 14-gauge core biopsy specimens was 1.34 and  
2.0 micrograms in studies performed at the Lombardi Cancer Center and MD 
Anderson Cancer Center, respectively.140,141  The success rate for getting a 
sufficient amount of good quality RNA was 92% and 75%, respectively, in 
these two studies. 
We have finished a pilot study of procuring core biopsy specimens in 
RNAlater from multiple institutions as part of a Phase II trial (GET) in 
locally advanced breast cancer conducted by the NSABP Foundation 
Research Program.  The trial had a sample size of 76 with a 100% 
procurement rate, using a shipping kit developed in the NSABP Division of 
Pathology.  In the GET trial, we were able to extract high quality total RNA 
from most of the core biopsies procured in RNAlater that were received from 
participating member sites using the in-house developed kits.  
The case illustrated in Figure 3 is from the NSABP GET trial.  Note clearly 
visible 18S and 28S ribosomal bands in the RNAlater sample as compared to 
highly degraded RNA extracted from the paraffin block. 
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Figure 3. Quality of RNA extracted from tissue procured in RNAlater versus same  
  tissue fixed in formalin and embedded in paraffin 
 
The second important aspect is the demonstration of the ability to amplify the 
RNA without losing the original representation of relative mRNA quantity in the 
samples.  In the GET pilot study, we tested the use of the Ovation RNA 
amplification and labeling kit (Nugen Technologies, San Carlos, CA) for 
Affymetrix GeneChip assays.  Using 9 nanograms of starting RNA extracted 
from core biopsies collected in RNAlater, we were able to identify 2698 genes 
that are differentially expressed between ER-positive and ER-negative cases 
(defined by member reported IHC assays).  The top gene was the estrogen-
receptor gene with geometric means of 1650 vs 146 in ER-positive and -negative 
cases, respectively.  As expected, other genes that were also found to be highly 
significant were GATA3 (335 vs 72), and HER4 (534 vs 82) as expected.  Using 
the Biometrics Research Branch (BRB) Array Tools and Prediction Analysis of 
Microarray (PAM), we tested the accuracy of a predictive model for estrogen 
receptor status based on gene expression levels with leave-one-out cross 
validation.141  Accuracy of 82% to 86% was obtained.  One example based on 
the Support Vector Machine is shown in Table 8.142  Considering the known 
misclassification rate of clinical ER immunohistochemistry assays performed by 
the NSABP member institutions (20% false-negative rate when compared to 
central ER assay), this degree of prediction accuracy, together with the 
identification of known genes including estrogen-receptor and GATA3, confirm 
our ability to conduct a microarray-based study using the Ovation RNA 
amplification protocol with total RNA extracted from core biopsies collected in 
RNAlater.143 
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TABLE 8.  Performance of the Support Vector Machine Classifier for ER 
Class Sensitivity Specificity PPV NPV 
N 0.833 0.829 0.806 0.853 
P 0.829 0.833 0.853 0.806 
 
The Significance Analysis of Microarray (SAM) also identified 278 genes 
differentially expressed between those cases with pCR vs non-pCR to the 
GET regimen with a false discovery rate of 0.0995.144  Among these genes, 
144 were also identified as significant by PAM.141  Similar to what has been 
described by Gianni et al using the RT-PCR method, our list includes, 
surprisingly, many immune-related genes.4  It is of interest that Damaria et al 
have observed that pretreatment lymphocytic infiltrate in the tumor was 
minimal in the majority of patients in their neoadjuvant study and showed no 
relationship with clinical response.145  In the patients without tumor 
infiltrating lymphocytes (TILs) before treatment, development of TILs after 
treatment was noted in 0/3 (0%) patients with stable disease, 3/12 (25%) 
patients with clinical partial response, and 4/6 (67%) patients with clinical 
complete response and pathological residual disease.  Therefore, 
immunological processes may influence the response of breast cancer 
patients to neoadjuvant treatment. However, performance of the gene 
expression as a predictor in our leave-one-out cross validation exercise was 
disappointing with accuracy of 62% to 76% with low-positive predictive and 
high-negative predictive value for predicting pCR.  This could be due to the 
fact that pCR rate in the GET study was 25% with a small sample size.  It is 
also possible that limited sampling of the tumor (single core) may not 
provide representative information for the entire tumor.  Regardless, these 
data clearly argue for exploration of complementary approaches for 
discovery of predictive markers for pCR including proteomics and cell-based 
approaches as included in this protocol. 
We have also tested the interbatch and intrabatch reproducibility of the 
Affymetrix GeneChip assay based on the Ovation kit and found it to be 
highly reproducible as shown in Figure 4.  This data is also supported by a 
recent study by Dobbin et al who also found high within-laboratory and 
between-laboratory correlations using frozen tumor tissue.146 
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Figure 4. Reproducibility of GeneChip assay using 9 nanograms of starting RNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
We will be using the RNAlater in this trial to procure pre-treatment core 
biopsy tissue.  While it is not yet clear whether RNAlater-procured tissue 
specimens are a suitable substrate for proteomics platforms, it does provide a 
method for investigators participating in NSABP trials to procure materials 
ideal for planned genomics studies. 
Use of core-biopsy specimens instead of the entire index tumor for gene 
expression profiling requires the potential impact of tumor heterogeneity to 
be addressed.  According to the data from Perou et al samples obtained from 
the same patients (index tumors vs metastasis or pre-chemotherapy vs post-
chemotherapy) always cluster together when compared to samples obtained 
from different patients.131  Two independent studies using either FNA or 
core biopsies in breast cancer have succeeded in demonstrating the feasibility 
of obtaining gene expression profiles potentially predictive of pCR to  
pre-operative therapy.2,136 
 Alternative approaches for gene expression profiling 
While the primary correlative science aim of B-40 is to profile gene 
expression using RNA extracted from tissue procured in RNAlater, ideal 
clinical tests would be the ones that can utilize routinely processed formalin-
fixed paraffin-embedded tissue blocks.  Several methods that allow gene 
expression profiling of many genes using fragmented RNA extracted from 
paraffin blocks have recently been developed.  These include quantitative 
real-time reverse transcription-polymerase chain reaction (QRT-PCR),147 
ASL (cDNA-mediated annealing, selection, extension and ligation),148 and 
microarray-based assays. Once an RNAlater based study yields a meaningful 
result, we will attempt to develop a predictive assay that works with paraffin 
blocks.  The core biopsy procured in formalin will be used for this purpose as 
well as for validation of gene expression profiling data with 
immunohistochemical assays for the estrogen and progesterone receptors, 
and HER2 by fluorescence in situ hybridization (FISH) assay. 
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The NSABP has been involved in the development of one such assay 
(OncotypeDx™ developed by Genomic Health, Inc, Redwood City, CA).129  
Using the method developed by scientists at Genomic Health, Inc., we were 
able to develop a multi-gene prognostic index for patients diagnosed with 
node-negative estrogen receptor-positive breast cancer treated with 
tamoxifen. 
In a subsequent study using blocks available from NSABP Protocol B-20, we 
have observed a statistically significant interaction (p=0.03 for DDFS and 
DFS) between the OncotypeDx assay results and a clinical benefit from 
CMF/MF regimen as shown in Figure 5.134  Patients in the low risk group 
had minimal benefit from chemotherapy whereas those in the high risk group 
had a large benefit.  We do not know whether these data will also be 
applicable to ER-negative or node positive patients or those receiving 
chemotherapy regimens different from those used in B-20.  Validation of this 
result will be important and the B-40 trial, despite the differences in regimens 
used, may provide insight as to the generalizability of this finding from the 
retrospective analysis of B-20. 
Figure 5.  Relative risk of patients receiving chemotherapy in addition to tamoxifen in  
 ER-positive and node negative patients enrolled in the B-20 trial 
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Using the same RT-PCR method, Dr. Luca Gianni’s group at Instituto 
Nazionale Tumori Milan has examined the expression of 384 genes in 89 
pre-treatment core biopsy specimens procured in their neoadjuvant study of 
doxorubicin/paclitaxel x 3 cycles  weekly paclitaxel x 12 cycles.4  They 
found expression of 83 genes that highly correlated with pCR.  The pCR 
correlated with higher expression of proliferation genes (CDC20, E2F1, 
MYBL2, TOPO2A, FBXO5, MCM2, MCM6, CDC25B), higher expression 
of immune-related genes (MCP1, CD68, CTSB, CD18, ILT-2, CD3z, FasL, 
HLA.DPB1), and lower expression of estrogen-related genes (PR, SCUBE2 
(CEGP1), ER, NPD009, GATA3, IGF1R, IRS1).  Protocol B-40 will provide 
a validation set for the latter 83 gene RT-PCR profile using higher quality 
RNA extracted from RNAlater-procured core biopsy tissue as well as paired 
paraffin blocks. 
Some methods (such as the Paradise kit™ from Arcturus Microgenomics or 
the DASL assay from Illumina) have been developed that allow more 
comprehensive gene expression profiling of degraded RNA extracted from 
paraffin blocks using microarray or bead array format.147,148  We are 
currently evaluating these methods using 600 core biopsy paraffin blocks 
collected in NSABP Protocol B-27.2.  If successful, we will have candidate 
predictive markers for AC and ACTaxotere before B-40 finishes accrual.  
B-40 will then provide a validation platform for a B-27.2 gene expression 
study. With the current methods in NSABP Pathology Laboratory, we can 
generate Affymetrix GeneChip data using a single 5 micron thick section 
from paraffin embedded core biopsy from B-27.2. Using RNA amplification 
method (Transplex Whole Transcriptome Amplification method from 
Rubicon Genomics), we are able to get gene expression profiles with over 
85% accuracy in predicting ER status defined by immumohistochemistry. 
Top in the list of genes identified as predictive genes by GeneChip are ER, 
GATA3, Keratin 7 suggesting that this method does work despite the fact 
that the number of genes we find is less than when using RNA extracted 
from RNAlater procured tissue. However, since we are still at an early stage 
of evaluating the feasibility of these methods, we will develop a separate 
protocol with a committed predictive model to validate the findings from  
B-27.2 using specimens collected in the B-40 protocol. 
At this point in time in the evolution of methodology, we have to make sure 
that we procure the most pristine material as logistically possible for gene 
expression studies.  Therefore, procurement of tissue in RNAlater still is 
necessary.  Once we complete the studies described in the B-40 protocol, we 
will be able to determine whether we can reliably predict response to 
chemotherapy using routinely available tissue or whether we will need to 
require RNAlater-procured tissue.   
 ChemoFx® chemoresponse assay 
While chemoresponse assays have shown promise in predicting clinical 
response to chemotherapy, they need to be studied within the context of 
large, prospective clinical trials for more widespread clinical utility and 
adoption.8 
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Viable explant cultures for testing in the ChemoFx® assay have been 
successfully grown in monolayers from a variety of solid tumors, including 
breast and ovarian tumors.  The average assessability rate for breast tumors 
in the ChemoFx® assay is 80%.  In a study of 148 primary, recurrent, or 
metastatic breast cancer specimens, in vitro patterns of response were shown 
to be similar to reported clinical population response rates.  In vitro, 69% of 
the specimens were responsive to the anticancer effects of 
cyclophosphamide, 57% to fluorouracil, 45% to doxorubicin, 39% to 
docetaxel, 27% to paclitaxel, and 36% to gemcitabine.149  Of note, the higher 
response rate noted in vitro in this study for doxorubicin, cyclophosphamide 
and fluorouracil, as compared to docetaxel, paclitaxel and gemcitabine, 
mimics clinical experience with these agents. In addition, when two of the 
agents (doxorubicin and cyclophosphamide) were tested in combination, the 
anticancer effect was additive (88% response rate) compared to the effect of 
either agent when tested alone (48% and 61%, respectively).150  In 
comparison, in the NSABP Protocol B-27, the overall clinical response rate 
after doxorubicin and cyclophosphamide combination treatment was 86%.36 
Similar studies were also performed using ovarian tumors.  In a study of the 
ChemoFx® assay, in vitro response rates to standard therapies (carboplatin, 
cisplatin, paclitaxel, docetaxel) for 268 primary and 15 recurrent ovarian 
tumors were determined and compared to clinical population response rates 
reported in the literature.  In primary ovarian tumors, nearly all in vitro 
results were highly correlative to clinical patterns of response.151  In an 
additional study, more than half of 51 primary ovarian cancer cases evaluated 
responded in vitro to treatment with nonstandard chemotherapy, such as 
cyclophosphamide, doxorubicin, gemcitabine and etoposide.152  In vitro, 
individual tumors demonstrate heterogeneity in responsiveness to both 
standard and nonstandard chemotherapeutic agents for a given tumor type.  
In some instances, in vitro response even differed among agents of the same 
mechanistic drug class for the same patient tumor.153  In light of the 
observed heterogeneity of responsiveness, it is suggested that in vitro 
chemoresponse testing is likely to increase the efficacy of the current 
chemotherapy decision-making process for each individual patient. 
In a retrospective review of 18 patients with late-stage, papillary, serous 
ovarian cancer undergoing 21 episodes of chemotherapy, the ChemoFx® 
assay appeared to predict clinical responsiveness.  The ChemoFx® assay had 
a positive predictive value (PPV) of 63.6% and a negative predictive value 
(NPV) of 100%.  In addition, a survival advantage was noted in patients 
whose tumor cells were ChemoFx® sensitive compared with patients whose 
tumor cells were ChemoFx® resistant.5  More recently, a large, retrospective 
clinical study in ovarian cancer has evaluated the ability of the ChemoFx® 
assay to predict progression-free interval (PFI) in patients with ovarian 
cancer.   Data were collected on 317 ovarian and peritoneal cancer specimens 
tested with the ChemoFx® assay between April 1997 and April 2002.  Of 
those, 256 cases had a partial or exact match between drug(s) assayed and 
those prescribed clinically, and displayed a statistically significant correlation 
between assay prediction of response (sensitive, intermediate, resistant) and 
clinical PFI.  For the 135 cases with an exact match between assay and 
clinical treatment, the hazard ratio (HR) for progression of the assay-resistant 
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group was 2.9 (CI: 1.4 to 6.3; P<0.01) compared to the assay-sensitive group; 
and the HR for the assay-intermediate group compared to the assay-sensitive 
group was 1.7 (CI: 1.2 to 2.5).  The PFI for assay-resistant patients was 9 
months, compared to 14 months for assay-intermediate patients, and “not 
achieved” for assay-sensitive patients.6  In a subsequent analysis of 84 cases 
of primary ovarian cancer treated clinically with platinum-based 
chemotherapy and evaluated in vitro with the ChemoFx® assay with a single 
agent platinum compound, the HR for progression in patients with assay-
predicted platinum resistance was 2.9 times that of patients with non-resistant 
tumors (p=0.007).  In addition, when prediction of response was graded 
(sensitive, intermediate, resistant), the HR of assay-resistant patient tumors 
was 3.6 times that of assay-sensitive patient tumors (p=0.005).  On 
multivariate analysis, the ChemoFx® assay was the strongest independent 
predictor of response when compared to known clinical, prognostic factors 
such as FIGO stage and debulking status (p=0.0006).7   
The reproducibility of the ChemoFx® assay has been evaluated with the use 
of immortalized human cell lines (HTB-77, ovarian adenocarcinoma;  
HTB-19, breast carcinoma; or HTB-26, breast adenocarcinoma; ATCC, 
Manassas, VA, USA).  In brief, each immortalized cell line was subjected to 
a non-overlapping subset of the twenty-one drugs commercially available on 
the ChemoFx® assay.  Percentage cell kill was recorded at each dose for a 
period of 7 months resulting in a minimum of 52 and a maximum of 76 
unique data points for each drug.  The assay was performed by multiple 
clinical laboratory personnel over the course of the reproducibility study.  
The average coefficient of variation of percentage cell kill across drug-dose 
combinations was found to be 18% for drug-dose combinations in which the 
percent reduction in cell survival was greater than 50%.7 
 Proteomics studies 
Susanne Ragg, MD, PhD, Assistant Professor of Pediatrics and Director of 
the Center for Computational Diagnostics, Indiana University, will be the 
coordinator for the proteomics studies. 
Serum protein markers that change early during the course of chemotherapy 
and are predictive of tumor response or toxicity will be extremely useful.  
Although there have been numerous studies demonstrating the potential of 
proteomics approaches, proteomics is still in its infancy, and we may have to 
wait for the field to mature to be able to effectively interrogate samples 
collected in this study to identify desired markers.  Most likely, the sera 
collected in this trial are not going to be the ideal materials for most of the 
demanding discovery oriented proteomics studies.  However, the sera may 
provide samples for validation studies for markers discovered from other 
studies due to expected variations in sample collection and processing in the 
multi-center trial setting.  We will make an effort, however, to collect 
samples at time points that may be most informative.  Picking the right point 
of sampling is tricky, however. Pusztai et al have examined protein changes 
on day 3 of neoadjuvant chemotherapy using Surface-enhanced laser 
desorption/ionization mass spectrometry (SELDI-MS) and found one peak 
that was induced by paclitaxel treatment, and this peak did not correlate with 
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response.154  This could be due to the fact that serum was collected too early 
on day 3 of treatment.  According to studies by Kiang et al and Vogelzang et 
al some serum/plasma markers may rise initially due to acute tumor cytolysis 
and then decline.155,156  Leukemia is probably the best example for utilizing 
risk-adapted therapy.  While it is usually very easy to find the very fast 
responders by following the blast count in the bone marrow, it is much 
harder to predict early who needs more aggressive therapy, and a later time 
point (day 14) has been more informative in this regard.  Since we are not 
sure when is the best timing of sampling to identify the markers, we will 
collect at three time points – before chemotherapy, before the 3rd cycle of T, 
TC, or TG, as well as at the end of chemotherapy. 
 Pharmacogenomics study 
Variation in drug disposition and response among patients is a major concern 
associated with many pharmaceuticals, particularly anticancer agents.135,157  
The clinical relevance of variability is most evident with drugs that have 
narrow therapeutic indices (i.e., the dose used is close to the dose that is 
likely to produce toxicity in most individuals).  Typically, anticancer drugs 
have low therapeutic indices because of their nonspecific cytotoxicity and 
because the doses necessary for optimal eradication of malignant cells are 
often close to those that damage normal cells.  
Every gene contains some level of polymorphism, with single nucleotide 
polymorphisms (SNPs) occurring every 1000–3000 base pairs throughout the 
human genome.  Genetic variations in both normal host tissue and tumor 
tissue can influence the net effects observed following administration of an 
anticancer drug.135,157  Polymorphisms in both host and tumor genes 
regulate drug availability, retention and efflux, determining whether or not 
anticancer drugs can access the tumor.  Polymorphisms occur in enzymes 
that metabolically activate or inactivate drugs both in the systemic circulation 
and within cells.  Variations in genes that control drug transport can alter the 
amount of drug absorbed into the systemic circulation following oral 
administration and across tumor cell membranes.  The tumor genome 
possesses most of the polymorphisms that affect tumor invasiveness and drug 
sensitivity.  The potential mechanistic targets of anticancer drugs are subject 
to polymorphisms and/or mutations that can alter or determine bioactivity.  
Furthermore, genes that control the cellular repair process following insult 
with an anticancer drug can have important variants.  On the other hand, host 
polymorphisms determine the risk of host toxicity (genes such as those that 
encode thiopurine methyltransferase or dihydropyrimidine dehydrogenase), 
with little contribution by the tumor genome.  
The net effect of the genetic variants in normal tissues is regulation of the 
amount of anticancer drug in the bloodstream over time (systemic exposure) 
resulting in altered pharmacological effects and/or toxicity for an individual 
patient.  The net effect of genetic variants in the tumor can have a profound 
influence on efficacy because of their control of both anticancer drug tumor 
concentration and pharmacological events such as receptor binding and 
cellular repair. 
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Numerous studies have demonstrated relationships between the systemic 
pharmacokinetics of anticancer drugs and their effects (primarily toxicity).  
This indicates that polymorphisms in genes that encode crucial drug-
metabolizing enzymes can be relevant clinically.  Table 9 summarizes some 
of the better-characterized polymorphic enzymes that are involved in the 
metabolism of anticancer drugs. 
TABLE  9.  Metabolic enzymes with polymorphisms that might affect the disposition of anticancer drugs135,157 
Metabolic enzyme Potential anticancer drug substrate 
CYP1B1* Estrogen metabolites 
CYP2B6* Cyclophosphamide 
CYP2C8* Paclitaxel 
CYP2C9* Cyclophosphamide 
CYP3A4,5,7* 
Cyclophosphamide, etoposide, teniposide, 
tamoxifen, docetaxel, steroids, ifosfamide, 
paclitaxel, irinotecan, anthracyclines and vinca 
alkaloids 
Aldehyde dehydrogenase (ALDH2) Cyclophosphamide 
Dihydropyrimidine dehydrogenase 5-Fluorouracil and capecitabine 
NAD(P)H:quinone oxidoreductase 1 Mitomycin C 
Thiopurine methyltransferase 6-Mercaptopurin and 6-thioguanine 
UDP-glucuronosyltransferase 1A1 Irinotecan 
Glutathione-S-transferases Carmustine and platinum analogs 
Sulfotransferases Estrogen and tamoxifen 
* Abbreviation: CYP, cytochrome P450.  
 
Genome variability can also influence the targets of anticancer agents. For 
example, genetic variability in enzymes that detoxify, activate and are 
involved in the response to 5-FU can influence the toxicity and efficacy of  
5-FU (and capecitabine).  Individuals who have a polymorphism in the gene 
encoding dihydropyrimidine dehydrogenase (DPD), the 5-FU-detoxification 
enzyme, might have a severe toxicity syndrome because of delayed 
elimination (i.e., high blood concentrations of 5-FU).  As shown in Figure 6, 
the dose of 5-FU tolerated in patients who are homozygous for the mutant 
allele (mut/mut) is substantially less than in those who are homozygous for 
the wild-type allele (wt/wt).  Thymidine phosphorylase (TP) is thought to 
increase the activation of 5-FU and be an angiogenic factor.158  Thus, 5-FU-
based therapy is more efficacious in patients with breast cancer who possess 
high concentrations of TP, compared with similar patients who have lower 
levels of TP. Folates are important co-factors required for binding the active 
metabolite of 5-FU to its target enzyme.  Methylenetetrahydrofolate 
reductase (MTHFR) regulates the metabolism of folates and, thus, a 
polymorphism in the gene encoding MTHFR can influence the efficacy of  
5-FU. An important mechanism that leads to 5-FU cytotoxicity is thought to 
be its inhibition of thymidylate synthase (TS).  The expression of TS is also 
influenced by a polymorphism that is associated with altered efficacy of  
5-FU.159  The human thymidylate synthase gene promoter is polymorphic, 
having either double or triple repeats of a 28-bp sequence.  Park et al have 
examined the correlation between TS gene polymorphism and response to 
capecitabine in advanced colorectal cancer.160  They found that 75% (3/4) of 
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individuals with the S/S variant responded to capecitabine, compared to 8% 
(1/12) and 25% (2/8) of those with the S/L and L/L variants, respectively. 
Figure 6. Effect of genetic variability on the toxicity and efficacy of 5-FU 
 
 
 
Although advances in molecular technology hold promise for reducing the 
cost and effort involved in genotyping individuals, the techniques to 
accurately genotype individuals for specific pharmacogenetic polymorphisms 
remain expensive and specialized, hindering their widespread use. We will 
collect adequate specimens (blood and tumor samples) for future analysis 
and conduct the study when technology becomes more affordable.  
8.3 Recommended processing of tissue at the time of definitive surgery to evaluate pCR  
While we are interested only in pre-treatment tumor and patient characteristics that can 
be used to predict response before we initiate treatment, since the primary endpoint of 
this trial is pCR rate rather than clinical outcome, accurate and reproducible assessment 
of pCR will be important.161  Rates of pCR may fluctuate between trials due to 
variability of the extent of tissue sampling for histopathologic examination at the time of 
definitive surgery.  Less extensive sampling will result in falsely high pCR rates.  
Therefore, a minimum of 10 to 15 paraffin blocks from the initial primary tumor site 
should be examined before assigning a response of pCR (see Appendix E).   
A description of the procedure for tissue processing of breast specimens at MD Anderson 
Cancer Center (MDACC) is provided in Appendix E of this protocol.  Participating 
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institutions will be encouraged to develop procedures which incorporate as many of the 
MDACC elements as is possible within their institution. 
8.4 Residual cancer burden 
Although pCR is a dichotomous variable, in reality, tumor response to chemotherapy is a 
continuous variable with non-response ranging from very small residual tumor burden to 
frankly resistant tumors with progressive disease.  Therefore, continuous measures of 
residual cancer burden (RCB) would be expected to be more predictive of clinical 
outcome than simple dichotomous classification as currently practiced. 
RCB determined from routine pathologic materials may be a significant predictor of 
distant relapse-free survival.162  Pathologic slides and reports were reviewed for 382 
patients who had received neoadjuvant chemotherapy at MD Anderson Cancer Center.  
Residual cancer burden was calculated as a continuous index combining pathologic 
measurements of primary tumor (size and cellularity) and nodal metastases (number and 
size).  RCB was independently prognostic in a multivariate model that included age, pre-
treatment clinical stage, hormone receptor status and hormonal therapy, and pathologic 
response (pCR versus RD) (HR, 2.50, CI, 1.70-3.69, P  0.001).  Although evaluated in 
the independent validation cohort of the MD Anderson study, RCB has not been 
validated in a prospectively designed large multi-institution study. 
Pathologists examining the specimen for pathologic response are required to provide 
information to generate RCB.  This information (listed below) will be collected on Form 
RCB for ALL B-40 patients enrolled after local IRB approval of Amendment #2 and will 
be used by the NSABP Biostatistical Center to calculate the RCB index. 
 size of the tumor bed 
 cellularity of residual primary tumor 
 percentage of DCIS component 
 number of positive nodes 
 size of macrometastasis 
For more information on RCB, refer to the publication by WF Symmans et al162 or 
www.mdanderson.org/breastcancer_RCB.  Appendix 1 of the WF Symmans et al article 
provides detailed pathology methods; note that this appendix is only accessible through 
the online version of the article, published at www.jco.org. 
8.5 Correlative studies aims 
Correlative science aims are as follows: 
 Discover predictive gene expression profiles for pCR to study regimens (TAC, 
TCapeAC, TGAC) using the Affymetrix GeneChip Assay (or other gene 
expression profiling platform that is identified as the best at the time of initiation of 
the marker study). 
 Discover and validate: (1) predictive ChemoFx® dose-response curves for clinical 
overall response (cOR) after treatment with T, TCape, or TG; (2) predictive 
ChemoFx® dose-response curves for pCR including dose-response curves for AC 
and either T, TCape, or TG depending on treatment arm. 
 Validate Genomic Health 21 gene Recurrence Score (OncotypeDx) and Milan 83 
gene predictive expression profile as predictors of pCR to chemotherapy with a 
02/15/08 
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hypothesis that there is an interaction between Recurrence Score and response to 
chemotherapy (higher pCR rate in higher RS category). 
 Validate Tau expression as a marker of pCR (by immunohistochemical assay as well 
as RT-PCR assay). 
 Identify serum markers that may predict pCR when measured early in the course of 
chemotherapy (This will be conducted in collaboration with Dr. Susan Ragg, Indiana 
University.  A separate protocol will be submitted to CTEP/NCI once the proper 
technical platform is decided; however, informed consent for future proteomics 
analyses will be obtained through this protocol.) 
 Identify genetic polymorphisms that correlate with pCR and severe toxicity (blood 
samples are collected for this purpose but a separate protocol will be developed for 
this aim once suitable technology is identified to achieve this aim). 
 Validate residual cancer burden index as a predictor of disease-free survival outcome. 
 
8.5.1 Discover predictive gene expression profiles for pCR to study regimens 
(TAC, TCapeAC, TGAC +/-bevacizumab) 
We will examine the gene expression profiles of pre-treatment core biopsy 
specimens procured in RNAlater using the Affymetrix GeneChip or another array 
platform determined to be best suited for our purpose to build a predictive model 
for pCR to combination regimens used in this protocol, i.e., TAC, TCapeAC 
and TGAC +/- bevacizumab.  Validation of these models will require 
additional trials.  We will also look for the presence of a common set of genes 
that are correlated with response to all regimens in this study to build a general 
predictor of response to chemotherapy. 
Method for the Affymetrix GeneChip 
Core biopsy specimens procured in RNAlater will be stored in a -70°C deep 
freezer until the time of batch assay.  The specimen is frozen-sectioned to assess 
tumor cellularity, and a grossly tumor-enriched area is dissected while the tissue 
is still in an OCT cold embedding medium.  We are currently evaluating whether 
microdissection is required by comparing microdissected vs macrodissected 
samples in the GeneChip analyses of the B-27.2 cases.  If found to be necessary, 
we will use a PixCell LCM® or PALM device to microdissect tumor cells before 
extracting RNA.  If microdissection is not to be used, macrodissected tissue will 
be kept frozen in RNAlaterICE solution (Ambion) at -70°C for at least 14 hours 
and then RNA will be extracted using the Qiagen RNAeasy kit.  One microliter 
of extracted RNA will be run on a Bioanalyzer (Agilent) to check the quality of 
RNA.  Only those samples with distinct ribosomal peaks will be used for the 
GeneChip assay.  Nine nanograms of total RNA will be linearly amplified and 
labeled with biotin using the Ovation™ kit (Nugen Technologies) and hybridized 
to the Affymetrix GeneChip.  Hybridization signals will be scanned using the 
Affymetrix scanner. 
Alternative method 
Depending on development in the field, we may choose to use other gene 
expression profiling methods such as DASL (Ilumina) if they are more robust 
and reproducible than the Affymetrix GeneChip based approach.148 
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8.5.2 Validate (1) predictive dose-response curves for cOR after treatment with T, 
TCape, and TG; (2) predictive dose-response curves for pCR including dose-
response curves for AC and either T, TCape, or TG depending on treatment 
arm. 
We will analyze the dose-response curves generated by the ChemoFx® assay to 
build a predictive algorithm for determining cOR after treatment with T, TCape, 
or TG.  For each arm of the trial, we will extend the algorithm to include 
prediction of pCR by incorporating additional information on the dose-response 
curves generated by the secondary treatment. 
Method: 
ChemoFx® Assay 
Two core biopsies will be obtained from each neoadjuvant breast cancer patient 
prior to the initiation of chemotherapy for use in the research version of the 
ChemoFx® assay to be performed by PTI.  PTI’s research version of the 
ChemoFx® assay involves in vitro isolation, short-term growth, and drug 
treatment of epithelial cells derived from solid tumors.  At the time of biopsy of 
the breast tumor site, two of the obtained core biopsies will be placed in the 
supplied bottle of the sterile shipping medium for PTI for overnight shipment to 
the laboratories of PTI in Pittsburgh, PA.  Upon arrival in the laboratory, the core 
biopsies are minced into small pieces and placed in culture media in three small 
flasks for cell outgrowth.  Over time, cells move out of the tumor pieces and 
form a monolayer on the bottom of the flask.  Once enough cells have migrated 
out of the in vitro explant pieces, they are then trypsinized and reseeded into 
microtiter plates for either the research version of the ChemoFx® assay or for 
immunohistochemsitry (IHC) analysis for confirmation of epithelial cell 
growth.163 
For the research version of the ChemoFx® assay, a cell suspension is prepared 
from the cell monolayer which is delivered to a large basin situated on the stage 
of the Oasis LM liquid handling machine (Dynamic Devices, Inc.).  The liquid 
handler then seeds a set number of cells into the wells of a 384-well microtiter 
plate in replicates of four per drug treatment.  Cells are then allowed to adhere to 
the plate and grow for 24 hours at 37°C.  Following this incubation, the liquid 
handler prepares ten doses of each drug or drug combination in the appropriate 
growth medium via serial dilutions in a 96-well deep-well microplate.  The 
appropriate volume of each dose of each drug or drug combination is then added 
to the appropriate well of cells in the 384-well plate via the liquid handler; each 
drug treatment will also contain a control well to which medium alone is added.  
The system ensures that all cells are treated with the correct drug or drug 
combination at the correct dosage.  The cells are incubated with drugs for 72 
hours, thus necessitating their preparation in complete growth medium.  At the 
end of the 72 hour drug incubation period, the liquid handler removes media and 
any nonadherent, dead cells from each well.  The remaining, live cells are fixed 
in 95% ethanol containing the DNA-intercalating blue fluorescent dye, 4',  
6-diamidino-2-phenylindole dihydrochloride (DAPI) (Molecular Probes).  As a 
result of the fixing and staining process, these cells become non-viable at the 
completion of the assay testing. 
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Following fixation and staining, an automated microscope captures UV images 
of the stained cells in each well.  Afterwards, the number of cells per well, in 
both visible and UV light, is quantified.  For each dose of each drug treatment 
tested, a cytotoxic index (CI) is calculated which represents the percentage of 
cells killed as a result of that treatment.  CI is determined using the following 
formula. 
CI (Cytotoxic Index) for each drug dose concentration = # cells counted in 
treated wells / # cells counted in untreated-control wells 
Using calculated CI values, a complete dose-response curve is generated for each 
drug or drug combination evaluated. 
We will take the data from the first 100 patients randomized to the T followed by 
AC control arm (Group 1A patients) to investigate various methods for using the 
ChemoFx® assay to predict cOR and pCR, in order to facilitate the final analysis 
on the ChemoFx® assay data.  
To this aim, we will discover and validate in the control arm (T followed by AC, 
no bevacizumab): (1) predictive ChemoFx® dose-response curves for clinical 
overall response (cOR) after treatment with T (without bevacizumab); predictive 
ChemoFx® dose-response curves for pCR including dose-response curves for  
T and AC (without bevacizumab); (3) prediction of pCR using ChemoFx® dose-
response curves for T and for AC and clinical response to T (without 
bevacizumab). 
8.5.3 Validate Genomic Health 21 gene Recurrence Score (OncotypeDx assay) and 
83 gene predictive gene expression profile as predictors of pCR to 
chemotherapy  
Gianni et al have examined gene expression levels of 380 genes in paraffin-
embedded core biopsy tissue procured from patients enrolled in a pre-operative 
chemotherapy study.4  Eighty-three genes were identified whose expression 
levels correlated with pCR.  In addition, Recurrence Scores (RS) based on 21 
genes were also correlated with pCR, with higher RS correlating with higher rate 
pCR (p=0.005).  In a recent analysis of NSABP B-20, statistically significant 
interaction between RS and chemotherapy was observed in ER+ N- patients who 
received tamoxifen.134  We will examine this set of 83 genes and use the 
OncotypeDx assay to validate their association with pCR.  
Method 
Two 5 micron thick sections from formalin fixed paraffin-embedded tumor 
blocks will be mounted on glass slides, and a tumor rich area will be 
macrodissected and sent to Genomic Health, Inc. QRT-PCR analysis will be 
performed as described previously.129,147 
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8.5.4 Validate predictive gene expression profiles for pCR to AC and ACTaxotere 
developed from B-27.2  
Soonmyung Paik, MD, Director of the NSABP Division of Pathology, is 
currently analyzing core biopsy specimens collected in NSABP B-27.2 using 
multiple gene expression profiling platforms including the Affymetrix GeneChip 
X3P (with Arcturus Paradise kit) and DASL assay.148  The gene expression 
profiles that correlate with pCR to AC and ACTaxotere may become available 
from this study during accrual of B-40.  Therefore, formalin-fixed cores collected 
from this trial embedded in paraffin will provide a validation set for such gene 
expression profiles.  Once a model is built from B-27.2, a separate validation 
study protocol will be written with a predefined model to use the samples from 
the B-40 protocol. 
8.5.5 Validate Tau expression as a marker of pCR  
Pusztai et al previously used DNA microarrays to identify gene expression 
patterns associated with pCR to preoperative taxane-containing chemotherapy in 
60 patients with breast cancer.164  Low mRNA expression of microtubule-
associated protein Tau in cancers at the time of diagnosis was significantly 
associated with pCR.  To validate this finding, Rouzier et al performed 
immunohistochemistry (IHC) on a tissue array containing 122 breast cancer 
specimens.  All patients received 24 weeks of preoperative paclitaxel followed by 
4 courses of anthracycline-containing chemotherapy.  None of these patients was 
included in the microarray study.  Thirty-eight patients experienced pathologic 
CR (31%). Cytoplasmic expression of Tau protein was seen in normal breast 
epithelium and blood vessels.  Sixty-four tumors (52%) were considered Tau-
negative, including 14 with complete absence of Tau by immunohistochemistry 
(IHC score 0) and 50 tumors with less Tau expression than normal controls (IHC 
score 1+).  Fifty-eight tumors (48%) were positive for Tau protein expression, 
defined as IHC score 2+ that had uniform staining of similar or slightly greater 
intensity than normal controls or IHC score 3+ that had uniform high intensity 
staining.  This dichotomization of staining results was determined after 
inspection of the distribution of results and without knowledge of the clinical 
outcome data.  There were more pathologic CRs among the Tau-negative tumors 
(28/64, 44%) than among the Tau-positive tumors (10/58, 17%).  Most tumors 
that achieved pathologic CR were Tau-negative (28/38, 74%).  The odds ratio for 
pathologic CR in Tau-negative tumors was 3.7 (95% confidence interval 1.6, 8.6, 
p = 0.0013).  A multiple logistic regression model with pCR as the outcome, and 
age, tumor size, nodal status and histology, nuclear grade, estrogen receptor 
(ER), progesterone receptor (PR), and HER2 expression as covariates identified 
high nuclear grade (p = 0.0018), ER-negative (p = 0.08) and Tau-negative status 
(p = 0.04) as independent predictors of pCR.  A similar multiple logistic 
regression model with Tau as the outcome and including the same 
clinicopathologic parameters as covariates, identified low or intermediate nuclear 
grade (p = 0.05), ER (p = 0.06) and PgR (p = 0.005) as independent predictors of 
Tau status. ER-negative and high-grade tumors tended to be Tau-negative.  The 
Tau-pCR odds ratio when adjusted for age, tumor size, nodal status, nuclear 
grade and ER, PgR, and HER2 status was 2.7 (0.9, 7.9) with p = 0.059.  These 
results confirm the microarray data that low Tau expression is associated with 
higher probability of achieving pCR.137 
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Method 
Unstained sections cut from core biopsy paraffin blocks at the NSABP Division 
of Pathology will be sent to Dr. Pusztai’s lab at MDACC for staining. Sections 
will be deparaffinized as per standard procedure.  Endogenous peroxidase 
activity will be blocked and antigen retrieval will be performed by heating the 
slides in citrate buffer (pH 6.0) x 10 minutes in a high temperature microwave 
oven.  The slides will be incubated with anti-Tau antibody (1:50 dilution, clone 
T1029, US Biological) overnight at 4°C.  Bound antibody will be detected by 
using an antimouse horseradish peroxidase-labeled polymer secondary antibody 
(DAKO Envision® TM+ System, DAKO, Carpentia, CA) with DAB substrate.  
Normal breast epithelium will serve as an internal positive control. Negative 
control will include omission of the primary antibody in a control slide. 
Cytoplasmic staining intensity will be graded as either negative (0/1+) or positive 
(2+/3+) based on our previously established cut-off system.  Slides will be scored 
independently by two pathologists (WF Symmans and S Paik) without 
knowledge of the clinical outcome. As an exploratory analysis, we will utilize the 
TMAx image analysis program (Beecher Instruments) based on Cellenger Engine 
(Definiens) that has capability to automatically distinguish tumor cells vs host 
cells and to quantify staining results as a continuous variable based on intensity 
of staining and percent positive cells.  The Aperio ScanScope will be used to 
scan stained slides at 200x magnification to be analyzed by TMAx.  
8.5.6 Identify serum markers that may predict pCR when measured early in the 
course of chemotherapy 
A serum marker that changes early during the course of chemotherapy and whose 
change correlates with eventual pCR at the completion of the chemotherapy 
would be a useful surrogate for pCR to allow us to stop non-efficacious treatment 
earlier.  We will collect serum before the initiation of therapy, just prior to the 
third cycle of the first chemotherapy regimen, and at the completion of 
chemotherapy.  The samples will undergo proteomics analysis to identify such 
markers and also will be used to validate predictive serum markers developed by 
other investigators. 
Method: 
Proteomics is a rapidly evolving field, and we will store the collected serum and 
wait until the end of the B-40 accrual to determine which method will be used. 
8.6 Pre-entry core biopsy specimens 
8.6.1 Requirements 
Procurement of core biopsies before study entry is an eligibility requirement for 
all patients.  Baseline biopsy specimens must be procured in RNAlater, formalin, 
and shipping medium for PTI using the kit supplied from Precision Therapeutics, 
Inc. 
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Provide one core to be immersed in RNAlater solution.  The core has to be 
immersed in RNAlater solution (kept at room temperature) immediately after the 
tissue is removed from the patient.  Any delay at this step will result in 
degradation of RNA and will negate the purpose of the procurement in RNAlater.  
Please note that it is critical that the specimen is rinsed in saline if it is 
contaminated with blood since it seems to result in suboptimal RNA protection 
either by poor penetration of RNAlater or dilution of the RNAlater solution.  The 
next two cores should be placed in the supplied bottle of shipping medium for 
PTI.  The final core sample should be placed in the formalin vial. 
8.6.2 Submission instructions 
Submit all 4 collected core biopsies directly to Precision Therapeutics, Inc.  Refer 
to the B-40 Pathology Instructions in the Members' Area of the NSABP Web site 
for submission instructions.  (CTSU investigators should refer to the CTSU Web 
site for the B-40 Pathology Instructions.) 
Place all three containers with the core samples in the specimen kit and seal.  Kits 
should be shipped immediately with cold packs.  If sent on Friday, mark the 
shipping envelope for Saturday delivery.  Keep the specimen kit in the 
refrigerator until pickup for shipping the same day. 
8.7 Paraffin blocks 
8.7.1 Requirements 
The submission of pathology materials from definitive surgery is required for all 
patients with gross residual disease  1 cm. 
 If grossly evident residual disease  1 cm: 
Tumor and lymph node blocks from definitive surgery  
At least one representative block of residual primary tumor and a positive 
lymph node containing the maximum amount of tumor are required.  We will 
use these blocks to evaluate pathologic response and also evaluate markers 
discovered in the future that may relate to drug resistance.  While tissue 
microarray is useful for mass screening of markers, we found in NSABP  
B-18 that tumor cell density tends to be low in post-chemotherapy specimens 
so that it is difficult to construct tissue microarrays with 0.6 mm cores.  We 
will be using 1 mm cores for these specimens.  However, to prevent 
destruction of diagnostic blocks, we will be sampling only one 1 mm core 
per block. 
Alternative submission  
While it is desirable that tissue blocks are submitted, for institutions that do 
not allow submission of the tissue blocks, we recommend submitting the 
following two items as a substitute: 
– 20-30 unstained sections of 4-5 micron thickness mounted on charged 
slides (do not oven bake slides); and 
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– a 2 mm diameter core sampling from a tumor-cell-rich area or a similar 
size fragment cut from the original block (Kits can be obtained from the 
NSABP Division of Pathology [see Information Resources on page v]). 
 If grossly evident residual disease  1 cm or if no grossly evident residual 
disease, tissue submission is not required. 
8.7.2 Submission 
Submit paraffin blocks (or alternative specimens as described in 8.7.1) to the 
NSABP Biostatistical Center at the address listed under “Information Resources” 
(see page v).  Refer to the B-40 Pathology Instructions in the Members' Area of 
the NSABP Web site for submission instructions.  (CTSU investigators should 
refer to the CTSU Web site for the B-40 Pathology Instructions.) 
8.8 Blood/serum specimens 
8.8.1 Requirements/timing of blood collections 
Specimens will be collected at the following 3 timepoints for patients who have 
consented to specimen collection: 
– At baseline before chemotherapy (blood and serum) 
 
– Before the 3rd cycle of T, TCape, or TG (serum) 
 
– At least 3 weeks after completion of chemotherapy but before surgery 
(serum) 
 
8.8.2 Submission instructions 
Refer to the B-40 Pathology Instructions in the Members' Area of the NSABP 
Web site for submission instructions.  (CTSU investigators should refer to 
additional information regarding supplies for serum collection in Section 3.0 in 
Appendix F and to the CTSU Web site for the B-40 Pathology Instructions.) 
05/30/07 
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9.0 TREATMENT REGIMEN 
9.1 Group 1A (docetaxel→AC) 
 Chemotherapy should begin as soon as possible following randomization and 
collection of baseline blood and serum (if patient has consented). 
 Central venous access is strongly recommended. 
 
TABLE 10.  Treatment regimen for Group 1A 
Drug Dose Dosing Interval Planned Duration 
Docetaxel 
100 mg/m2 IV over 60 minutes 
 
(See footnote a for docetaxel pre-
medication regimen and footnote b 
for REQUIRED cytokine support) 
Day 1 
q 21 days 4 cycles 
21 days after Day 1 of the last cycle of docetaxelc 
Doxorubicin 60 mg/m2 IV over 15 minutes 
Cyclophosphamide 600 mg/m2 IV over 30 minutes 
Day 1 
q 21 days 4 cycles 
BREAST SURGERYd 
a Pre-medication for docetaxel: All patients should receive the following before each docetaxel dose: 
 Dexamethasone 8 mg po BID the day before and the morning of chemotherapy.  At the physician’s 
discretion, dexamethasone may be continued after chemotherapy. 
 At the discretion of the investigator, other non-steroidal pre-medications such as diphenhydramine 
hydrochloride 50 mg IV and H-2 blocker IV (cimetidine 300 mg, ranitidine 50 mg, or famotidine 
20 mg) may be given in addition to the dexamethasone. 
b Cytokine support: Primary prophylaxis with pegfilgrastim or filgrastim is REQUIRED for Group 1A 
docetaxel cycles.  Use of pegfilgrastim is preferred. 
 Pegfilgrastim should be administered on Day 2 at a fixed dose of 6 mg SQ. 
 Filgrastim, if used, should be administered according to the package insert. 
c Prior to initiation of AC, all adverse events must be resolved to  grade 1, except ANC, which must be 
  1200/mm3, and bilirubin, which must be  the baseline grade. 
d After recovery from chemotherapy and after the LVEF assessment before surgery (MUGA or 
echocardiogram) and final clinical response assessment have been performed. 
 
02/15/08 
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9.2 Group 1B (docetaxel + bevacizumabAC + bevacizumab) 
 Chemotherapy and bevacizumab should begin as soon as possible following 
randomization and collection of baseline blood and serum (if patient has consented). 
 Central venous access is strongly recommended.  A delay in initiation of 
chemotherapy and bevacizumab of 1 week following vascular access device  
placement is recommended but not required. 
TABLE 11.  Treatment regimen for Group 1B 
Drug Dose Dosing Interval Planned Duration 
Bevacizumab 
15 mg/kg IV over: 
 90 minutes – 1st dosea 
 60 minutes – 2nd dosea 
 30 minutes – all subsequent dosesa 
Flush infusion lineb 
Docetaxel 
100 mg/m2 IV over 60 minutes 
(See footnote c for docetaxel pre-medication regimen 
and footnote d for REQUIRED cytokine support) 
Day 1 
q 21 days 4 cycles 
21 days after Day 1 of  the last cycle of docetaxele 
Bevacizumab 15 mg/kg IV over 30 minutes
a 
Flush infusion lineb 
2 cycles 
(only with AC 
cycles 1 & 2) 
Doxorubicin 60 mg/m2 IV over 15 minutes 
Cyclophosphamide 600 mg/m2 IV over 30 minutes 
Day 1 
q 21 days 
4 cycles 
BREAST SURGERYf 
At least 4-6 weeks after surgery, initiate postoperative bevacizumabg 
Bevacizumab 15 mg/kg IV over 30 minutesh Every 21 days 10 cyclesi 
a See Table 29 in Section 11.3 for instructions regarding infusion-related or allergic reactions with bevacizumab. 
b Add an additional 50 mL of 0.9% NaCl for injection to the bevacizumab infusion bag (or use a new 50 mL bag of 0.9% NaCl) and 
infuse a volume equal to the volume contained in the tubing. 
c Pre-medication for docetaxel: All patients should receive the following before each docetaxel dose: 
 Dexamethasone 8 mg po BID the day before and the morning of chemotherapy.  At the physician’s discretion, dexamethasone 
may be continued after chemotherapy. 
 At the investigator's discretion, other non-steroidal pre-medications such as diphenhydramine hydrochloride 50 mg IV and H-2 
blocker IV (cimetidine 300 mg, ranitidine 50 mg, or famotidine 20 mg) may be given in addition to the dexamethasone. 
d Cytokine support: Primary prophylaxis with pegfilgrastim or filgrastim is REQUIRED for Group 1B docetaxel cycles.  Use of 
pegfilgrastim is preferred. 
 Pegfilgrastim should be administered on Day 2 at a fixed dose of 6 mg SQ. 
 Filgrastim, if used, should be administered according to the package insert. 
e Prior to initiation of AC, all adverse events must be resolved to  grade 1, except ANC, which must be  1200/mm3, and bilirubin, 
 which must be  the baseline grade. 
f After recovery from chemotherapy and after the LVEF assessment before surgery (MUGA or echocardiogram) and final clinical 
response assessment have been performed (see Section 9.9.2 for important instructions regarding the timing of surgery). 
g See Section 11.2 (Table 28) for the LVEF requirements for initiating postoperative bevacizumab.  If the LVEF meets requirements, 
bevacizumab should resume no sooner than 28 days after breast surgery.  The surgical incision must be healed before resuming 
therapy.  If bevacizumab cannot begin  84 days after surgery, postoperative bevacizumab may not be given. 
h Infusion time for the postoperative bevacizumab should be at the rate that was tolerated preoperatively.  If premedications were 
required for preoperative bevacizumab, premedications should continue to be administered with postoperative bevacizumab.  See 
Table 29 in Section 11.3 for instructions regarding infusion-related or allergic reactions with bevacizumab. 
i Bevacizumab must end by 18 months following study entry whether or not 10 postoperative cycles have been administered. 
02/15/08 
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9.3 Group 2A (docetaxel + capecitabine  AC) 
 Chemotherapy should begin as soon as possible following randomization and 
collection of baseline blood and serum (if patient has consented). 
 Central venous access is strongly recommended. 
TABLE 12.  Treatment regimen for Group 2A 
Drug Dose Dosing Interval Planned Duration 
Docetaxel 
75 mg/m2 IV over 60 minutes 
 
(See footnote a for docetaxel 
pre-medication regimen.) 
Day 1 
q 21 days 
Capecitabine 825 mg/m2 po BID 
Days 1-14 
q 21 days 
4 cycles 
21 days after Day 1 of the last cycle of docetaxel + capecitabineb 
Doxorubicin 60 mg/m2 IV over 15 minutes 
Cyclophosphamide 600 mg/m2 IV over 30 minutes 
Day 1 
q 21 days 4 cycles 
BREAST SURGERYc 
a Pre-medication for docetaxel: All patients should receive the following before each docetaxel dose: 
 Dexamethasone 8 mg po BID the day before and the morning of chemotherapy.  At the physician’s 
discretion, dexamethasone may be continued after chemotherapy. 
 At the discretion of the investigator, other non-steroidal pre-medications such as diphenhydramine 
hydrochloride 50 mg IV and H-2 blocker IV (cimetidine 300 mg, ranitidine 50 mg, or famotidine 20 mg) 
may be given in addition to the dexamethasone. 
b Prior to initiation of AC, all adverse events must be resolved to  grade 1, except ANC, which must be  
  1200/mm3, and bilirubin, which must be  the baseline grade. 
c After recovery from chemotherapy and after the LVEF assessment before surgery (MUGA or echocardiogram) 
 and final clinical response assessment have been performed. 
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9.4 Group 2B (docetaxel + capecitabine + bevacizumab  AC + bevacizumab) 
 Chemotherapy should begin as soon as possible following randomization and 
collection of baseline blood and serum (if patient has consented). 
 Central venous access is strongly recommended.  A delay in initiation of 
chemotherapy and bevacizumab of 1 week following vascular access device 
placement is recommended but not required. 
TABLE 13.  Treatment regimen for Group 2B 
Drug Dose Dosing Interval Planned Duration 
Bevacizumab 
15 mg/kg IV over: 
 90 minutes – 1st dosea 
 60 minutes – 2nd dosea 
 30 minutes – all subsequent dosesa 
Flush infusion lineb 
Docetaxel 
75 mg/m2 IV over 60 minutes 
(See footnote c for docetaxel pre-medication regimen.) 
Day 1 
q 21 days 
Capecitabine 825 mg/m2 po BID Days 1-14 q 21 days 
4 cycles 
21 days after Day 1 of the last cycle of docetaxel + capecitabined 
Bevacizumab 15 mg/kg IV over 30 minutes
a 
Flush infusion lineb 
2 cycles 
(only with AC cycles 
1 & 2) 
Doxorubicin 60 mg/m2 IV over 15 minutes 
Cyclophosphamide 600 mg/m2 IV over 30 minutes 
Day 1 
q 21 days 
4 cycles 
BREAST SURGERYe 
At least 4-6 weeks after surgery, initiate postoperative bevacizumabf 
Bevacizumab 15 mg/kg IV over 30 minutesg Every 21 days 10 cyclesh 
a See Table 29 in Section 11.3 for instructions regarding infusion-related or allergic reactions with bevacizumab. 
b Add an additional 50 mL of 0.9% NaCl for injection to the bevacizumab infusion bag (or use a new 50 mL bag of 0.9% NaCl) and 
infuse a volume equal to the volume contained in the tubing. 
c Pre-medication for docetaxel: All patients should receive the following before each docetaxel dose: 
 Dexamethasone 8 mg po BID the day before and the morning of chemotherapy.  At the physician’s discretion, dexamethasone 
may be continued after chemotherapy. 
 At the investigator's discretion, other non-steroidal pre-medications such as diphenhydramine hydrochloride 50 mg IV and H-2 
blocker IV (cimetidine 300 mg, ranitidine 50 mg, or famotidine 20 mg) may be given in addition to the dexamethasone. 
d Prior to initiation of AC, all adverse events must be resolved to  grade 1, except ANC, which must be  1200/mm3, and bilirubin, 
which must be  the baseline grade. 
e After recovery from chemotherapy and after the LVEF assessment before surgery (MUGA or echocardiogram) and final clinical 
response assessment have been performed (see Section 9.9.2 for important instructions regarding the timing of surgery). 
f See Section 11.2 (Table 28) for the LVEF requirements for initiating postoperative bevacizumab.  If the LVEF meets 
requirements, bevacizumab should resume no sooner than 28 days after breast surgery.  The surgical incision must be healed 
before resuming therapy.  If bevacizumab cannot begin  84 days after surgery, postoperative bevacizumab may not be given. 
g Infusion time for the postoperative bevacizumab should be at the rate that was tolerated preoperatively.  If premedications were 
required for preoperative bevacizumab, premedications should continue to be administered with postoperative bevacizumab.  See 
Table 29 in Section 11.3 for instructions regarding infusion-related or allergic reactions with bevacizumab. 
h Bevacizumab must end by 18 months following study entry whether or not 10 postoperative cycles have been administered. 
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9.5 Group 3A (docetaxel + gemcitabine AC) 
 Chemotherapy should begin as soon as possible following randomization and 
collection of baseline blood and serum (if patient has consented). 
 Central venous access is strongly recommended. 
TABLE 14. Treatment regimen for Group 3A 
Drug Dose Dosing Interval Planned Duration 
Docetaxel 
75 mg/m2 IV over 60 minutes 
(See footnote a for docetaxel pre-
medication regimen.) 
Day 1 
q 21 days 
Gemcitabine 1000 mg/m2 IV over 30 minutes 
Day 1 and 
Day 8 
q 21 days 
4 cycles 
21 days after Day 1 of the last cycle of docetaxel + gemcitabineb 
Doxorubicin 60 mg/m2 IV over 15 minutes 
Cyclophosphamide 600 mg/m2 IV over 30 minutes 
Day 1 
q 21 days 4 cycles 
BREAST SURGERYc 
a Pre-medication for docetaxel: All patients should receive the following before each docetaxel dose: 
 Dexamethasone 8 mg po BID the day before and the morning of chemotherapy.  At the physician’s 
discretion, dexamethasone may be continued after chemotherapy. 
 At the discretion of the investigator, other non-steroidal pre-medications such as diphenhydramine 
hydrochloride 50 mg IV and H-2 blocker IV (cimetidine 300 mg, ranitidine 50 mg, or famotidine 
20 mg) may be given in addition to the dexamethasone. 
b Prior to initiation of AC, all adverse events must be resolved to  grade 1, except ANC, which must be 
  1200/mm3, and bilirubin, which must be  the baseline grade. 
c After recovery from chemotherapy and after the LVEF assessment before surgery (MUGA or 
 echocardiogram) and final clinical response assessment have been performed. 
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9.6 Group 3B (docetaxel + gemcitabine + bevacizumab  AC + bevacizumab) 
 Chemotherapy should begin as soon as possible following randomization and 
collection of baseline blood and serum (if patient has consented). 
 Central venous access is strongly recommended.  A delay in initiation of 
chemotherapy and bevacizumab of 1 week following vascular access device 
placement is recommended but not required. 
TABLE 15. Treatment regimen for Group 3B 
Drug Dose Dosing Interval Planned Duration 
Bevacizumab 
15 mg/kg IV over: 
 90 minutes – 1st dosea 
 60 minutes – 2nd dosea 
 30 minutes – all subsequent dosesa 
Flush infusion lineb 
Docetaxel 
75 mg/m2 IV over 60 min. 
(See footnote c for docetaxel pre-medication 
regimen.) 
Day 1 
q 21 days 
Gemcitabine 1000 mg/m2 IV over 30 minutes 
Day 1 and 
Day 8 
q 21 days 
4 cycles 
21 days after Day 1 of the last cycle of docetaxel + gemcitabined 
Bevacizumab 15 mg/kg IV over 30 minutes
a 
Flush infusion lineb 
2 cycles 
(only with AC cycles 
1 and 2) 
Doxorubicin 60 mg/m2 IV over 15 minutes 
Cyclophosphamide 600 mg/m2 IV over 30 minutes 
Day 1 
q 21 days 
4 cycles 
BREAST SURGERYe 
At least 4-6 weeks after surgery, initiate postoperative bevacizumabf 
Bevacizumab 15 mg/kg IV over 30 minutesg Every 21 days 10 cyclesh 
a See Table 29 in Section 11.3 for instructions regarding infusion-related or allergic reactions with bevacizumab. 
b Add an additional 50 mL of 0.9% NaCl for injection to the bevacizumab infusion bag (or use a new 50 mL bag of 0.9% NaCl) and 
infuse a volume equal to the volume contained in the tubing. 
c Pre-medication for docetaxel: All patients should receive the following before each docetaxel dose: 
 Dexamethasone 8 mg po BID the day before and the morning of chemotherapy.  At the physician’s discretion, dexamethasone 
may be continued after chemotherapy. 
 At the investigator's discretion, other non-steroidal pre-medications such as diphenhydramine hydrochloride 50 mg IV and H-2 
blocker IV (cimetidine 300 mg, ranitidine 50 mg, or famotidine 20 mg) may be given in addition to the dexamethasone. 
d Prior to initiation of AC, all adverse events must be resolved to  grade 1, except ANC, which must be  1200/mm3, and 
 bilirubin, which must be  the baseline grade. 
e After recovery from chemotherapy and after the LVEF assessment before surgery (MUGA or echocardiogram) and final clinical 
 response assessment have been performed (see Section 9.9.2 for important instructions regarding the timing of surgery). 
f See Section 11.2 (Table 28) for the LVEF requirements for initiating postoperative bevacizumab.  If the LVEF meets 
 requirements, bevacizumab should resume no sooner than 28 days after breast surgery.  The surgical incision must be healed 
 before resuming therapy.  If bevacizumab cannot begin  84 days after surgery, postoperative bevacizumab may not be given. 
g Infusion time for the postoperative bevacizumab should be at the rate that was tolerated preoperatively.  If premedications 
 were required for preoperative bevacizumab, premedications should continue to be administered with postoperative 
 bevacizumab.  See Table 29, Section 11.3 for instructions if infusion-related or allergic reactions occur with bevacizumab. 
h Bevacizumab must end by 18 months following study entry whether or not 10 postoperative cycles have been administered. 
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9.7 Dose determinations 
9.7.1 Calculation of BSA and chemotherapy doses 
 Based on the patient’s weight and BSA, recommended chemotherapy and 
bevacizumab doses will be provided by the NSABP at study entry.  
Recalculations of BSA and doses are required if the patient has a ≥ 10 lb. 
weight change from baseline.  Drug doses may be recalculated prior to each 
chemotherapy and bevacizumab cycle at the physician’s discretion. 
 The first postoperative bevacizumab dose should be recalculated. 
 
 At the physician’s discretion, the dose(s) may be capped using a BSA of  
2.2 m2. 
   
9.7.2 Rounding drug doses 
 Doxorubicin, cyclophosphamide, docetaxel, gemcitabine, and bevacizumab: 
rounding of doses is optional.  If the treating physician decides to round the 
dose(s), follow these guidelines.  (These also apply to dose modifications.) 
 Bevacizumab (15 mg/kg IV) 
 
Doses should be rounded to the nearest 5 mg. 
 Cyclophosphamide (600 mg/m2 IV) 
 
Doses should be rounded to the nearest 25 mg. 
 Docetaxel (Group 1 – 100 mg/m2 IV; Groups 2 and 3 – 75 mg/m2 IV) 
 
Doses should be rounded to the nearest mg. 
 Doxorubicin (60 mg/m2 IV) 
 
Doses should be rounded to the nearest mg. 
 Gemcitabine (1000 mg/m2 IV on Days 1 and 8) 
 
Doses should be rounded to the nearest 25 mg. 
 Capecitabine (825 mg/m2 po BID) 
Refer to Appendix D for dose instructions based on BSA. 
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9.8 Supportive therapy 
Patients should receive full supportive care. 
9.8.1 G-CSF 
 G-CSF must be used as primary prophylaxis during docetaxel cycles for 
Groups 1A and 1B patients (see Tables 10 and 11). 
 G-CSF will be used as secondary prophylaxis during treatment with AC (all 
groups), docetaxel and capecitabine (Groups 2A and 2B), and docetaxel and 
gemcitabine (Groups 3A and 3B).  Refer to the appropriate tables in Section 
10.0.  (Note: Pegfilgrastim is not permitted with capecitabine.) 
9.8.2 Prophylactic antibiotics 
At the investigator's discretion, primary prophylaxis with fluoroquinilones may 
be administered, e.g., levofloxacin 500 mg po qd or ciprofloxacin 500 mg po 
BID, administered.  Other antibiotics may be used as an alternative in case of 
allergy prohibiting levofloxacin and ciprofloxacin. 
Note: Prophylaxis with an antibiotic may not be used as a substitute for required 
cytokine support or dose modifications. 
9.8.3 Erythropoietin 
Administration of erythropoiesis-stimulating agents should be consistent with the 
approved indication for cancer patients receiving chemotherapy in current 
package inserts, and in accordance with dose recommendations and 
modifications as well as safety warnings.  Choice of agent is at the investigator's 
discretion. 
9.8.4 Mucositis prophylaxis for Groups 2A and 2B patients 
During docetaxel/capecitabine, it is recommended that patients in Groups 2A and 
2B use nystatin mouth rinse TID Days 2 through 6 of each regimen.  Salt and 
soda mouth rinse can also be used as needed. 
9.8.5 Antiemetic therapy 
Antiemetic therapy should be administered at the physician's discretion according 
to National Comprehensive Cancer Network (NCCN) or American Society of 
Clinical Oncology (ASCO) clinical practice guidelines. 
9.9 Surgery 
9.9.1 Marking the primary tumor site prior to initiation of therapy 
Patients who are considered candidates for breast conservation should have the 
primary tumor site marked prior to initiating chemotherapy.  This can be 
achieved with such methods as insertion of a radiopaque marker or clip, tattoos 
of the tumor boundary on the skin (especially for smaller breasts), or by making a 
transparent template with the tumor site marked on it.  Other techniques are 
acceptable, as long as they provide assurance that the primary tumor site can be 
located and excised.  If a clip is used, a specimen radiograph should be 
performed to confirm its removal. 
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9.9.2 Breast surgery 
 As soon as possible following recovery from chemotherapy, final clinical 
tumor assessment, and preoperative LVEF assessment the patient should 
undergo a lumpectomy or mastectomy. 
For patients randomized to Groups 1B, 2B, and 3B, who complete 4 cycles 
of AC, breast surgery will occur at least 9 weeks following the last dose of 
bevacizumab.  This schedule was selected to minimize the risk of 
bevacizumab increasing rates of postoperative wound complications.  If for 
any reason the patient discontinues therapy before completion of the 4 cycles 
of neoadjuvant AC, surgery should be delayed at least 6 weeks following the 
last dose of bevacizumab.  If the investigator determines that a 6-week delay 
is unacceptable for management of the breast cancer, surgery may take place 
sooner than 6 weeks but MUST be delayed at least 4 weeks after the last 
dose of bevacizumab. 
 Breast conservation may be selected according to patient and surgeon 
preferences. 
 Patients who are deemed to be good candidates for breast conservation 
will undergo segmental excision of the primary tumor bed.  If the 
residual tumor is non-palpable, methods to ensure adequate excision of 
the primary tumor site should be used to guide the excision.  If tumor 
location was marked with clips, a specimen radiograph should be 
obtained intraoperatively to document that the lesion has been removed 
including the clips. 
 The margins of the resected specimen of patients treated with breast 
conservation must be histologically free of invasive tumor and DCIS.  In 
patients for whom pathologic examination demonstrates tumor at the 
margin, additional operative procedures should be performed to obtain 
clear margins. 
 Patients who are not considered candidates for breast conservation or do 
not desire breast conservation will undergo a total mastectomy. 
 Breast reconstruction 
 Important reminder: Surgical incisions must be healed before 
postoperative bevacizumab is administered. 
 For patients randomized to receive bevacizumab (Groups 1B, 2B, and 
3B) who choose to have breast reconstruction using tissue expanders, 
expansion is prohibited within the 2 weeks prior to the first postoperative 
bevacizumab dose.  Expansion or any surgical procedure (such as 
exchanging tissue expanders for permanent implants) is prohibited 
throughout therapy with bevacizumab and for at least 6 weeks after the 
last dose of bevacizumab.  The following instructions must be employed: 
1. Tissue expanders can be placed at the time of mastectomy, with or 
without acellular dermis placed in the lower pole. 
2. Partial expansion in the operating room is allowed according to 
individual practitioner preference. 
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3. If the postoperative course proceeds normally, one or two expansions 
may be performed within the first 2 weeks BUT no later, since 
bevacizumab will be resumed as early as 4 weeks following surgery. 
4. If prolonged postoperative drainage occurs (greater than 10 days), no 
additional expansion should be contemplated. 
5. No attempt should be made to complete expansion prior to resuming 
bevacizumab nor to delay resuming bevacizumab for the purpose of 
expansion. 
9.9.3 Axillary staging 
 Post-neoadjuvant therapy axillary staging is required for all patients. 
 Use of sentinel node (SN) biopsy procedure following completion of 
neoadjuvant therapy is at the discretion of the investigator. If SN biopsy was 
not performed, surgical evaluation of the axilla is required. 
 If the post-neoadjuvant therapy SN biopsy is positive, additional surgical 
evaluation of axilla is required. 
 
 If the post-neoadjuvant therapy SN biopsy is negative, further surgical 
nodal staging procedure is not required.  However, if the only SN 
identified by isotope scan is in the internal mammary nodal chain, the 
axilla should be explored for a blue or suspicious node. 
 
 If axillary nodal staging procedures were performed before study entry (see 
Section 5.3.3), follow these guidelines. 
 Even if FNA or core biopsy of an axillary node(s) was performed before 
initiation of neoadjuvant therapy, surgical evaluation of the axilla (either 
SN biopsy and/or axillary dissection as described in the bullet above) 
must be performed following completion of neoadjuvant therapy, 
regardless of whether FNA or core biopsy was positive or negative. 
 Performance of SN biopsy prior to initiation of neoadjuvant therapy is 
discouraged.  However, patients who undergo a SN biopsy prior to 
initiation of neoadjuvant therapy do not require post-therapy surgical 
evaluation of the axilla if the pre-neoadjuvant therapy SN biopsy was 
negative.  If the pre-neoadjuvant therapy SN biopsy was positive, 
surgical evaluation of the axilla should be performed following 
completion of neoadjuvant therapy. 
 
9.9.4 Tissue processing and collection 
See Section 8.7 for recommended processing of tissue at the time of definitive 
surgery and Section 8.1 for tissue collection requirements.  Also see Appendix E 
for suggested procedure for evaluation of postneoadjuvant therapy surgical 
specimens. 
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9.10 Postoperative radiation therapy 
 Post-lumpectomy breast radiation therapy (RT) must be given. 
 Partial breast irradiation techniques utilizing brachytherapy are not permitted for 
patients in either treatment group. 
 Post-mastectomy chest wall RT is at the physician's discretion. 
 Regional nodal RT is at the physician's discretion. 
 For patients in Groups 1B, 2B, and 3B, RT may be administered concurrently with 
postoperative bevacizumab therapy. 
 All other decisions about the RT method and fractionation are at the physician's 
discretion. 
 
Refer to the NSABP Guidelines for Breast Cancer Radiation Therapy on the NSABP 
Web site. 
9.11 Postoperative adjuvant hormonal therapy 
Patients with ER-positive and/or PgR-positive tumors should receive a minimum of  
5 years of hormonal therapy following completion of neoadjuvant chemotherapy and 
surgery.  Selection of agents will be at the physician’s discretion. 
9.12 Non-protocol therapy guidelines 
The following types of treatment, in addition to any cancer therapy other than that 
specified in the protocol, are prohibited until the time of development of the first tumor 
progression or breast cancer recurrence or second primary cancer. 
9.12.1 Other postoperative adjuvant systemic therapy 
For patients who have received a total of 6 to 8 cycles of preoperative therapy, 
postoperative systemic therapy (other than bevacizumab [for patients in Groups 
1B, 2B, and 3B] and hormonal therapy as described in Section 9.11) is 
prohibited.  For any patient who received fewer than 6 preoperative 
chemotherapy cycles and who had residual disease at the time of surgery, 
postoperative chemotherapy is at the physician’s discretion.  However, 
postoperative bevacizumab may not be administered if postoperative 
chemotherapy is used. 
9.12.2 Radiation therapy 
Partial breast irradiation techniques utilizing brachytherapy are not permitted for 
patients in either treatment group. 
9.12.3 Hormonal therapy 
The following types of hormonal therapy are prohibited: 
 SERMs other than tamoxifen and toremifene 
 Sex hormonal therapy, e.g., estrogen or progesterone-replacement therapy 
(including low-dose estrogen in the form of vaginal cream) and hormonal 
contraceptives 
 Femring® 
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9.12.4 Recommendations for management of menopausal vaginal symptoms 
 Non-hormonal therapy interventions (e.g., Astroglide® or Replens®) are 
strongly encouraged for management of vaginal symptoms. 
 Although the use of vaginal hormonal therapies is not encouraged, the 
following are permitted: 
 Conjugated estrogen ring (Estring®). 
 Vagifem® (permitted for patients who are unable to tolerate Estring®). 
For patients receiving an AI for adjuvant hormonal therapy, use of these 
products is strongly discouraged as they may increase circulating estradiol 
levels and reduce the effectiveness of the AI. 
9.12.5 Trastuzumab 
Patients who are candidates for adjuvant trastuzumab (IHC 3+ or FISH positive) 
are excluded from participation in B-40.  If analysis of residual disease following 
protocol therapy indicates the patient may be a candidate for trastuzumab  
(IHC 3+ or FISH positive), trastuzumab may be given at the investigator's 
discretion.  However, if trastuzumab is administered, bevacizumab must not be 
given postoperatively. 
9.12.6 Participation in other clinical trials 
 Patients may participate in the Suppression of Ovarian Function Trial 
(SOFT). 
 If a B-40 patient is considering participation in another clinical trial 
(including supportive therapy trials), contact the NSABP Clinical 
Coordinating Division (see Information Resources on page v). 
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10.0 CHEMOTHERAPY DOSE MODIFICATIONS AND DELAYS 
Patients should receive 4 cycles of both of their assigned chemotherapy regimens unless there is 
evidence of progressive disease or excessive toxicity. 
10.1 General instructions for dose modifications and delays for all patients 
 Dose modifications are detailed in Tables 16 through 27. 
 The Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0) 
must be used to grade the severity of adverse events (AEs). 
 All doses should be based on the AE requiring the greatest modification. 
 Doses that have been reduced may not be escalated. 
 Chemotherapy should be held for at least 1 week until any AE requiring dose 
modification returns to  grade 1.  The exceptions are neutrophils, which must be  
 1200/mm3, and bilirubin, which must be at or below baseline grade.  If recovery to 
 grade 1 has not occurred after 3 weeks of delay, protocol therapy must be 
discontinued.  Further treatment is at the investigator's discretion. 
10.2 Dose modification for docetaxel alone (Groups 1A and 1B) 
 All dose modifications for docetaxel alone are based on the dose level changes in 
Table 16. 
 Instructions for management of toxicities related to docetaxel are listed on Tables 17, 
18, 24, and 25. 
 The use of G-CSF as primary prophylaxis is REQUIRED for all Group 1A and 
Group 1B patients. 
 If docetaxel is discontinued early due to toxicity, proceed to treatment with AC at 
Dose Level 0 when toxicities from docetaxel are  grade 1.  Exceptions are 
neutrophils, which must be  1200/mm3, and bilirubin, which must be at or below the 
baseline grade. 
 If docetaxel is discontinued early due to tumor progression, further treatment is at the 
discretion of the investigator.  (Note: For patients also receiving bevacizumab, 
surgery may occur no sooner than 28 days after the last dose of bevacizumab.) 
 
TABLE 16.  Dose levels for docetaxel (Groups 1A and 1B) 
 
Dose Level 0 
Starting Dose 
(mg/m2) 
Dose Level -1 
(mg/m2) 
Dose Level -2 
(mg/m2) Dose Level -3 
Docetaxel 100 75 60 Discontinue 
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TABLE 17. Dose modifications and delays for docetaxel alone (Groups 1A and 1B) (Also see Tables 20, 24, and 25) 
Important table instructions: 
 Dose modifications must be based on AEs observed during the cycle (column 2) and AEs present on the scheduled cycle Day 1  
(column 3). 
 Dose modifications must be based on the AE requiring the greatest modification. 
NCI CTCAE v3.0 
Category/Grade 
Modifications for AEs that 
occurred during a cycle but 
DID NOT REQUIRE A DELAY IN 
THE NEXT CYCLE OF 
TREATMENTa 
Modifications for AEs that 
REQUIRED A DELAY IN THE NEXT  
TREATMENT CYCLEb,c 
Blood/bone marrow: 
Neutrophils/granulocytes 
Grades 2 (1000-1199/mm3), 3, 4 
 
 
Maintain dose 
ANC: Hold until ≥ 1200/mm3.  If recovery takes: 
1 week – maintain dose  
2 - 3 weeks –   one dose level 
Platelets 
Grades 2, 3 
 
Maintain dose 
Platelets: Hold until ≥ 75,000/mm3.  If recovery takes: 
1 week – maintain dose 
2 to 3 weeks - ↓ one dose level 
Grade 4 ↓ one dose level ↓ one dose level 
GI (if related to chemotherapy): 
Diarrhea 
Grade 2 
 
 
Maintain dose 
 
 
↓ one dose level 
Grade 3 ↓ one dose level ↓ one dose level 
Grade 4 ↓ two dose levels or D/C ↓ two dose levels or D/C 
Mucositis/stomatitis 
Grade 2 
 
Maintain dose 
 
↓ one dose level 
Grade 3 ↓ one dose level ↓ one dose level 
Grade 4 ↓ two dose levels or D/C ↓ two dose levels or D/C 
Vomiting (despite antiemetics) 
Grade 2 
 
↓ one dose level (optional) 
 
↓ one dose level 
Grades 3, 4 ↓ one dose level or D/C ↓ two dose levels or D/C 
Hepatic function: 
Bilirubin or AST or alk phos 
Grade 2 
 
 
↓ one dose level 
Hold until bilirubin returns to the baseline grade 
and AST and alk phos have returned to ≤ grade 1. 
↓ one dose level 
Grade 3 ↓ two dose levels ↓ two dose levels 
Grade 4 D/C D/C 
Infection:  
Febrile neutropenia/ Infection with 
grade 3 or 4 ANC 
Grade 3 
 
 
 
 one dose level 
 
 
 
 one dose level 
Grade 4  two dose levels or D/C  two dose levels or D/C 
Infection with normal ANC 
Grade 3 
 
Maintain dose or  one dose level 
 
Maintain dose or  one dose level 
Grade 4  two dose levels or D/C  two dose levels or D/C 
Other clinically significant AEsd: 
Grade 3 
 
↓ one dose level 
 
↓ one dose level 
Grade 4 ↓ two dose levels or D/C D/C 
a Treatment may not proceed until toxicity is ≤ grade 1, except for ANC/AGC which must be ≥ 1200/mm3 and bilirubin, which must be 
 the baseline grade. 
b Hold and check weekly.  With exception of ANC/AGC and bilirubin, resume treatment when toxicity is ≤ grade 1.   
c If toxicity has not resolved to ≤ grade 1 after 3 weeks of delay, D/C protocol therapy.  Further therapy is at the investigator's discretion. 
d Determination of "clinically significant" AEs is at the discretion of the investigator. 
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10.3 Dose modifications and delays for docetaxel and capecitabine (Groups 2A and 2B) 
 All dose modifications for docetaxel and capecitabine are based on the dose level 
changes outlined in Table 18. 
 Instructions for management of toxicities related to docetaxel and capecitabine are 
listed on Table 19. 
 Instructions for management of hand-foot skin reaction are listed on Table 20. 
 Instructions for management of docetaxel-specific toxicities are listed on Tables 24 
and 25. 
 Please note that use of pegfilgrastim is prohibited with capecitabine.  (Refer to 
footnote d on Table 19.) 
 If both docetaxel and capecitabine are discontinued early due to toxicity, proceed to 
treatment with AC at Dose Level 0 when toxicities from docetaxel and capecitabine 
are  grade 1.  Exceptions are neutrophils, which must be  1200/mm3, and bilirubin, 
which must be at or below the baseline grade. 
 If docetaxel and capecitabine are discontinued early due to tumor progression, further 
treatment is at the discretion of the investigator.  (Note: For patients also receiving 
bevacizumab, surgery may occur no sooner than 28 days after the last dose of 
bevacizumab.) 
 
TABLE 18.  Dose levels for docetaxel and capecitabine (Groups 2A and 2B) 
 
Dose Level 0 
Starting Dose 
(mg/m2) 
Dose Level -1 
(mg/m2) 
Dose Level -2 
(mg/m2) Dose Level -3 
Docetaxel 75 60 50 Discontinue 
Capecitabine 825 (BID) 650 (BID) 500 (BID) Discontinue 
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TABLE 19. Dose modifications and delays for docetaxel and capecitabine (Groups 2A and 2B) (Also, see Tables 20, 
24, and 25 for hand-foot skin reaction, neurosensory and musculoskeletal toxicities.) 
Important table instructions: 
 Dose modifications must be based on AEs observed during the cycle (column 2) and AEs present on the scheduled Cycle Day 1 (column 3). 
 UNLESS SPECIFIED OTHERWISE, MODIFICATIONS IN DOSE LEVELS APPLY TO BOTH DRUGS. 
 Dose modifications must be based on the AE requiring the greatest modification. 
NCI CTCAE v3.0  
Category/Grade 
Modifications for AEs that occurred 
during a cycle but 
DID NOT REQUIRE A DELAY IN 
THE NEXT CYCLE OF 
TREATMENTa 
Modifications for AEs that  
REQUIRED A DELAY IN THE NEXT TREATMENT 
CYCLEb,c 
Blood/bone marrow: 
Neutrophils/granulocytes 
Grades 2 (1000-1199/mm3), 3, 4 
 
 
Maintain dose  
ANC:  Hold until > 1200/mm3  If recovery takes:  
 1 week - maintain dose and add filgrastimc 
 2-3 weeks -  docetaxel one dose level & add filgrastimd. 
Platelets 
Grades 2, 3 
 
Maintain dose 
Platelets:  Hold until > 75,000/mm3  If recovery takes: 
 1 week - maintain dose 
 2-3 weeks -  docetaxel one dose level. 
Grade 4  docetaxel one dose level  docetaxel one dose level 
GI (if related to chemotherapy): 
Diarrhea or mucositis 
Grades 2, 3 
 
 
Hold and delay treatment until < grade 1.  If resolved to < grade 1, may resume capecitabine up to day 
14.  Missed doses will not be made up. 
1st occurrence –  capecitabine one dose level 
2nd occurrence –  docetaxel one dose level 
3rd occurrence – discontinue capecitabine & maintain the docetaxel dose 
Grade 4 
 
1st occurrence –  docetaxel and capecitabine one dose level or D/C 
2nd occurrence – discontinue capecitabine & maintain the docetaxel dose or D/C 
Vomiting (despite antiemetics) 
Grade 2 
 
 one dose level (optional) 
 
 one dose level 
Grades 3, 4  one dose level or D/C  two dose levels or D/C 
Dysphagia 
Grade 3 
 
 capecitabine one dose level 
 
↓ one dose level 
Grade 4  one dose level or D/C D/C 
Hepatic function: 
Bilirubin, alk phos, or AST 
Grade 2 
 
 
 docetaxel one dose level 
Hold until bilirubin returns to baseline grade and  AST and 
alk phos are < grade 1. 
 docetaxel one dose level 
Grade 3  one dose level  two dose levels 
Grade 4 D/C D/C 
Infection including febrile neutropenia, 
infection with grade 3 or 4 ANC, and 
infection with normal ANC: 
Grade 3 (First episode) 
 
 
 
Maintain dose; add filgrastimd 
 
 
 
Maintain dose; add filgrastimd 
Grade 3 (Subsequent episodes)  one dose level  one dose level 
Grade 4 (First episode)  docetaxel one dose level ;  
 add filgrastimd  
 docetaxel one dose level ; add filgrastimd  
Grade 4 (Subsequent episodes) D/C D/C 
Renal: 
Serum creatinine 
Grades 2, 3, 4 
 
Hold until serum creatinine  grade 1 and calculated creatinine clearance is  50 mL/min.  (see 
Appendix C).  Maintain dose unless other AE requires dose reduction. 
Other clinically significant AEse 
Grade 3 
 
 one dose levele 
 
 one dose levele 
Grade 4  two dose levels or D/Ce D/Ce 
a Treatment may not proceed until toxicity is ≤ grade 1, except for ANC/AGC, which must be ≥ 1200/mm3 and bilirubin, which must be  the 
baseline grade. 
b Hold and check weekly.  With exception of ANC/AGC and bilirubin, resume treatment when toxicity is ≤ grade 1.   
c If toxicity has not resolved to ≤ grade 1 after 3 weeks of delay, D/C protocol therapy.  Further therapy is at the investigator's discretion. 
d Begin filgrastim on Day 2 and continue according to drug package insert.  Do not administer pegfilgrastim with capecitabine. 
e Determination of "clinically significant" AEs is at the discretion of the investigator.  Also at investigator's discretion, the dose levels of 
capecitabine and docetaxel can be modified independently. 
 NSABP B-40 – Page 73 
TABLE 20.   Dose modifications and delays for hand-foot skin reaction (Groups 2A and 2B) 
Hand-Foot Skin Reaction Treatment Modifications* 
Grade 2 
1st occurrence –  capecitabine one dose level 
2nd occurrence –  docetaxel one dose level 
3rd occurrence – discontinue capecitabine & maintain the docetaxel dose 
Grade 3 
1st occurrence –  docetaxel and capecitabine one dose level 
2nd occurrence –  capecitabine one additional dose level 
3rd occurrence – discontinue capecitabine & maintain the docetaxel dose 
* Hold and delay capecitabine until < grade 1.  If resolved to < grade 1, may resume up to Day 14.  
 (Do not make up missed doses.) 
 
10.4 Dose modifications and delays for docetaxel and gemcitabine (Groups 3A and 3B) 
10.4.1 Pulmonary toxicity related to gemcitabine (Groups 3A and 3B) 
 Hold gemcitabine if any of the following occur: 
 Dyspnea  grade 2 
 Hypoxia  grade 2 
 Pneumonitis/pulmonary infiltrates  grade 2 
 Pulmonary fibrosis  grade 2 
 Cough  grade 3 
 
 Rule out interstitial lung disease: 
 If non-infectious interstitial lung disease is confirmed, gemcitabine must 
be discontinued.  Continuation of docetaxel will be at the discretion of 
the investigator. 
 If non-infectious interstitial disease is ruled out and infection (if any) has 
resolved, patients may resume treatment with persistent grade 2 dyspnea 
or hypoxia at the discretion of the investigator. 
 
10.4.2 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura 
(HUS/TTP) possibly related to gemcitabine (Groups 3A and 3B) 
If persistent  grade 2 thrombocytopenia is noted, evaluate for HUS/TTP.  If 
confirmed, discontinue chemotherapy.  The diagnosis of HUS should be 
considered if the patient develops anemia with evidence of microangiopathic 
hemolysis, elevation of bilirubin or LDH, reticulocytosis, severe 
thrombocytopenia, or renal insufficiency. 
10.4.3 Dose modifications for docetaxel and gemcitabine (Groups 3A and 3B) 
 All dose modifications for docetaxel and Day 1 gemcitabine are based on the 
dose level changes outlined in Table 21. 
 Instructions for management of toxicities related to docetaxel and Day 1 
gemcitabine are listed on Table 22. 
 Instructions for dose modifications for Day 8 gemcitabine are listed on  
Table 23. 
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 Instructions for management of docetaxel-specific toxicities are listed on 
Tables 24 and 25. 
 If both docetaxel and gemcitabine are discontinued early due to toxicity, 
proceed to treatment with AC at Dose Level 0 when toxicities from docetaxel 
and gemcitabine are  grade 1.  Exceptions are neutrophils, which must be  
 1200/mm3, and bilirubin, which must be at or below the baseline grade. 
 If discontinued early due to tumor progression, further treatment is at the 
discretion of the investigator.  (Note: For patients receiving bevacizumab, 
surgery may occur no sooner than 28 days after the last dose of 
bevacizumab.) 
 
TABLE 21.  Dose levels for docetaxel and Day 1 gemcitabine (Groups 3A and 3B) 
 
Dose Level 0 
Starting Dose 
(mg/m2) 
Dose Level -1 
(mg/m2) 
Dose Level -2 
(mg/m2) Dose Level -3 
Docetaxel 75 60 50 Discontinue 
Gemcitabine 1000 750 600 Discontinue 
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TABLE 22. Dose modifications and delays for docetaxel and Day 1 gemcitabine (Groups 3A and 3B)  (Also, see 
 Table 23 for Day 8 gemcitabine instructions and Tables 24 and 25 for docetaxel-specific toxicities.) 
Important table instructions: 
 Dose modifications must be based on AEs observed during the cycle (column 2) and AEs present on the scheduled Cycle Day 1 (column 3). 
 UNLESS OTHERWISE SPECIFIED, MODIFICATIONS IN DOSE LEVELS APPLY TO BOTH DRUGS. 
 Dose modifications must be based on the AE requiring the greatest modification. 
NCI CTCAE v3.0 
Category/Grade 
Modifications for AEs that occurred during a 
cycle but DID NOT REQUIRE A  
DELAY IN THE NEXT CYCLE OF 
TREATMENTa 
Modifications for AEs that 
REQUIRED A DELAY IN THE NEXT TREATMENT 
CYCLEb,c 
Blood/bone marrow: 
Neutrophils/granulocytes 
Grades 2 (1000-1199/mm3), 3, 4 
 
 
Maintain dose 
ANC: Hold until  1200/mm3. If recovery takes: 
 1 week – maintain dose 
 2 to 3 weeks –  gemcitabine one dose level and 
  add filgrastim.d 
Platelets 
Grades 2, 3 
 
Maintain dose 
Platelets: Hold until  75,000/mm3.  If recovery takes: 
 1 week – maintain dose 
 2 to 3 weeks -  one dose level 
Grade 4   gemcitabine one dose level  gemcitabine one dose level 
GI (if related to chemotherapy): 
Diarrhea 
Grade 2 
 
 
Maintain dose 
 
 
 one dose level 
Grade 3  one dose level  one dose level 
Grade 4  two dose levels or D/C  two dose levels or D/C 
Mucositis/stomatitis 
Grade 2 
 
Maintain dose 
 
 one dose level 
Grade 3  one dose level  one dose level 
Grade 4  two dose levels or D/C  two dose levels or D/C 
Vomiting (despite antiemetics) 
Grade 2 
 
 one dose level (optional) 
 
 one dose level 
Grades 3,4  one dose level or D/C  two dose levels or D/C 
Hepatic function: 
Bilirubin or AST or alk phos 
Grade 2 
 
 
 gemcitabine one dose level 
Hold until bilirubin returns to the baseline grade and 
AST and alk phos have returned to  grade 1. 
 gemcitabine one dose level 
Grade 3  one dose level  two dose levels 
Grade 4 D/C D/C 
Infection: including febrile 
neutropenia, infection with grade 3/4 
ANC; infection with normal ANC: 
Grade 3 (First episode) 
 
 
 
Maintain dose; add filgrastimd 
 
 
 
Maintain dose; add filgrastimd 
Grade 3 (Subsequent episodes)  one dose level  one dose level 
Grade 4 (First episode)  one dose level; add filgrastimd  one dose level; add filgrastimd 
Grade 4 (Subsequent episodes) D/C D/C 
Dermatology/skin: 
Grade 2 
 
Maintain dose or  gemcitabine one dose level 
 
 gemcitabine one dose level 
Grades 3, 4 D/C gemcitabine D/C gemcitabine 
Other clinically significant AEse 
Grade 3 
 
 one dose levele 
 
 one dose levele 
Grade 4  two dose levels or D/Ce D/Ce 
a Treatment may not proceed until toxicity is  grade 1, except for ANC/AGC, which must be  1200/mm3 and bilirubin, which must be  the 
baseline grade. 
b Hold and check weekly.  With exception of ANC/AGC, and bilirubin, resume treatment when toxicity is  grade 1. 
c If toxicity has not resolved to  grade 1 after 3 weeks of delay, D/C protocol therapy.  Further therapy is at the investigator's discretion. 
d Begin filgrastim on Day 2 and continue through Day 7.  Management guidelines for treatment beyond Day 7 are provided on Table 23. 
e Determination of "clinically significant" AEs is at the discretion of the investigator. Also at the investigator's discretion, the dose levels of 
gemcitabine and docetaxel can be modified independently. 
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TABLE 23.  Dose modifications for Day 8 gemcitabine administration* (Groups 3A and 3B) 
NCI CTCAE v3.0 
Category/Grade Dose Modification 
Blood/bone marrow: 
Neutrophils/granulocytes 
Grades 0-2 
 
 
Treat at Day 1 gemcitabine dose given for that cycle 
Grade 3 
 
 
 
 
 
 
 
 
Treat at 75% of Day 1 gemcitabine dose given that cycle. 
 If the patient was not on secondary prophylaxis, 
administer pegfilgrastim 6 mg subcutaneously on Day 9.  
As an alternative, filgrastim can be initiated on Day 9 
and continued through Day 15 and ANC  5000.  Use 
secondary prophylaxis for subsequent cycles. 
 If the patient was on secondary prophylaxis administer 
pegfilgrastim 6 mg subcutaneously on Day 9.  As an 
alternative, filgrastim can be resumed on Day 9 and 
continued through Day 15 and ANC  5000. 
Grade 4 
 
 
 
 
 
 
 
Omit Day 8 gemcitabine 
 If patient was not on secondary prophylaxis, use of 
prophylactic filgrastim will be required for subsequent 
cycles.  Decision to manage Day 8 Grade 4 neutropenia 
with filgrastim or pegfilgrastim will be at investigator's 
discretion. 
 If patient was on secondary prophylaxis, continue daily 
filgrastim through Day 10 and ANC  5000. 
Platelets 
Grades 0-1 
 
Treat at Day 1 gemcitabine dose given that cycle. 
Grade 2 Treat at 75% of Day 1 gemcitabine dose given that cycle. 
Grade 3-4 Omit Day 8 gemcitabine. 
Non-hematologic toxicities:** 
Grade 1 - regardless of attribution 
 
Treat at Day 1 gemcitabine dose for that cycle. 
Grade 2 - related to gemcitabine Omit Day 8 gemcitabine. 
Grade 2 - not related to gemcitabine Treat at Day 1 gemcitabine dose given for that cycle. 
Grades 3, 4 - regardless of attribution Omit Day 8 gemcitabine 
 
* These dose modifications apply only to Day 8 gemcitabine (use the percentages listed on this table, 
not the dose levels in Table 21).  The patient will resume the appropriate Day 1 dose of gemcitabine 
using the dose levels on Table 21 with the next cycle of chemotherapy. 
**  Determination of attribution will be at the investigator's discretion. 
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10.5 Management of docetaxel-related neurosensory toxicity (all groups) 
TABLE 24.  Dose modifications for neurosensory toxicity related to docetaxel 
Paresthesias/Dysesthesias 1 – 7 Days Duration 
Persistent for  7 Days or 
Caused the Next Cycle  
to be Delayed 
Grade 1 – Paresthesias/dysesthesias 
that do not interfere with function Maintain dose Maintain dose 
Grade 2 – Paresthesias/dysesthesias 
interfering with function, but not 
activities of daily living 
Maintain dosea Decrease docetaxel one dose levelb 
Grade 3 – Paresthesias/dysesthesias 
with pain or with function 
impairment that also interfere with 
activities of daily living 
First episode: 
Decrease docetaxel  
one dose levela 
 
Second episode: 
Discontinue docetaxel 
Discontinue docetaxel 
Grade 4 – Persistent 
paresthesias/dysesthesias that are 
disabling or life-threatening 
Discontinue docetaxel Discontinue docetaxel 
a Must be resolved to  grade 1 on Day 1 of the next cycle. 
b Hold chemotherapy for persistent grade 2 neurosensory toxicity.  When ≤ grade 1, resume 
treatment with dose modification.  If grade 2 toxicity persists after 3 weeks of delay, discontinue 
docetaxel and proceed with other chemotherapy (if applicable). 
 
10.6 Management of docetaxel-related musculoskeletal pain (all groups) 
TABLE 25. Dose modifications for musculoskeletal pain attributed to docetaxel and not controlled by 
analgesics* 
Musculoskeletal Pain 1 – 7 Days Duration 
Persistent for  7 Days or 
Caused the Next Cycle  
to be Delayed 
Grade 1 Maintain dose Maintain dose 
Grade 2 Maintain dose 
Maintain dose 
OR 
Decrease docetaxel 
one dose level 
Grade 3 
First episode: 
Decrease docetaxel 
one dose level  
 
Second episode: 
Discontinue docetaxel 
 
First episode: 
Decrease docetaxel 
one dose level 
OR 
Discontinue docetaxel 
 
Second episode: 
Discontinue docetaxel 
 
Grade 4 Discontinue docetaxel Discontinue docetaxel 
* Use of narcotics and NSAIDs is encouraged to maintain dose of docetaxel if possible. 
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10.7 Dose modifications and delays for AC (all groups) 
10.7.1 Left ventricular dysfunction 
Discontinue AC if the patient develops ≥ grade 2 left ventricular systolic 
dysfunction or ≥ grade 3 left ventricular diastolic dysfunction.  Refer to Section 
11.2 for additional instructions. 
10.7.2 Dose modifications for AC 
 All dose modifications for AC are based on the dose level changes in  
Table 26. 
 Instructions for management of toxicities related to AC are listed on  
Table 27. 
 If secondary prophylactic use of G-CSF was required during treatment with 
the docetaxel/capecitabine or docetaxel/gemcitabine regimens, or dose 
reduction due to infection was required with docetaxel alone, it should be 
continued during treatment with AC.  If secondary prophylaxis with G-CSF 
was not required with docetaxel/capecitabine or docetaxel/gemcitabine or 
infections did not occur with docetaxel supported by primary prophylaxis 
with G-CSF, primary prophylaxis with G-CSF for AC will be at the 
investigator's discretion. 
 If AC is discontinued early: 
 Due to toxicity, the patient should proceed to surgery. 
 Due to tumor progression, all study therapy must be discontinued and 
further treatment is at the discretion of the investigator.  Note: See 
Section 9.9.2 for instructions regarding the timing of surgery for patients 
who have received bevacizumab.  For patients who receive fewer than a 
total of 6 cycles of preoperative chemotherapy and have residual disease 
at the time of surgery, refer to Section 9.12.1 for instructions regarding 
postoperative therapy. 
TABLE 26.  Dose levels for AC (all groups) 
 Dose Level 0 
Starting Dose 
(mg/m2) 
Dose Level -1 
(mg/m2) 
Dose Level -2 
(mg/m2) Dose Level -3 
Doxorubicin 60 50 40 Discontinue 
Cyclophosphamide 600 500 400 Discontinue 
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TABLE 27.  Dose modifications and delays for AC (all groups) 
Important table instructions: 
 Dose modifications must be based on AEs observed during the cycle (column 2) and AEs present on the scheduled Cycle Day 1 (column 3). 
 ALL MODIFICATIONS IN DOSE LEVELS APPLY TO BOTH DRUGS. 
 Dose modifications must be based on the AE requiring the greatest modification.   
NCI CTCAE v3.0 
Category/Grade 
Modifications for AEs that 
occurred during a cycle but 
DID NOT REQUIRE A 
DELAY IN THE NEXT 
CYCLE OF TREATMENTa 
Modifications for AEs that 
REQUIRED A DELAY IN THE NEXT 
TREATMENT CYCLEb,c 
Blood/bone marrow: 
Neutrophils/granulocytes 
Grades 2 (1000-1199/mm3), 3, 4 
 
 
Maintain dose 
ANC: Hold until ≥ 1200/mm3.  If recovery takes: 
1 week – maintain dose and add G-CSFd 
2 - 3 weeks –   one dose level and add G-CSFd 
Platelets 
Grades 2, 3 
 
Maintain dose 
Platelets: Hold until ≥ 75,000/mm3.  If recovery takes: 
1 week – maintain dose 
2 to 3 weeks - ↓ one dose level 
Grade 4 ↓ one dose level ↓ one dose level  
GI (if related to chemotherapy): 
Diarrhea 
Grade 2 
 
 
Maintain dose 
 
 
↓ one dose level 
Grade 3 ↓ one dose level ↓ one dose level 
Grade 4 ↓ two dose levels or D/C ↓ two dose levels or D/C 
Mucositis/stomatitis 
Grade 2 
 
Maintain dose 
 
↓ one dose level 
Grade 3 ↓ one dose level ↓ one dose level 
Grade 4 ↓ two dose levels or D/C ↓ two dose levels or D/C 
Vomiting (despite antiemetics) 
Grade 2 
 
↓ one dose level (optional) 
 
↓ one dose level 
Grades 3, 4 ↓ one dose level or D/C ↓ two dose levels or D/C 
Hepatic function: 
Bilirubin or AST or alk phos 
Grade 2 
 
 
↓ one dose level 
Hold until bilirubin returns to the baseline grade 
and AST and alk phos have returned to ≤ grade 1. 
↓ one dose level 
Grade 3 ↓ two dose levels ↓ two dose levels 
Grade 4 D/C D/C 
Infection including febrile neutropenia, 
infection with grade 3 or 4 ANC, and 
infection with normal ANC: 
Grade 3 (First episode) 
 
 
 
Maintain dose & add G-CSFd 
 
 
 
Maintain dose & add G-CSFd  
Grade 3 (Subsequent episodes) ↓ one dose level ↓ one dose level  
Grade 4 (First episode) ↓ one dose level; add G-CSFd ↓ one dose level; add G-CSFd 
Grade 4 (Subsequent episodes) D/C D/C 
Other clinically significant AEse: 
Grade 3 
 
↓ one dose level 
 
↓ one dose level 
Grade 4 ↓ two dose levels or D/C D/C 
a Treatment may not proceed until toxicity is ≤ grade 1, except for ANC/AGC which must be ≥ 1200/mm3 and bilirubin, which must be  the baseline 
grade. 
b Hold and check weekly.  With exception of ANC/AGC and bilirubin, resume treatment when toxicity is ≤ grade 1.   
c If toxicity has not resolved to ≤ grade 1 after 3 weeks of delay, discontinue AC (and preoperative bevacizumab) and proceed to surgery. 
d Add G-CSF if not initiated previously.  Pegfilgrastim is preferred, at a fixed dose of 6 mg SQ on Day 2.  Filgrastim, if used, should be administered 
according to the drug package insert. 
e Determination of "clinically significant" AEs is at the discretion of the investigator. 
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11.0 BEVACIZUMAB TREATMENT DELAYS 
Instructions in Section 11.0 are for Groups 1B, 2B, and 3B patients. 
11.1 General instructions 
 The CTCAE v3.0 must be used to grade the severity of adverse events (AEs). 
 Treatment decisions should be based on the AE requiring the greatest modification. 
 There are no reductions in the bevacizumab dose.  If adverse events occur that 
require holding bevacizumab, the dose will remain 15 mg/kg when treatment 
resumes. 
 Bevacizumab must end 18 months following study entry, regardless of treatment 
delays due to toxicity or for any other reason (even if all 10 postoperative doses have 
not been administered). 
 If chemotherapy is held due to chemotherapy-related adverse events, bevacizumab 
must also be held. 
 If all remaining chemotherapy is discontinued for a chemotherapy-related toxicity 
before completion of the scheduled 8 cycles of chemotherapy, preoperative 
bevacizumab may not be continued as a single agent and the patient should proceed 
to surgery.  (Postoperative bevacizumab may be administered.) 
 If alternative (non-protocol) therapy is given at any time, bevacizumab must be 
discontinued. 
 If tumor progression occurs, bevacizumab must be discontinued. 
 If bevacizumab must be discontinued before completion of chemotherapy, the 
remaining chemotherapy cycles should be continued as per protocol.  For patients in 
Groups 1B, 2B, and 3B, bevacizumab may not be re-initiated postoperatively. 
 Instructions regarding cardiac function adverse events are described in Section 11.2 
(Table 28).  See Section 11.3 (Table 29) for other adverse events requiring delays or 
permanent discontinuation of bevacizumab. 
11.2 Cardiac adverse events 
11.2.1 Asymptomatic decrease in LVEF 
 To determine if the patient has had an asymptomatic decrease in LVEF, all 
patients will undergo a scheduled LVEF assessment 3-4 weeks after the post-
chemotherapy cycle (before surgery) using the method (MUGA or 
echocardiogram) that was performed at baseline.  Also, patients in Groups 
1B, 2B, and 3B who receive any bevacizumab (preoperatively or 
postoperatively) will undergo a scheduled LVEF assessment at 18 months 
after study entry. 
For patients in Groups 1B, 2B, and 3B, the result of the LVEF assessment 
performed following the last chemotherapy cycle (before surgery) will be 
used to determine if bevacizumab can be resumed postoperatively as outlined 
on Table 28.  Depending on the LVEF result at this time point, additional 
LVEF assessments may be required for the initiation and continuation of 
postoperative bevacizumab (see Table 28 for additional instructions). 
02/15/08 
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 In asymptomatic Groups 1B, 2B, and 3B patients, the decision to continue or 
stop bevacizumab is based upon two factors: 
 the measured ejection fraction as it relates to the cardiac imaging 
facility's lower limit of normal.  Note: If the cardiac imaging facility 
cannot provide a LLN, use 50% as the LLN value. 
 the change in ejection fraction from baseline. 
 Table 28 summarizes the LVEF requirements for bevacizumab therapy in 
asymptomatic patients.  Bevacizumab may not be administered to patients 
who have a symptomatic decrease in LVEF (see Section 11.2.2). 
TABLE 28.  Summary of LVEF requirements for continuation of bevacizumab in asymptomatic patients 
(Groups 1B, 2B, and 3B) 
Absolute change in LVEF between baseline 
(before study entry) and any assessment 
performed following study entry 
Instructions for continuation of bevacizumab 
and for repeat LVEF assessments 
Increase or no change from baseline Continue bevacizumab 
No more than 15 percentage points below baseline LVEF 
and 
No more than 5 percentage points below the cardiac 
imaging facility's LLN 
Continue bevacizumab 
16 or more percentage points below baseline LVEF 
or 
6 or more percentage points below the cardiac imaging 
facility's LLN 
HOLD BEVACIZUMAB 
Follow instructions below based on specific 
LVEF time points* 
*INSTRUCTIONS WHEN BEVACIZUMAB IS HELD: 
 Based on the scheduled post-chemotherapy LVEF assessment (prior to surgery): Repeat the LVEF 
assessment 3-5 weeks after surgery. 
 If the repeat LVEF does not meet the criteria to continue bevacizumab, bevacizumab may NOT be 
initiated postoperatively. 
 If the repeat LVEF meets the criteria to continue bevacizumab postoperatively, postoperative 
bevacizumab may be initiated.  However, for these patients, an additional LVEF assessment will be 
required after 4 postoperative doses of bevacizumab.  If the LVEF obtained after 
4 postoperative doses does NOT meet criteria for continuing bevacizumab, postoperative 
bevacizumab must be permanently discontinued. 
 Based on a discretionary LVEF assessment performed at any time during bevacizumab therapy: 
The investigator should repeat the LVEF assessment in 4 weeks. 
 If the repeat LVEF meets criteria to continue bevacizumab, bevacizumab may be resumed. 
 If the repeat LVEF does NOT meet criteria to continue bevacizumab, further bevacizumab therapy 
may not be given. 
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11.2.2 Symptomatic decrease in LVEF 
 Congestive heart failure (grade 3): Patients should be monitored for signs 
and symptoms of CHF (i.e., dyspnea, tachycardia, cough, neck vein 
distention, cardiomegaly, hepatomegaly, paroxysmal nocturnal dyspnea, 
orthopnea, peripheral edema, etc.).  If the patient develops these signs and 
symptoms, bevacizumab (and chemotherapy) must be held. 
The investigator must confirm the diagnosis of CHF with an LVEF 
assessment (MUGA scan or echocardiogram).  A chest x-ray is also required. 
If the diagnosis of CHF is confirmed, bevacizumab and AC are prohibited.  
If CHF occurs during the docetaxel-based regimen and bevacizumab, 
continuation of the docetaxel-based chemotherapy regimen is at the 
investigator's discretion. 
Report  grade 3 left ventricular systolic dysfunction and left ventricular 
diastolic dysfunction in an expedited manner via AdEERS (see 
Section14.2.2).  All reports and supporting documentation must be submitted 
with Form LVA to the NSABP Biostatistical Center within 4 weeks 
following the LVEF assessment. 
The protocol-specified schedule for obtaining LVEF assessments should be 
followed even after the discontinuation of protocol therapy or occurrence of 
a cardiac event. 
 Severe refractory CHF or requiring intubation (grade 4): Discontinue all 
study therapy and submit Form LVA (if MUGA or echocardiogram was 
performed), and supporting documentation. 
11.2.3 Cardiac ischemia/infarction 
If the patient develops grade 3 or 4 cardiac ischemia/infarction, protocol therapy 
must be discontinued.  Further therapy is at the investigator's discretion. 
11.2.4 Other cardiac symptoms 
 If the patient develops grade 2, 3, or 4 cardiac conduction abnormality, grade 
3 or 4 supraventricular arrhythmia, or grade 2, 3, or 4 ventricular arrhythmia 
during the docetaxel-based regimen and bevacizumab, protocol therapy 
should be discontinued.  When symptoms have resolved to  grade 1, the 
patient should proceed to surgery.  Postoperative bevacizumab is prohibited. 
 If these conditions occur while receiving AC and bevacizumab, AC and 
bevacizumab must be discontinued.  When symptoms have resolved to  
 grade 1, the patient should proceed to surgery.  Postoperative bevacizumab 
is prohibited. 
11.3 Bevacizumab delays and instructions for non-cardiac toxicities 
Refer to Table 29 for a summary of bevacizumab instructions for non-cardiac adverse 
events. 
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TABLE 29. Bevacizumab treatment delays and instructions for non-cardiac adverse events (See Section 11.2 for 
 cardiac adverse events.) 
Adverse Event 
Grade 
CTCAE 
v3.0 
Action to be Taken 
1, 2 or 3  
- If infusion-related or allergic reactions occur, pre-meds should be given with the next dose, but 
 the infusion time may not be ↓ for the subsequent infusion.  If the next dose is well-tolerated 
 with pre-meds, the subsequent infusion time may be ↓ by 30 ± 10 min. as long as pre-meds 
 continue to be used.  If infusion-related AEs occur with the 60-min. infusion, all subsequent 
 doses should be given over 90 ± 15 min. (with pre-meds).  If infusion-related AEs occur with the 
 30-min. infusion, all subsequent doses should be given over 60 ± 10 min. (with pre-meds). 
 
- For patients with grade 3 reactions, the bevacizumab infusion should be stopped and not re-
 started on that day.  At the physician's discretion, bevacizumab may be permanently 
 discontinued or re-instituted with pre-medications and at a rate of 90 ± 15 minutes.  If the 
 reaction occurred at the 90-minute rate, initially challenge at a slower infusion rate and gradually 
 increase to 90 minutes.  When bevacizumab is re-instituted, the patient should be monitored, per 
 physician's usual practice, for a duration comparable to duration of reaction. 
Cytokine release syndrome/acute 
infusion reaction 
 
or 
 
Allergic reaction/hyper-
sensitivity (e.g., fever, rash, 
urticaria, bronchospasm) 
 
4 Permanently discontinue bevacizumab. 
Hemorrhagea 3 or 4 Permanently discontinue bevacizumab. 
2 or 3 
Hold bevacizumab until clinical resolution. 
 If the planned duration of full-dose anticoagulation is  2 weeks, hold bevacizumab until 
anticoagulation is complete.  
 If the planned duration of full-dose anticoag is  2 weeks, bevacizumab may be resumed 
during anticoag if no grade 3 or 4 hemorrhage event occurred while on therapy and 
coagulation testing shows results within the therapeutic range. 
Discontinue bevacizumab if thromboembolic events worsen or recur after resuming therapy. 
Thrombosis/thrombus/ 
embolism-venous (including 
vascular access device) 
 
4 Permanently discontinue bevacizumab. 
Visceral or peripheral arterial 
ischemia 2
b,c, 3 or 4 Permanently discontinue bevacizumab. 
CNS ischemia 3 or 4 Permanently discontinue bevacizumab. 
Signs/symptoms of RPLS 
(see Section 15.4.2)  1 
For clinical features suggestive of RPLS, hold bevacizumab and obtain MRI.  If RPLS is 
diagnosed or if ANY symptoms were grade 4, permanently D/C bevacizumab.  If RPLS is not 
diagnosed, bevacizumab may be resumed when presenting symptoms are  grade 1 and blood 
pressure  150/90. 
GI perforation including GI leak 
and GI fistula  1 Permanently discontinue bevacizumab. 
Non-GI fistula  1 Permanently discontinue bevacizumab. 
3 Hold bevacizumab until resolved. Intra-abdominal abscessd 4 Permanently discontinue bevacizumab. 
1 
Hold bevacizumab for at least 1 month.  If, in the physician's opinion, substantial healing has taken 
place within 1-3 months, bevacizumab may be resumed.  If wound dehiscence recurs, permanently 
discontinue bevacizumab. 
Complication, non-infectious-
wound dehiscencee 
2, 3, or 4 Permanently discontinue bevacizumab. 
3 Hold bevacizumab until UPC ratio improves to  grade 2.  Re-check UPC ratio every 3-6 weeks.  If UPC ratio does not improve to  grade 2 within 6 weeks, permanently discontinue bevacizumab. Proteinuriaf 
4 Permanently discontinue bevacizumab. 
3 
Bevacizumab may be continued in conjunction with standard anti-hypertensive therapy at 
physician discretion.  Bevacizumab should be held for uncontrolled or symptomatic hypertension 
present on the day that the bevacizumab dose is to be given.  If BP is not controlled with 
medication within 1 month, permanently discontinue bevacizumab. 
 
 
Hypertension 
4 Permanently discontinue bevacizumab. 
3 Hold until AE has resolved to  grade 1. Other clinically significant AEsg 
4 Permanently discontinue bevacizumab. 
a  If coagulation disorders develop secondary to other medical conditions, hold bevacizumab until the PT/INR and PTT return to  grade 1. 
b  New grade 2 events. (Therapy may be continued for grade 2 conditions present at baseline.) 
c Pts. who develop brief, reversible, exercise-induced claudication (grade 2) not attributable to arterial thromboembolic events may continue on study. 
d Refer to grading criteria listed for the appropriate adverse event in the Infection Section of the CTCAE v 3.0. 
e  Refer to Dermatology/Skin Section of the CTCAE v 3.0. 
f For the purpose of this study, CTCAE v3.0 criteria for grading proteinuria in g/24 hours will be estimated by UPC ratio (see Appendix B). 
g Determination of "clinically significant" is at the physician’s discretion and applies to those adverse events that are not clearly associated with 
chemotherapy and could be related to bevacizumab.  
02/15/08 
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12.0 ASSESSMENT OF EFFECT 
12.1 Clinical assessment of effect 
For the purposes of this study, all clinical measurements will be assessed by physical 
examination of the breast and the axilla. Measurements, response, and progression will be 
determined using the international criteria proposed by the Response Evaluation Criteria 
in Solid Tumors (RECIST) Committee.127 
12.1.1 Timing of clinical assessments 
Clinical tumor measurement is obtained at baseline (prior to study entry), at the 
completion of the assigned docetaxel regimen (before starting AC therapy), and 
at the conclusion of the sequential regimens (prior to surgery).  It is 
recommended that patients also be examined before each cycle of preoperative 
therapy to ensure that there is no disease progression.  In the event of progressive 
disease (defined below), treatment will be at the discretion of the investigator. 
12.1.2 Definition of target and non-target lesions at baseline 
During the baseline assessment, all lesions detected in the breast and the axilla 
are classified as either target lesions or non-target lesions before the start of 
protocol treatment. 
 Target lesions include: 
 
 Breast tumors  2.0 cm on baseline physical examination 
 
 Axillary nodes  2.0 cm on baseline physical examination 
 
 Non-target lesions include: 
 
 Breast tumors < 2.0 cm on baseline physical examination 
 
 Axillary nodes < 2.0 cm on baseline physical examination 
 
12.1.3 Clinical measurement 
For each target lesion in the breast and the axilla, the longest unidimensional 
measurement (longest diameter, LD) is recorded.  The clinical measurement for 
this assessment is the sum of the LD measurements of the target lesions. 
02/15/08 
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12.1.4 Criteria for evaluation of clinical response 
The following criteria will be employed at the completion of the assigned 
docetaxel regimen (before starting AC therapy) and at the conclusion of the 
sequential regimens (before surgery).  These criteria are summarized in Table 30. 
 Clinical complete response (cCR) 
Disappearance of all target and non-target lesions identified at baseline, with 
no evidence of disease progression. 
 Clinical partial response (cPR) 
 
At least a 30% decrease in the sum of the longest diameter (LD) of target 
lesions (taking as reference the baseline sum of the longest diameter).  No 
definite progression of non-target lesions.  No evidence of new lesions. 
 Clinical stable disease (cSD) 
 
Neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for progressive disease. 
 Progressive disease (PD) 
 
At least a 20% increase in the sum of the longest diameter (LD) of the target 
lesions (taking as reference the smallest sum of the LD recorded).  Other 
manifestations of progressive disease would also be classified as disease 
progression, e.g.: appearance of one or more new lesions in the breast, 
regional lymph nodes or distant sites; unequivocal progression of existing 
non-target lesions; appearance of inflammatory carcinoma on clinical exam. 
TABLE 30. Criteria for evaluation of clinical response 
Target Lesions Non-Target  Lesions 
New Lesions or  
Other Signs of 
Progression 
Clinical Response 
Classification 
CR CR No CR 
CR Incomplete response or SD No PR 
PR Non-PD* No PR 
SD Non-PD* No SD 
PD Any category Yes or No PD 
Any category PD* Yes or No PD 
Any category Any category Yes PD 
* For non-target lesions, PD is defined as the unequivocal progression, as determined by the 
 investigator, of existing non-target lesions. 
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12.2 Pathologic assessment of effect 
12.2.1 Timing of evaluation 
The determination of pCR will be performed by the local pathologist following 
examination of tissue (breast and nodes) removed at the time of surgery.  See 
Appendix E for the suggested procedures for evaluation of surgical specimens for 
pCR. 
12.2.2 Criteria for evaluation of pathologic complete response 
 Pathologic complete response in the breast (pCR breast) 
 
No histologic evidence of invasive tumor cells in the surgical breast 
specimen. 
 Pathologic complete response in breast and axillary lymph nodes as well as 
non-axillary sentinel nodes (pCR breast & nodes) 
 
No histologic evidence of invasive tumor cells in the surgical breast 
specimen, axillary nodes, and sentinel nodes identified after neoadjuvant 
chemotherapy. 
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13.0 DIAGNOSIS OF BREAST CANCER RECURRENCE AND OTHER CANCER EVENTS 
 The diagnosis of a first breast cancer recurrence or second primary cancer can be made only 
when both the clinical and laboratory findings meet "acceptable" criteria as defined below.  
Suspicious findings do not constitute criteria for breast cancer recurrence, nor are they an 
indication to alter protocol therapy. 
 Please submit a copy of the clinic/office note summarizing the work-up and treatment plan 
for a recurrence or a second primary cancer. 
 Treatment of a breast cancer recurrence or second primary cancer will be at the discretion of 
the investigator. 
13.1 Local recurrence 
Recurrent tumor is defined as evidence of invasive or in situ breast cancer (except LCIS) 
in the ipsilateral breast or skin of the breast.  Patients who develop clinical evidence of 
tumor recurrence in the remainder of the ipsilateral breast must have a biopsy of the 
suspicious lesion to confirm the diagnosis.   
 Acceptable: positive cytology or histologic biopsy 
13.1.1 Ipsilateral breast tumor recurrence (IBTR) 
An IBTR event is defined as recurrent tumor in either the ipsilateral breast 
parenchyma or skin of the breast occurring after lumpectomy. 
13.1.2 Other local recurrence 
Defined as recurrence in the skin of the chest wall (exclusive of the breast) or 
chest wall. 
13.2 Regional recurrence 
Defined as the development of tumor in the ipsilateral internal mammary, ipsilateral 
supraclavicular, ipsilateral infraclavicular and/or ipsilateral axillary nodes, as well as the 
soft tissue of the ipsilateral axilla, after operation. 
 Acceptable: positive cytology or histologic biopsy 
13.3 Distant recurrence 
Defined as evidence of tumor in any area of the body, with the exception of those 
described in Sections 13.1 and 13.2. 
13.3.1 Skin, subcutaneous tissue, and lymph node (other than local or regional) 
metastases 
 Acceptable: (i) positive cytology, histologic biopsy, or (ii) radiologic 
evidence of metastatic disease 
02/15/08 
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13.3.2 Bone marrow metastasis 
 Acceptable: (i) positive cytology, histologic biopsy, or (ii) MRI scan 
13.3.3 Lung metastasis 
 Acceptable: (i) positive cytology, histologic biopsy, or (ii) radiologic 
evidence of multiple pulmonary nodules that are judged 
to be consistent with pulmonary metastases 
NOTE:  If a solitary lung lesion is found and no other lesions are present on lung 
tomograms, CT scan, or MRI scan, further investigations such as biopsy or 
needle aspiration must be performed.  Proof of neoplastic pleural effusion must 
be established by cytology or pleural biopsy. 
13.3.4 Skeletal metastasis 
 Acceptable: (i) x-ray, CT, or MRI evidence of lytic or blastic lesions 
consistent with bone metastasis; or (ii) biopsy proof of 
bone metastases; or (iii) bone scan that is clearly positive 
for bone metastases 
NOTE:  If the diagnosis is equivocal by bone scan or radiologic evaluation, a 
biopsy is strongly recommended.  Any positive bone scan in joints or in a recent 
area of trauma (surgical or otherwise) cannot be used as a criterion for breast 
cancer recurrence. 
13.3.5 Liver metastasis 
 Acceptable: (i) an abdominal CT scan, liver scan, ultrasound, or MRI 
consistent with liver metastases, or (ii)  liver biopsy 
confirmation of the metastatic disease 
NOTE: If the radiologic findings are not definitive (especially with solitary liver 
nodules), a liver biopsy is recommended; however, if a biopsy is not performed, 
serial scans must be obtained to document stability or progression. 
13.3.6 Central nervous system metastasis 
 Acceptable: (i)  positive CT scan or MRI scan, usually in a patient 
with neurological symptoms, or (ii)  biopsy or cytology 
(for a diagnosis of meningeal involvement) 
13.4 Second primary breast cancer 
Defined as evidence of invasive or in situ breast cancer (except LCIS) in the contralateral 
breast or chest wall.  The diagnosis of a second primary breast cancer must be confirmed 
histologically. 
 Acceptable:  positive histologic biopsy 
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13.5 Second primary cancer (non-breast) 
Any non-breast second primary cancer other than squamous or basal cell carcinoma of 
the skin, melanoma in situ, carcinoma in situ of the cervix, or colon carcinoma in situ will 
be considered an event in the analysis of DFS.  The diagnosis of a second primary cancer 
must be confirmed histologically whenever possible. 
13.6 Documentation requested following death 
 Autopsy reports should be secured whenever possible and should be submitted to the 
NSABP Biostatistical Center.   
 A copy of the death certificate should be forwarded to the NSABP Biostatistical 
Center if it is readily available or if it contains important cause-of-death information 
that is not documented elsewhere. 
 Please submit the last clinic/office note made before the death or the physician's note 
summarizing events resulting in death. 
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14.0 ADVERSE EVENT REPORTING REQUIREMENTS 
Please refer to Coordinator Online in the Members' Area of the NSABP Web site for general 
information regarding adverse event reporting. 
14.1 B-40 definitions for adverse event reporting 
14.1.1 Investigational agent 
The investigational agents in B-40 are capecitabine, gemcitabine, and 
bevacizumab.  Capecitabine and gemcitabine are being tested as neoadjuvant 
therapy for breast cancer; bevacizumab is being tested as both neoadjuvant and 
adjuvant therapy. 
14.1.2 Commercial agents 
The commercial agents in B-40 are cyclophosphamide, doxorubicin, and 
docetaxel. 
14.1.3 Investigational combination therapy 
This study includes both investigational and commercial agents.  When an 
investigational agent (gemcitabine, capecitabine, or bevacizumab) is 
administered concurrently or sequentially with a commercial agent 
(cyclophosphamide, doxorubicin, or docetaxel), and an adverse event occurs 
that is expected for the commercial agent(s), but is not listed for the 
investigational agent, the adverse event should be considered expected for the 
combination.  However, if based on clinical judgment, the investigator believes 
the adverse event is possibly, probably, or definitely related to the 
investigational agent (gemcitabine, capecitabine, or bevacizumab) rather than 
the commercial agent(s) (cyclophosphamide, doxorubicin, or docetaxel), the 
adverse event should then be considered unexpected for the combination. 
14.1.4 Adverse event assessment 
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 must 
be used to identify the type and to grade the severity of adverse events in B-40. 
14.2 Expedited reporting of adverse events 
The NSABP follows procedures for centralized reporting of adverse events.  Adverse 
events must be reported to the NSABP Biostatistical Center. The NSABP forwards 
reports to the appropriate regulatory agencies and pharmaceutical companies involved in 
the trial.  B-40 utilizes the NCI's Adverse Event Expedited Reporting System (AdEERS) 
for all expedited reporting of adverse events.  NCI's guidelines for creating an AdEERS 
report can be found at http://ctep.cancer.gov. 
05/30/07 
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The NSABP Biostatistical Center is identified in AdEERS as the NSABP Lead Group for 
NSABP protocols which require AdEERS reporting.  An AdEERS report must be 
submitted to the NSABP Lead Group using the electronic web-based application located 
at http://ctep.cancer.gov. If Web access is not available, the NCI Adverse Event 
Expedited Report-Multiple Agents template (located at http://ctep.cancer.gov) must be 
completed and faxed to the NSABP Biostatistical Center at (412) 622-2113.  When 
initiating an AdEERS report, the reporter will be directed to refer to the protocol for 
expedited reporting requirements. 
14.2.1 Expedited reporting methods 
 AdEERS-24 Hour Notification: requires that an AdEERS 24-hour 
notification is electronically submitted to the NSABP Lead Group within 24 
hours of learning of the adverse event.  Each AdEERS 24-hour notification 
must be followed by a complete AdEERS report within 5 calendar days of 
learning of the event. 
 
 AdEERS 5 Calendar Day Report: requires that an AdEERS report is 
electronically submitted to the NSABP Lead Group within 5 calendar days 
of the investigator learning of the adverse event. 
 
 Supporting documentation is required for all expedited (AdEERS) reports.  
Include the protocol number, patient's study number, and AdEERS ticket 
number on each page, and fax supporting documentation to the NSABP 
Biostatistical Center at (412) 622-2113. 
 
14.2.2 Expedited reporting requirements – AdEERS-24, AdEERS and other protocol 
requirements 
Expedited reporting requirements begin with the administration of the first dose 
of B-40 study therapy.  Expedited reporting requirements including protocol-
specific requirements and exceptions for expedited reporting for all B-40 patients 
who receive study therapy are provided in Table 31 and Table 32. 
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TABLE 31. AdEERS expedited reporting requirements for adverse events that occur within 30 days  
  of the last dose of an investigational agent (gemcitabine, capecitabine, or bevacizumab)a 
Grade 2 Grade 3 Grade 4c Grade 5b,c 
Protocol-Specific 
Requirements/ 
Exceptions Attribution 
Unexpected Unexpected Expected Unexpected Expected Unexpected Expected 
Unrelated  
or Unlikely    AdEERS 
 
AdEERS   
Possible, 
Probable, 
Definite 
 AdEERS if hospitalized  
AdEERS-24 
and 
AdEERS 
 
AdEERS 
 
AdEERS-24 
and 
AdEERS 
 
   AdEERS 
-See footnote 
(d) for other 
requirements 
-See footnote (e) 
for special 
requirements 
-See footnote (f) 
for special 
exceptions 
AdEERS-24: Indicates an AdEERS 24-hour notification must be electronically submitted to the NSABP Lead Group within 24 hours 
  of learning of the event. 
AdEERS: Indicates a complete expedited report must be electronically submitted to the NSABP Lead Group within 5 calendar  
  days of learning of the event. 
Hospitalization: Hospitalization associated with an adverse event is defined as any hospitalization lasting > 24 hours (or a prolongation of 
  an existing hospitalization). 
All Reports:  On all reports, use the NCI protocol number, AdEERS ticket number, and the protocol-specific patient ID provided 
 during trial registration.  Fax supporting documentation to the NSABP Biostatistical Center.   
a Refer to Section 14.1.3 for instructions regarding assignment of attribution and expectedness for Investigational Combination Therapy. 
b All deaths within 30 days after the last dose of the investigational agent require both routine and expedited reporting regardless of causality. 
Attribution to treatment or other cause should be provided. Although an AdEERS 24-hour notification is not required for death clearly 
related to progressive disease, a complete AdEERS report is required as outlined in the table. 
c Adverse events that occur greater than 30 days after the last dose of the investigational agent with attribution of possible, probable or 
definite to the investigational agent require reporting as follows: 
 AdEERS 24-hour notification followed by a complete AdEERS report within 5 calendar days of learning of the event for:   
- grade 4 unexpected events  
- grade 5 unexpected events 
 AdEERS 5-calendar day report for:   
- grade 5 expected events 
d Any event that results in persistent or significant disabilities/incapacities, congenital anomalies, or birth defects must be reported via 
AdEERS if the event occurs following treatment. 
e Protocol-specific expedited reporting requirements: For this study, the adverse events listed below, regardless of attribution, require 
expedited reporting via AdEERS to the NSABP Lead Group within 5 calendar days of learning of the event. 
 Hypertension  grade 4 
 Thrombosis/thrombus/embolism  grade 4 
 Hemorrhage  grade 3 
 Perforation, GI  grade 3 
 Proteinuria  grade 3 (if based on UPC ratio – see Appendix B) 
 Intra-abdominal abscess/infection ≥ grade 3 
 Wound complication, non-infectious  grade 3 
 Cardiac ischemia ≥ grade 4 
 CNS ischemia ≥ grade 4 
 Peripheral arterial ischemia ≥ grade 4 
 Visceral arterial ischemia ≥ grade 4 
 Left ventricular systolic dysfunction  grade 3 
 Left ventricular diastolic dysfunction  grade 3 
 Reversible Posterior Leukoencephalopathy Syndrome  
 (RPLS)  grade 1 reported as Neurology – other 
 (leukoencephalopathy syndrome) (see Section 15.4.2) 
f Protocol-specific expedited reporting exceptions: For this study, the adverse events listed below which occur, including hospitalizations 
for these events, do not require expedited reporting via AdEERS: 
 Blood/Bone Marrow: grades 3 and 4 leukocytes (total WBC), neutrophils/granulocytes, lymphopenia, and platelets (Note: These events 
are exclusions from expedited reporting only during chemotherapy.  Beginning 30 days following the last dose of chemotherapy and 
when a patient is receiving bevacizumab alone, these grade 3 and 4 events should be reported in an expedited manner. 
 Constitutional: grades 3 and 4 fatigue 
 Endocrine: grade 3 hot flashes/flushes 
 Gastrointestinal: grade 3 constipation and heartburn/dyspepsia 
 Infection: grades 3 and 4 febrile neutropenia  (Beginning 30 days following the last dose of chemotherapy and when a patient is 
receiving bevacizumab alone, these grade 3 and 4 events should be reported in an expedited manner.) 
 Metabolic: glucose, serum – high (grade 3) 
 Pain: perineum (grade 3); Pain: uterus (grade 3) 
 Renal/Genitourinary: grade 3 urinary frequency/urgency 
 Secondary Malignancy: grade 3 and 4 
 Sexual/Reproductive Function: Irregular menses (change from baseline) (grade 3) 
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TABLE 32. AdEERS expedited reporting requirements for adverse events that occur within 30 days  
  of the last dose of study therapy with a commercial agent (cyclophosphamide,   
  doxorubicin, and docetaxel) 
Grade 2 Grade 3 Grade 4b Grade 5a,b 
Protocol-Specific 
Requirements/ 
Exceptions Attribution 
Unexpected Unexpected Expected Unexpected Expected Unexpected Expected 
Unrelated  
or Unlikely    AdEERS 
 
AdEERS  
Possible, 
Probable, 
Definite 
 AdEERS if hospitalized  
AdEERS-24 
and 
AdEERS 
 
 
AdEERS-24 
and 
AdEERS 
 
  AdEERS 
-See footnote 
(c) for other 
requirements  
-See footnote (d) 
for special 
requirements 
-See footnote (e) for 
special exceptions 
AdEERS-24: Indicates an AdEERS 24-hour notification must be electronically submitted to the NSABP Lead Group within 24 hours of 
  learning of the event. 
AdEERS: Indicates a complete expedited report must be electronically submitted to the NSABP Lead Group within 5 calendar days 
  of learning of the event. 
Hospitalization: Hospitalization associated with an adverse event is defined as any hospitalization lasting > 24 hours (or a prolongation of 
  an existing hospitalization). 
All Reports:  On all reports, use the NCI protocol number, AdEERS ticket number, and the protocol-specific patient ID provided 
 during trial registration.  Fax supporting documentation to the NSABP Biostatistical Center.   
a All deaths within 30 days of the last dose of study therapy require both routine and expedited reporting regardless of causality.  Attribution to 
 treatment or other cause should be provided. Although an AdEERS 24-hour notification is not required for death clearly related to 
 progressive disease, a complete AdEERS report is required as outlined in the table. 
b Adverse events that occur greater than 30 days after the last dose of study therapy with attribution of possible, probable or definite to 
 study therapy require reporting as follows: 
 AdEERS 24-hour notification followed by a complete AdEERS report within 5 calendar days of learning of the event for:   
- grade 4 unexpected events  
- grade 5 unexpected events 
 AdEERS 5-calendar day report for: 
- grade 5 expected events 
c Any event that results in persistent or significant disabilities/incapacities, congenital anomalies, or birth defects must be reported via 
 AdEERS if the event occurs following treatment. 
d Protocol-specific expedited reporting requirements: For this study, the adverse events listed below, regardless of attribution, require 
 expedited reporting via AdEERS to the NSABP Lead Group within 5 calendar days of learning of the event. 
 Hypertension  grade 4 
 Thrombosis/thrombus/embolism  grade 4 
 Hemorrhage  grade 3 
 Perforation, GI  grade 3 
 Proteinuria  grade 3 (if based on UPC ratio – see Appendix B) 
 Intra-abdominal abscess/infection ≥ grade 3 
 Wound complication, non-infectious  grade 3 
 Cardiac ischemia ≥ grade 4 
 CNS ischemia ≥ grade 4 
 Peripheral arterial ischemia ≥ grade 4 
 Visceral arterial ischemia ≥ grade 4 
 Left ventricular systolic dysfunction  grade 3 
 Left ventricular diastolic dysfunction  grade 3 
 Reversible Posterior Leukoencephalopathy Syndrome 
(RPLS)  grade 1 reported as Neurology – other 
(leukoencephalopathy syndrome) (see Section 15.4.2) 
e Protocol-specific expedited reporting exceptions: For this study, the adverse events listed below which occur, including 
 hospitalizations for these events, do not require expedited reporting via AdEERS:  
 Blood/Bone Marrow: grades 3 and 4 leukocytes (total WBC), neutrophils/granulocytes, lymphopenia, and platelets 
 Constitutional: grades 3 and 4 fatigue 
 Endocrine: grade 3 hot flashes/flushes 
 Gastrointestinal: grade 3 constipation and heartburn/dyspepsia 
 Infection: grades 3 and 4 febrile neutropenia  
 Metabolic: glucose, serum – high (grade 3) 
 Pain: perineum (grade 3); Pain: uterus (grade 3) 
 Renal/Genitourinary: grade 3 urinary frequency/urgency 
 Secondary Malignancy: grade 3 and 4 
 Sexual/Reproductive Function: Irregular menses (change from baseline) (grade 3) 
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14.2.3 Other recipients of adverse event reports 
Adverse events determined to require expedited reporting must also be reported 
by the investigator to the Institutional Review Board responsible for safety and 
oversight of the patient according to the local policy and procedures. 
14.2.4 Reporting secondary AML/MDS/ALL 
All cases of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) 
and acute lymphocytic leukemia (ALL) that occur in patients on NCI-sponsored 
trials following their chemotherapy for cancer must be reported to the 
Investigational Drug Branch (IDB) of the NCI Cancer Therapy Evaluation 
Program (CTEP).  Submit the following information within 30 days of an 
AML/MDS/ALL diagnosis occurring after treatment for cancer on NCI-
sponsored trials: 
 completed NCI/CTEP Secondary AML/MDS Report Form; 
 copy of the pathology report confirming the AML/MDS/ALL; and 
 copy of the cytogenetics report (if available). 
 
Submit the information to the NSABP Biostatistical Center.  The NSABP 
will submit the form and any accompanying reports to the IDB of the NCI. 
Note: If a patient has been enrolled in more than one NCI-sponsored study, the 
NCI/CTEP Secondary AML/MDS Report Form must be submitted for the most 
recent trial. The NSABP must also be provided with a copy of the report even if 
the NSABP study was not the patient’s most recent trial. 
14.2.5 Pregnancy occurring while patient is on protocol therapy 
If the patient becomes pregnant while receiving protocol therapy, discontinue 
study therapy and notify the NSABP Clinical Coordinating Division (see 
Information Resources on page v) immediately. 
14.3 Routine reporting of adverse events 
14.3.1 Reporting on the B-40 Adverse Event Form 
 All grade 3 adverse events not reported via AdEERS (see Table 31 and 
Table 32 for expedited reporting requirements) are to be reported on the 
Adverse Event Form. 
 Select grade 2 adverse events must be reported on the Adverse Event Form.  
Refer to the Adverse Event Form for instructions. 
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 The following adverse events are not reported on the Adverse Event Form: 
 Adverse events that require expedited reporting (see Table 31 and  
Table 32) 
 Adverse events that occur after breast cancer recurrence or secondary 
primary cancer 
 Secondary cancers 
 Adverse events related to surgery should be reported on the B-40 
Assessment of Surgical Complications Form.  (These adverse events as 
specified on Tables 31 and 32 must also be reported via AdEERS.) 
 Supporting documentation for each adverse event reported on the Adverse 
Event Form must be maintained in the patient's research record.  When 
submission of supporting documentation to the NSABP Biostatistical Center 
is required, fax to 412-622-2111.  Remove patient names and identifiers such 
as social security number, address, telephone number, etc. from reports and 
supporting documentation. 
14.3.2 Submission of the B-40 Adverse Event Form 
Submit the B-40 Adverse Event Form according to the following B-40 study 
group schedule: 
 Groups 1A, 2A, and 3A: submit the Adverse Event Form at the end of each 
chemotherapy cycle. 
 Groups 1B, 2B, and 3B: submit the Adverse Event Form at the end of each 
chemotherapy cycle, after every other dose of bevacizumab when given 
postoperatively, and 30 days after the last dose of bevacizumab. 
Note: Online submission of the B-40 Adverse Event Form is available (but not 
mandatory) through the Online Data Entry function located in the Study 
Management Area of Coordinator Online in the Members' Area of the NSABP 
Web site.  If not submitted through Coordinator Online, fax the Adverse Event 
Form to 412-622-2111. 
14.4 Reporting cancer recurrence and second primary cancer 
Report breast cancer recurrence and all second primary malignancies (including 
AML/MDS/ALL) on the NSABP B-40 Follow-up Form.  Attach supporting 
documentation that confirms the breast cancer recurrence or second primary cancer 
diagnosis. 
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15.0 DRUG INFORMATION 
15.1 Commercial chemotherapy 
Doxorubicin, cyclophosphamide, and docetaxel must be obtained from commercial 
sources.  Please refer to the current FDA-approved package inserts provided with the 
chemotherapy or the Physicians’ Desk Reference for information about possible side 
effects and instructions for preparation, handling, and storage of the drugs. 
15.2 Capecitabine 
Please refer to the current FDA-approved package insert for additional information for 
capecitabine. 
15.2.1 Description 
Capecitabine (Xeloda®) is a fluoropyrimidine carbamate with antineoplastic 
activity.  It is an orally administered systemic prodrug of 5'-deoxy-5-
fluorouridine (5' DFUR) which is converted to 5-fluorouracil. 
Capecitabine is a white to off-white crystalline powder with an aqueous 
solubility of 26 mg/ml at 20° C.  It is supplied as biconvex, oblong film-coated 
tablets for oral administration.  Each light peach-colored tablet contains 150 mg 
capecitabine and each peach-colored tablet contains 500 mg capecitabine. 
The inactive ingredients in capecitabine include: anhydrous lactose, 
croscarmellose sodium, hydroxypropyl methylcellulose, microcrystalline 
cellulose, magnesium sterate, and purified water.  The peach or light peach film 
coating contains hydroxypropyl methylcellulose, talc, titanium dioxide, and 
synthetic yellow and red iron oxides. 
15.2.2 Storage 
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F), keep 
tightly closed. 
15.2.3 Toxicity 
Diarrhea: Capecitabine can induce diarrhea, sometimes severe.  Patients with 
severe diarrhea should be carefully monitored and given fluid and electrolyte 
replacement if they become dehydrated. 
Nausea & vomiting: Can be severe and dose limiting.  Initiation of prophylactic 
treatment is recommended. 
Stomatitis: Should be treated symptomatically.  
Hand-foot syndrome: Is common and dose-limiting.  (Redness, pain, numbness, 
tingling, blistering, and moist desquamation).  Syndrome may recur with a 
rechallenge. 
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Other known toxicities include: Abdominal pain, constipation, loss of appetite 
or decreased appetite, dehydration, tiredness, weakness, dizziness, headache, 
neutropenia, and fever. 
15.2.4 Precautions/warnings 
 Capecitabine/warfarin interaction: Patients receiving concomitant 
capecitabine and oral coumarin-derivative anticoagulant therapy should have 
their anticoagulant response (INR or prothrombin time) monitored frequently 
in order to adjust the anticoagulant dose accordingly.  A clinically important 
Xeloda-Warfarin drug interaction was demonstrated in a clinical 
pharmacology trial.  Altered coagulation parameters and/or bleeding, 
including death, have been reported in patients taking capecitabine 
concomitantly with coumarin-derivative anticoagulants such as warfarin and 
phenprocoumon.  Postmarketing reports have shown clinically significant 
increases in prothrombin time (PT) and INR in patients who were stabilized 
on anticoagulants at the time capecitabine was introduced.  These events 
occurred within several days and up to several months after initiating 
capecitabine therapy and, in a few cases, within 1 month after stopping 
capecitabine.  These events occurred in patients with and without liver 
metastases.  Age greater than 60 and a diagnosis of cancer independently 
predispose patients to an increased risk of coagulopathy. 
 Hypersensitivity to 5-fluorouracil: Capecitabine is contraindicated in patients 
who have a known hypersensitivity to 5-fluorouracil. 
 Renal insufficiency: Capecitabine is also contraindicated in patients with 
severe renal impairment (creatinine clearance below 30 ml/min). 
15.2.5 Procurement 
Capecitabine will be supplied free-of-charge by Roche Laboratories, Inc., and 
will be distributed by an external vendor.  Capecitabine is available as a 500 mg 
tablet in bottles containing 120 tablets and as a 150 mg tablet in bottles 
containing 60 tablets. 
Capecitabine (NSC #712807) must be requested by the principal investigator (or 
his/her authorized designee) at each participating institution. Investigators must 
request drug through the NSABP Biostatistical Center (see Information 
Resources page v).  Capecitabine will be distributed directly to the treating 
investigators whose sites are participating in B-40.  Capecitabine may not be 
used outside the scope of this protocol, nor can capecitabine be transferred or 
licensed to any party not participating in this clinical study.  The transfer of 
capecitabine between institutions is not permitted. 
Drug Inventory Records – The investigator, or a responsible party designated by 
the investigator, must maintain a careful record of the inventory and disposition 
of all capecitabine received for this study and be accountable for all inventory. 
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15.3 Gemcitabine 
Please refer to the current FDA-approved package insert for additional information on 
gemcitabine. 
15.3.1 Description 
Gemcitabine HCl (Gemzar®) is a nucleoside analogue that exhibits antitumor 
activity.  Gemcitabine HCl is 2'-deoxy-2', 2'-difluorocytidine monohydrochloride 
(β-isomer).  Gemcitabine HCl is a white to off-white solid.  It is soluble in water, 
slightly soluble in methanol, and practically insoluble in ethanol and polar 
organic solvents. 
The clinical formulation is supplied in a sterile form for intravenous use only.  
Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine HCl (expressed 
as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium 
acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.  
Hydrochloric acid and/or sodium hydroxide may have been added for pH 
adjustment. 
15.3.2 Storage 
Gemcitabine must be stored at controlled room temperature [20-25°C (68-77°F)] 
in a limited access area at the study site.  Reconstitute with 0.9% NaCl; diluted 
solution is stable for 24 hours and should be stored at room temperature.  (Do not 
refrigerate the reconstituted drug as crystallization may occur.)  Discard any 
unused portion.  Expiration dates on individual vials must be strictly adhered to. 
15.3.3 Toxicity 
Hematologic: Suppression of bone-marrow function as manifested by 
leukopenia, neutropenia, thrombocytopenia, and anemia can occur.  
Myelosuppression is usually the dose-limiting toxicity. 
Gastrointestinal: Nausea and vomiting (mild to moderate), diarrhea, and 
stomatitis can occur. 
Dermatologic: Rash may occur in 30% of patients.  The rash is typically a 
macular or finely granular maculopapular pruritic eruption of mild to moderate 
severity involving the trunk and extremities.  More severe events, including 
desquamation and bullous skin eruptions, had been reported very rarely. 
Fever: May occur in the absence of clinical infection.  Fever, usually associated 
with other flu-like symptoms, is usually mild. 
Infection: May occur; sepsis has occurred rarely. 
Hepatic: Transient elevations of one or both serum transaminases may occur.  
Serious hepatotoxicity, including liver failure and death, has been reported very 
rarely. 
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Neurotoxicity: Mild paresthesias may occur; rare cases of severe paresthesias 
have been reported. 
Renal: Mild proteinuria and hematuria may occur.  Hemolytic Uremic Syndrome 
(HUS) has been reported rarely.  The diagnosis of HUS should be considered if 
the patient develops anemia with evidence of microangiopathic hemolysis, 
elevation of bilirubin or LDH, reticulocytosis, severe thrombocytopenia, and/or 
evidence of renal failure (elevation of serum creatinine or BUN).  Gemcitabine 
therapy should be discontinued immediately if HUS occurs.  Renal failure may 
not be reversible even with discontinuation of therapy and dialysis may be 
required.  Renal failure leading to death has been rarely reported. 
Pulmonary: Dyspnea, unrelated to underlying disease, has been reported.  
Dyspnea was occasionally accompanied by bronchospasm.  Parenchymal 
toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary 
edema, and adult respiratory distress syndrome, has been reported rarely 
following one or more doses of gemcitabine administered to patients with various 
malignancies.  Some patients experienced the onset of pulmonary symptoms up 
to 2 weeks after the last gemcitabine dose.  Respiratory failure and death, despite 
discontinuation of therapy, have occurred very rarely. 
Anaphylactic reaction: Has been reported rarely. 
Cardiovascular: Congestive heart failure and myocardial infarction have rarely 
occurred in patients receiving gemcitabine.  Arrhythmias, predominately 
supraclavicular in nature, have been reported very rarely. 
Vascular: Clinical signs of peripheral vasculitis and gangrene have been 
reported very rarely. 
15.3.4 Precautions/warnings 
 Prolongation of infusion time beyond 60 minutes has been shown to increase 
toxicity. 
 Gemcitabine can cause fetal harm when administered to pregnant women.  
Gemcitabine is embryotoxic causing fetal malformations (cleft palate, 
incomplete ossification) at doses of 1.5 mg/kg/day in mice (about 1/200 the 
recommended human dose on a mg/m2 basis).  There are no studies of 
gemcitabine in pregnant women. 
Pregnant women are not eligible for this study.  If a woman becomes 
pregnant while on the study, discontinue the gemcitabine immediately. 
15.3.5 Procurement 
Gemcitabine will be supplied free-of-charge by Eli Lilly and Company and will 
be distributed by an external vendor. 
Gemcitabine (NSC #613327) 200 mg (10 mL vial) and 1000 mg (50 mL vial) 
injection must be requested by the principal investigator (or his/her authorized 
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designee) at each participating institution.  Investigators must request drug 
through the NSABP Biostatistical  Center (see Information Resources page v).  
Gemcitabine will be distributed directly to the treating investigators whose sites 
are participating in B-40.  Gemcitabine may not be used outside the scope of this 
protocol, nor can gemcitabine be transferred or licensed to any party not 
participating in this clinical study. 
Drug Inventory Records – The investigator, or a responsible party designated by 
the investigator, must maintain a careful record of the inventory and disposition 
of all gemcitabine received for this study and be accountable for all inventory. 
15.4 Bevacizumab 
15.4.1 Chemical information 
 Classification: Recombinant humanized monoclonal antibody 
 
 Molecular weight: Approximate molecular weight is 149,000 daltons 
 
 Mode of action: Bevacizumab blocks the binding of vascular endothelial 
growth factor (VEGF) to its receptors resulting in inhibition of angiogenesis. 
 
 Description: Bevacizumab is a recombinant humanized anti-VEGF 
monoclonal antibody, consisting of 93% human and 7% murine amino acid 
sequences.  The agent is composed of human IgG framework and murine 
antigen-binding complementarity-determining regions. 
 
 How supplied: Bevacizumab is supplied as a clear to slightly opalescent, 
sterile liquid ready for parenteral administration in a 400 mg  
(25 mg/mL – 16 mL fill) glass vial that contains bevacizumab with 
phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP. 
 Preparation: Withdraw the necessary amount of bevacizumab for a dose of  
15 mg/kg and dilute in a total volume of 100 mL of 0.9% Sodium Chloride 
Injection, USP.  For heavier patients, the dose of 15 mg/kg may be diluted in 
a total volume of 200 to 250 mL of 0.9% sodium chloride injection, USP.  
Discard any unused portion left in a vial, as the product contains no 
preservatives.  Parenteral drug products should be inspected visually for 
particulate matter and discoloration prior to administration.  No 
incompatibilities between bevacizumab and polyvinylchloride or polyolefin 
bags have been observed.  Bevacizumab should not be administered or mixed 
with dextrose solutions. 
 
 Storage and stability 
 Storage 
Upon receipt, bevacizumab should be refrigerated (2º to 8º C).  
Do not freeze.  Do not shake.  Protect from light. 
 Stability 
Shelf-life studies of rhuMAb VEGF are ongoing.  The sterile single use 
vials contain no antibacterial preservatives.  Therefore, vials should be 
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discarded 8 hours after initial entry.  Once diluted in 0.9% sodium 
chloride, solutions of bevacizumab must be administered within 8 hours. 
 Route of administration: Intravenous – Do not administer as an IV push or 
bolus. 
 
 Dose specifics: 15 mg/kg IV as per Sections 9.2, 9.4, and 9.6. 
15.4.2 Toxicity 
Refer to the Investigator's Brochure for bevacizumab.  The package insert was 
prepared for commercial Avastin® but not the investigational bevacizumab being 
used in this protocol.  The package insert should, therefore, only be used as a 
reference in combination with the Investigator's Brochure. 
Reported adverse events and potential risks utilizing CTCAE v3.0 terminology: 
 Allergy/immunology: Allergic reaction/hypersensitivity (including drug 
fever); allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) 
 Blood/bone marrow: Hemoglobin; leukocytes (total WBC); 
neutrophils/granulocytes (ANC/AGC); platelets 
 Cardiac arrhythmia: Supraventricular arrhythmia NOS; ventricular 
fibrillation 
 Cardiac general: Cardiac ischemia/infarction; cardiac troponin I (cTnI); 
hypertension; hypotension; left ventricular diastolic dysfunction; left 
ventricular systolic dysfunction; pulmonary hypertension 
 Constitutional symptoms: Fatigue (asthenia, lethargy, malaise); fever (in the 
absence of neutropenia (where neutropenia is defined as ANC  
 1.0 x 109/L); rigors/chills; weight loss 
 Dermatology/skin: Pruritus/itching; rash/desquamation; ulceration; urticaria 
(hives, welts, wheals); wound complication – non-infectious 
 Gastrointestinal: Anorexia; colitis; constipation; diarrhea; fistula; 
heartburn/dyspepsia; Ileus (functional obstruction of bowel, i.e., 
neuroconstipation); GI leak (including anastomotic): large bowel; 
mucositis/stomatitis; nausea; GI perforation; vomiting; ulcer, GI - Select; 
taste alteration 
 Hemorrhage/bleeding: GI hemorrhage; CNS hemorrhage; GU: vagina 
hemorrhage; pulmonary/upper respiratory: nose hemorrhage, lung hemorrhage 
 Infection: Infection with normal ANC or grade 1 or 2 neutrophils; infection 
with normal ANC or grade 1 or 2 neutrophils – Select (pelvis, peritoneal 
cavity, rectum, scrotum, skin, wound) 
 Metabolic/laboratory: Alkaline phosphatase; ALT (SGPT); AST (SGOT); 
bilirubin; creatinine; proteinuria; hyponatremia; hypokalemia 
 Musculoskeletal/soft tissue: Gait/walking 
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 Neurology: CNS cerebrovascular ischemia; dizziness; confusion; 
Neurology – Other: (Leukoencephalopathy syndrome including reversible 
posterior leukoencephalopathy syndrome [RPLS]) 
RPLS or clinical syndromes related to vasogenic edema of the white matter 
have been rarely reported in association with bevacizumab therapy ( 1%).  
Clinical presentations are variable and may include headache, altered 
mental status, seizure, and cortical visual deficit.  Hypertension is a 
common risk factor and was present in most (though not all) patients on 
bevacizumab who developed RPLS.  MRI scans are key to diagnosis and 
typically demonstrate vasogenic edema (hyperintensity in T2 and FLAIR 
images and hypointensity in T1 images) predominantly in the white matter 
of the posterior parietal and occipital lobes; less frequently, the anterior 
distributions and the gray matter may also be involved.  RPLS should be in 
the differential diagnosis in patients presenting with unexplained mental 
status change, visual disturbance, seizure, or other CNS findings.  RPLS is 
potentially reversible with early recognition of symptoms and timely 
correction of the underlying causes, including control of blood pressure and 
interruption of the offending drug, which are important in order to prevent 
progression to irreversible tissue damage. 
 Ocular/visual: Watery eye 
 Pain: Abdomen NOS; chest/thorax NOS; head/headache; joint; muscle; 
NOS 
 Pulmonary/upper respiratory: Bronchospasm/wheezing; cough; dyspnea; 
fistula, pulmonary/upper respiratory – Select; nasal cavity/paranasal sinus 
reactions; voice changes/dysarthria (e.g., hoarseness, loss or alteration in 
voice, laryngitis); pulmonary/upper respiratory – other (nasal – septal 
perforation); ARDS; pneumonitis/pulmonary infiltrates; pneumothorax 
 Renal/genitourinary: Fistula, GU – Select; perforation, GU – Select; renal 
failure; urinary frequency 
 Syndromes: Cytokine release syndrome/acute infusion reaction 
 Vascular: Thrombosis/thrombus/embolism; visceral arterial ischemia (non-
myocardial) 
15.4.3 Administration 
Method of Administration 
The initial dose should be administered over a minimum of 90 minutes.  If no 
adverse reactions occur, the second dose should be administered over a minimum 
of 60 minutes.  If no adverse reactions occur after the second dose, all subsequent 
doses should be administered over a minimum of 30 minutes.  If infusion-related 
adverse reactions occur, all subsequent infusions should be administered over the 
shortest period that was well tolerated. 
To insure complete delivery of bevacizumab, the IV infusion line must be 
flushed with 0.9% sodium chloride.  The following are two recommended 
methods for flushing the bevacizumab IV infusion line: 
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Method 1: When the bevacizumab infusion is complete, add an additional 50 mL 
of 0.9% sodium chloride for injection to the bevacizumab infusion 
bag.  Continue the infusion until a volume equal to that of the volume 
contained in the tubing has been administered. 
Method 2: Replace the empty bevacizumab infusion bag with a 50 mL bag of 
0.9% sodium chloride for injection and infuse a volume equal to the 
volume contained in the tubing.  
Note: the flush is not included in the total recommended infusion times. 
15.4.4 Procurement 
Bevacizumab will be supplied free-of-charge by Genentech, Inc. and will be 
distributed by an external vendor. 
The bevacizumab to be supplied for this protocol is intended for clinical trial use 
only and is not the commercially available Avastin.®  Investigational 
bevacizumab and commercially available Avastin® may be produced at separate 
facilities and some difference may exist between the two products, although both 
are required to meet similar product testing criteria and are expected to be very 
similar in safety and activity.  For further details and molecule characterization, 
see the updated bevacizumab Investigator Brochure. 
Bevacizumab (NSC# 704865) 400 mg (25 mg/mL – 16 mL fill) vials must be 
requested by the principal investigator (or his/her authorized designee) at each 
participating institution.  Investigators must request drug through the NSABP 
Biostatistical Center (see Information Resources on page v).  Bevacizumab will 
be shipped directly to the treating investigator whose sites are participating  
in B-40. 
Bevacizumab may not be used outside the scope of this protocol, nor can 
bevacizumab be transferred or licensed to any party not participating in this 
clinical trial. 
15.4.5 Drug accountability 
Drug Inventory Records – The investigator, or a responsible party designated by 
the investigator, must maintain a careful record of the inventory and disposition 
of all bevacizumab received for this study and be accountable for all inventory. 
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16.0 PATIENT ENTRY AND WITHDRAWAL PROCEDURES 
16.1 Patient consent form 
Before the patient is enrolled, the consent form (see Appendix G), including any addenda, 
must be signed and dated by the patient and the person who explains the study to that 
patient. 
As part of this consent, all patients have agreed to have a second biopsy procedure during 
which four core biopsy tissue samples will be obtained (see Section 8.0).  All biopsy 
samples will be identified by the PTI Control Number (a unique coded number provided 
by the NSABP Biostatistical Center).  Patients eligible for, and consenting to participate 
in, the B-40 treatment study, must have the PTI Control Number of their biopsy sample 
recorded on Form A.  Biopsy samples from patients who are ineligible for B-40, or who 
choose not to participate in the B-40 treatment study, will be destroyed. 
16.2 Regulatory requirement for Canadian institutions 
Any Canadian institution that will utilize PET scans in the conduct of this protocol must 
indicate the intent to do so to the NSABP Division of Regulatory Affairs at the NSABP 
Operations Center prior to initiating patient enrollment at the institution (and any 
satellites).  Use of PET scans as part of this protocol may require submission by the 
NSABP of specific documentation to Health Canada before activation of the trial at the 
institution. 
16.3 Entry 
16.3.1 NSABP Investigators 
Note: NSABP investigators who also are registered with the CTSU must enroll 
B-40 patients through the NSABP; they are not permitted to enter patients 
through the CTSU. 
Patient entry instructions can be found in the “Patient Entry Guidelines” 
section of the Members’ Area of the NSABP Web site, 
https://members.nsabp.pitt.edu. 
16.3.2 CTSU Investigators 
CTSU investigators must follow procedures outlined in Appendix F, Section 1.0, 
Site Registration and Patient Entry for CTSU Investigators. 
16.4 NSABP Patient ID number 
After all of the eligibility criteria have been met, the institution will receive the patient’s 
nine-digit NSABP Patient ID number. 
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16.5 Patient-initiated discontinuation of study therapy 
Even after a patient agrees to take part in this study, she may stop study therapy or 
withdraw from the study at any time.  If study therapy is stopped but she still allows the 
study doctor to submit information, study data and other materials should be submitted 
according to the study schedule. 
16.6 Withdrawal from the study 
If a patient chooses to have no further interaction regarding the study, the investigator 
must provide the NSABP Biostatistical Center with written documentation of the 
patient’s decision to fully withdraw from the study. 
16.7 Investigator-initiated discontinuation of study therapy 
In addition to the conditions outlined in the protocol, the investigator may require a 
patient to discontinue study therapy if one of the following occurs: 
 the patient develops a serious side effect that she cannot tolerate or that cannot be 
controlled with other medications, 
 the patient’s health gets worse, 
 the patient is unable to meet the study requirements, or 
 new information about the study drugs or other treatments for breast cancer becomes 
available. 
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17.0 REQUIRED FORMS AND MATERIALS 
17.1 Data collection 
A table of required forms and materials is provided in the "Forms and Documents" 
section in Members' Area of the NSABP Website for Protocol B-40 
http://www.nsabp.pitt.edu.  (CTSU investigators should also refer to Appendix F of the 
B-40 Protocol and the B-40 Web page located on the CTSU Registered Member Web 
site.) 
Data will be collected on patient characteristics, tumor characteristics from the core 
needle biopsy performed prior to randomization, protocol therapy, clinical response, 
surgical management, pathologic tumor response in the breast and other pathologic 
findings including those needed for calculation of residual cancer burden, adverse events 
during systemic therapy, surgical complications, assessments of left ventricular ejection 
fraction, congestive heart failure, and follow-up for disease-free survival. 
17.2 Adverse event reporting 
Routine and expedited adverse event reporting requirements are addressed in Section 
14.0. 
17.3 Pathology specimens 
See Section 8.0 for tissue, blood, and serum requirements and submission instructions.  
(CTSU investigators should also refer to Appendix F in the B-40 protocol.) 
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18.0 STATISTICAL CONSIDERATIONS 
18.1 Randomization and treatment assignments 
Assignments of treatment to patients will be balanced with respect to clinical nodal status 
(negative, positive), clinical tumor size (2.0 - 4.0 cm,  4.0 cm), hormone receptor status 
(ER-positive and/or PgR-positive, ER-negative and PgR-negative), and age ( 50,  50 
years old).  A biased coin minimization procedure will be utilized for the randomization 
procedure to avoid imbalance by these factors and extreme inequality in treatment 
assignment within an institution.165 
18.2 Endpoints 
The primary endpoint for the study is pathologic complete response (pCR) of the primary 
tumor in the breast.   
The secondary endpoints are pathologic complete response of the primary tumor in the 
breast, sentinel lymph nodes removed following protocol chemotherapy, and axillary 
lymph nodes (pCR breast and nodes); clinical overall response rate (cOR) following 
docetaxel alone, docetaxel/capecitabine, and docetaxel/gemcitabine (with or without 
bevacizumab), as assessed by physical exam at the completion of the docetaxel-based 
portion of the chemotherapy program; clinical complete response rate (cCR) following 
docetaxel alone, docetaxel/capecitabine, and docetaxel/gemcitabine (with or without 
bevacizumab), as assessed by physical exam at the completion of the docetaxel-based 
portion of the chemotherapy program; clinical overall response rate (cOR) following the 
sequential chemotherapy program assessed by physical exam at the completion of the 
sequential chemotherapy regimens; clinical complete response (cCR) following the 
sequential chemotherapy program assessed by physical exam at the completion of the 
sequential chemotherapy regimens; the percentage of cardiac events defined as NYHA 
Class III/IV congestive heart failure among the patients with docetaxel-anthracycline 
regimens only and that among patients with both bevacizumab and docetaxel-
anthracycline regimens; the percentage of surgical complications from mastectomy, 
lumpectomy, and axillary staging procedures, which include wound dehiscence, 
infection, seroma, and hematoma; and disease-free survival (DFS). Events for DFS are 
defined as local recurrence following mastectomy, local recurrence in the ipsilateral 
breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast 
cancer, second primary cancer (other than squamous or basal cell carcinoma of the skin, 
melanoma in situ, carcinoma in situ of the cervix, colon carcinoma in situ, or lobular 
carcinoma in situ of the breast), and death from any cause prior to these events. 
18.3 Statistical analysis 
The intent-to-treat principle will be used for the analyses of all the primary and secondary 
endpoints.  Accordingly, the analyses will be performed on all patients with endpoint 
status ascertained and will use the treatment assignments made at randomization. 
The rate of pathologic complete response in the breast (pCR breast) of the docetaxel 
followed by AC (TAC) arm (with or without bevacizumab) will be compared to the 
pCR (breast) rates of the docetaxel with capecitabine followed by AC (TCAC) and 
docetaxel with gemcitabine followed by AC (TGAC), with or without bevacizumab.   
The maximum of the standardized pair-wise differences between the TAC arm and the 
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other two arms, with or without bevacizumab, will be used as the test statistic in order to 
adjust for multiple comparisons.166,167  The significance level is 0.05.  After adjusting 
for interim analyses, the significance level for the final comparison is 0.0498 and the 
corresponding critical value for the test statistic is 2.213. 
Each of the above pair-wise comparisons of pathologic complete response rates between 
the TAC arm and the other two arms, with or without bevacizumab, will be tested and 
will be judged to be significant if the corresponding standardized pCR rate difference 
exceeds the critical value 2.213.  The pCR rates of the (TCAC) and (TGAC) arms 
will also be compared and the significance level for the test statistic is 0.05. 
The rate of pathologic complete response in the breast (pCR breast) of bevacizumab 
additional to the docetaxel-anthracycline based regimens (TAC, TCAC, and 
TGAC) will be compared to the pCR (breast) rate of the docetaxel-anthracycline based 
regimens without bevacizumab. The 2-sided significance level is 0.05. After adjusting for 
interim analyses, the significance level for the final comparison is 0.0498 and the 
corresponding critical value for the test statistic is 1.962. 
The comparison of the pCR rates of breast and nodes and the cOR and cCR rates that are 
assessed after the docetaxel-based portion of chemotherapy regimens (T, TC, and TG) or 
at the completion of the sequential chemotherapy regimens will be performed in a similar 
manner. 
The percentage of surgical complications, from mastectomy, lumpectomy and axillary 
staging procedures, among the patients with bevacizumab will be compared with that 
among the patients without bevacizumab. 
For docetaxel-anthracycline based regimens without bevacizumab and docetaxel-
anthracycline based regimens with bevacizumab, distribution of DFS will be estimated by 
the Kaplan-Meier method.168  Difference in DFS between these two groups will be 
assessed by the stratified log-rank test169, controlling for docetaxel-based treatment, 
clinical tumor size, clinical nodal status, hormone receptor status, and age. As a 
diagnostic check, secondary treatment comparisons using Cox modeling will control for 
additional prognostic variables such as number of positive nodes and tumor grade. This 
will be done even though the method of balanced randomization used in the assignment 
of treatments makes it highly unlikely that prognostic factors could confound the 
treatment comparison. Tests of treatment by covariate interaction will be carried out by 
adding interaction terms one at a time to the Cox model. All interaction tests will be two-
sided and will be controlled at the 0.05 significance level. 
18.4 Sample size requirements and accrual rates 
In this trial, patients will be randomized to three docetaxel-anthracycline based regimens 
(TAC, TCAC, and TGAC) with or without bevacizumab. Therefore two primary 
hypotheses will be evaluated in this trial: 
 Whether TCAC or TGAC is superior to TAC, with or without 
bevacizumab, with respect to pCR in breast? 
 Whether docetaxel-anthracycline based regimens with bevacizumab are superior 
to docetaxel-anthracycline based regimens alone with respect to pCR in breast? 
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The sample size for the trial is 1200 patients (200 per treatment arm).  We project that the 
patient population in this protocol will be similar to that of NSABP B-27.  Among 
patients who had preoperative AC plus docetaxel in NSABP B-27, about 26% had 
pathologic complete response. 
For the first primary hypothesis, the test statistic is the maximum of two standardized 
pair-wise differences, the critical value for a 0.05 significance level is 2.21167 and this 
critical value is corresponding to a 2-sided significance level 0.0271 for a standardized 
pair-wise comparison.  Hence power justification for comparing two binomial 
distributions with a 2-sided significance level 0.0271 should approximate the power 
justification for the original test statistic with a 2-sided significance level 0.05.  Assuming 
that the pCR rate in the control arm  (TAC, with or without bevacizumab) is 26% and a 
type I error rate of α = .05, a sample size of 400 per docetaxel-anthracycline based 
regimen (with or without bevacizumab) would provide 80% power to detect as 
significantly different a pCR rate in one of the other  regimens of 36%.  With the same 
sample size and type I error rate, the study would have 90% power to detect as 
significantly different pCR rate of 37.5%. 
For the second primary hypothesis, the test statistic is the standardized pair-wise 
difference. The critical value is 1.96 corresponding to a 2-sided significance level 0.05. 
Assuming that the pCR rate in the control arm (docetaxel-anthracycline based regimens 
without bevacizumab) is 29% and a type I error rate of  α = .05, this sample size will 
provide 91% power to detect as significantly different a pCR rate of 38% in the 
docetaxel-anthracycline based regimens with bevacizumab. 
If accrual rates on this study are similar to those in NSABP B-27, then we could expect 
an accrual rate as high as 600 patients per year.  A definitive analysis of the primary 
endpoint will be performed when pathologic response statuses of all patients are 
available.  It is anticipated, that the definitive analysis could be performed at a time that 
would be 3 years after the initiation of accrual (after 2 years to accrue 1200 patients plus 
1.0 additional year of follow-up). 
For the comparison on DFS, with 80% power and a 2-sided type one error rate 0.05, 252 
events need to be observed in order to detect a 30% reduction in hazard rate from adding 
bevacizumab to the docetaxel-anthracycline based chemotherapy regimens.  Based on 
that the pre-op ACT arm in the NSABP B-27 study has a DFS annual hazard rate 0.07, 
plus the assumption that additional capecitabine or gemcitabine may reduce the hazard 
rate by 10%, we would expect that the group without bevacizumab has a DFS annual 
hazard rate 0.0665.  The definitive analysis on DFS could be performed at about 6.75 
years after the initiation of the accrual. 
18.5 Cardiac safety analysis 
Cardiac toxicities from the patients who receive bevacizumab will be monitored and 
formal analysis will be conducted based on the first 200 patients who receive 
bevacizumab, regardless of the docetaxel-anthracycline based regimen. The endpoint for 
the cardiac safety analysis is the percentage of cardiac events defined as NYHA Class 
III/IV congestive heart failure among these 200 patients documented prior to surgery. 
The monitoring and tabulation of cardiac toxicity will be continuous starting with the first 
patient who receives bevacizumb.  Randomization to bevacizumab in this study will be 
stopped if more than ten cardiac events are observed at any point in the accrual of the 
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first 200 patients.  Otherwise, randomization of patients to bevacizumab will continue as 
planned.  If the rate of cardiac events on the regimens with bevacizumab is 3%, there is a 
0.04 chance that the randomization of bevacizumab will be terminated; if the rate of 
cardiac events on the regimens with bevacizumab is 10%, there is a 0.992 chance that the 
randomization of bevacizumab will be terminated. 
All patients who develop symptomatic left ventricular dysfunction will have source 
documentation submitted for review by the B-40 Protocol Officer to determine if the 
patient experienced NYHA Class III or IV CHF.  This will be used for the primary 
endpoint of the cardiac safety analysis.  The rates of CTCAE grade 2 and 3 left 
ventricular dysfunction will also be determined. 
The cardiac toxicity rate of the patients with bevacizumab will be compared with that of 
the patients without bevacizumab, regardless of the docetaxel-anthracycline based 
regimens. 
18.6 Pathology statistical design 
Within each docetaxel-anthracycline based regimen (with or without bevacizumab), 
baseline genomic profiles of pathologic complete responders to preoperative 
chemotherapy will be compared to those of non-complete responders.  The expression 
intensities of about 33,000 genes will be evaluated.  For each gene, the difference in 
average log-intensities between responders and non-responders, divided by the 
corresponding standard error, is used as the test statistic.  The corresponding p-values 
based on these test statistics under appropriate T-distribution approximation, will be rank 
ordered from the smallest to the largest.  In order to control the family-wise error rate at 
0.05, we will use the Westfall-Young step-down algorithm to compute adjusted p-values 
≤ 0.05 to determine genes that are differentially expressed between the responders and 
non-responders.170  Since control of the family-wise error rate at 0.05 for about 33,000 
genes is extremely stringent, the algorithm of Korn et al will be applied to control the 
number of false positives at most 2 with confidence = 95%.171  Using this mechanism, a 
list of candidate markers for response to each treatment will be obtained. 
For each docetaxel-anthracycline based regimen (with or without bevacizumab), 
statistical models will be explored to predict response based on the corresponding list of 
candidate genes and some standard and potentially prognostic factors such as age, clinical 
tumor size, nodal status and ER status.  After considering attrition from improper sample 
handling, RNA degradation and other reasons, we anticipate 80% of these patients, 320 
out of 400, will have their gene expression data collected.  We plan to build a statistical 
prediction model for pathologic complete response based on data from 240 of these 320 
patients, and data from the other 80 patients will be used for validation of the prediction 
model.  For each treatment arm, the top 100 individual genes from the available rank list 
will be considered for the model building.  The correlation among these genes will then 
be explored and a subgroup of these 100 genes that are representative but not mutually 
highly correlated will be considered as candidates for the prediction model.  Some 
standard factors such as age, clinical tumor size and nodal status will also be considered.  
Then a logistic regression prediction model will be selected based on an automatic hybrid 
algorithm of a stepwise selection and "best" sub-models with the same number of 
predictors. The resulted prediction model will be applied to the rest of the 80 patients for 
validation.  A permutation-based procedure, where the response statuses of the patients 
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for model building are randomly permuted and similar model building and validation are 
conducted, will be used to assess the statistical significance of the classification. 
For each treatment arm, a support vector machine (SVM) classifier will be developed 
based on the same group of 100 candidate genes and the training sample of about 240 
patients, then applied to the validation sample of about 80 patients.172  The performance 
of this SVM classifier will be compared to the above logistic regression prediction model.  
The better method will then be applied to all the patients in that treatment regimen to 
build a final prediction model or classifier to predict pCR (pCR breast) to that treatment 
sequence in future trials. 
If 26% have a pCR (pCR breast), there will be 104 complete pathologic responders and 
296 non-responders within each docetaxel-anthracycline based regimen (with or without 
bevacizumab).  Because of attrition from improper sample handling, RNA degradation 
and other reasons, we anticipate 80% of all patients will be available to have their gene 
expression determined. This would provide gene expression data for 83 responders and 
237 non-responders.  Under the more conservative Bonferoni justification, compared to 
the algorithm of Westfall and Young, the nominal α = 0.05/33,000 = 1.52 x 10-6 and it 
will give a conservative bound for power.  Under the current sample size, we expect to 
have power of 0.75 to detect any gene for which the mean log-intensity of responders 
differs by 0.7 of standard deviation from that of non-responders.  The power would be 
0.93 for a separation by 0.8 of the standard deviation.  If the group separation is as large 
as 1 standard deviation, identification of such genes is almost certain. Based on 
experience with cDNA gene expression arrays, we have estimated that the majority of 
genes have between-patient standard deviations of no more than 1 on the base 2 log 
scale.173  Therefore, we expect to have power of 0.75 to detect any gene for which the 
ratio of average expression level in responders versus that of non-responders is either 
smaller than 2-0.7=0.62 or larger than 20.7=1.62.  We would have power of 0.93 to detect 
any gene for which the ratio of average expression level in responders versus that of non-
responders is either smaller than 2-0.8=0.57 or larger than 20.8=1.74. 
Search and validation of baseline genomic profiles to predict pCR in breast for each 
docetaxel-anthracycline based regimen only and each docetaxel-anthracycline based 
regimen with bevacizumab will be conducted in similar procedures. 
Based on gene lists that are associated with pCR with these treatment arms, we will build 
a general prediction model for pCR to chemotherapy.  Similar gene expression data 
analysis will be conducted with outcomes such as pCR of breast and nodes and cOR 
following docetaxel-based treatments. Gianni et al4 identified genes that are correlated 
with pCR.  Adjusting for multiple comparisons, we will use t-tests to check whether the 
pCR-related 83 genes and the other 16 genes are differentially expressed among the pCR 
responders and non-responders in this study, regardless of the assigned treatment arms.  
We will build a multivariate model based on these genes.  Then apply the final model to 
predict the pCR for all patients and assess the accuracy of the prediction by the 
percentage of patients being correctly classified as responders or non-responders. 
Two core biopsies will be obtained from each patient prior to the initiation of 
chemotherapy and ChemoFx® assay will be performed on tumor tissues from these 
biopsies.  The ChemoFx® assay results in a set of scores that characterize the sensitivity 
and resistance of individual patients to chemotherapy.  The prognostic utility of these 
scores on cOR of primary breast cancer patients following 4 cycles of docetaxel-based 
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treatments (T, TC, and TG), without bevacizumab, will be investigated. We expect at 
least 80% of patients will have sufficient tissue to perform the assay. For this purpose, 
600 patients from each treatment group are split into two groups: 400 patients as the 
training set and 200 patients as the validation set.  Given the 80% success rate, we expect 
at least 320 will be usable for training and 160 for validation.   
We will use the training set to define an optimal algorithm with cutoffs to allow us to 
classify patients as sensitive or resistant to specific chemotherapy regimens where the 
chemotherapeutic regimen may be part of the algorithm.  Among the methods used to 
determine the best algorithm (in the training set) will be fitting of a logistic model with 
response as the dependent variable and one or more ChemoFx scores and treatment as 
independent variables that minimizes partial least squares.  We will also look at ROC 
curves for different ChemoFx scores and/or linear combinations of the scores allowing 
for modifications for different treatments.  However, once the training is completed, an 
optimal algorithm that forms a rule to classify every patient for each treatment as 
sensitive or resistant will be carried forward to the validation set.  The validation set will 
then be stratified into resistant and sensitive groups and the observed cOR rates among 
these two groups will be compared and tested. 
Similar analyses of ChemoFx® assay scores will be performed using the dose-response 
curves for AC and each docetaxel-based treatment, to predict pCR with the 
corresponding sequential chemotherapy regimens.  Further analyses that control for the 
clinical response status after the docetaxel-based treatment for the prediction of pCR will 
be considered. We will explore the prediction of cOR after four cycles of docetaxel, 
docetaxel/capecitabine, docetaxel/gemcitabine, docetaxel with bevacizumab, 
docetaxel/capecitabine with bevacizumab, and docetaxel/gemcitabine with bevacizumab 
and investigate whether the addition of bevacizumab has an impact on the prediction of 
cOR using the dose-response curves for these docetaxel-based treatments. Other analyses 
such as using ChemoFx® assay data to predict cOR, pCR and DFS after sequential 
chemotherapy regimens with bevacizumab will also be explored. 
In order to facilitate the definitive analysis of using ChemoFx® assay scores to predict 
cOR after docetaxel-based treatments and pCR after the sequential chemotherapy 
regimens, we will take data from the first 100 patients that will be randomized to the 
TAC without bevacizumab arm and study various prediction methods.  
The B-27.2 study will provide us a prediction model using a set of gene markers to 
predict pCR to AC plus docetaxel for tissues procured by RNAlater.  We will apply this 
prediction model to patients enrolled in the AC plus docetaxel arm and assess the 
classification accuracy.  For tumor materials obtained from paraffin-embedded blocks, 
the B-27.2 study will provide another prediction model based on the same set of 
candidate gene markers to predict pCR to AC plus docetaxel.  We will apply this model 
to patients enrolled in the AC plus docetaxel too and compare the false-positive and false-
negative rates of these two models.  In the meanwhile, we will compare the expression of 
these candidate genes and study how different methods of tissue procurement affect 
expression levels of these candidate genes. 
We will test the relationship between pCR and protein Tau statuses: Tau-positive and 
Tau-negative by Chi-square test.  Then we will build a multivariate model, including 
patient age, tumor size, histological type and grade, estrogen receptor, progesterone 
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receptor, HER-2 and Tau staining intensity to predict pCR.  This prediction model will be 
applied to classify pCR of patients and the classification rate will be assessed. 
The residual cancer burden (RCB) index was created based on an MD Anderson Cancer 
Center study to describe response to neoadjuvant chemotherapy as a continuous 
measurement to better reflect association between response and distant relapse-free 
survival.162  It was determined by the pathologic response status, size and cellularity of 
residual tumor, and nodal metastasis status.  In this study, Cox proportional hazards 
models will be applied to validate the prognostic utility of RCB on DFS after neoadjuvant 
regimens.  Further exploration on the systemic relationship among treatment, baseline 
characteristics such as patient age, tumor size and estrogen receptor, characteristics of 
residual tumor at surgery, and DFS will also be conducted. 
18.7 Monitoring of adverse events 
The occurrence of adverse events, including toxicities and deaths, will be monitored.  
Summaries of all adverse events will be prepared and discussed at regularly scheduled 
meetings of the NSABP Medical Affairs Division. 
In addition, throughout the periods in which the protocol is open to accrual or patients are 
receiving therapy, semi-annual progress reports will be made to the NSABP Data 
Monitoring Committee (DMC).  These reports will include an assessment of toxicities 
and on-study deaths; a comparison of actual and projected accrual; and an assessment of 
data quality, including data delinquency and rates of eligibility.  After accrual is closed, 
reports of adverse events, together with the results of planned interim analyses of the 
primary endpoints will be presented to the DMC in accordance with the schedule 
presented below. 
18.8 Interim analyses of the primary endpoint 
For the comparison on pCR in breast, three formal analyses of endpoints will be 
conducted.  Two interim analyses will occur when pathologic response status is available 
from 400 and 800 patients.  We will consider stopping the trial if the 
docetaxel/capecitabine followed by AC regimen or the docetaxel/gemcitabine followed 
by AC regimen, with or without bevacizumab, is shown superior to the control arm 
(docetaxel alone followed by AC with or without bevacizumab), with a two-sided p-value 
less than 0.00025 at the first look or less than 0.00025 at the second look.  After adjusting 
for these two interim analyses, the significance level for the final analysis is 0.0498.174 
We will consider modifying the trial to assign bevacizumab to all subsequently enrolled 
patients if the docetaxel-anthracycline based regimen with bevacizumab is shown 
superior to the docetaxel-anthracycline based regimen without bevacizumab with a two-
sided p-value less than 0.00025 at the first look or less than 0.00025 at the second look. 
After adjusting for these two interim analyses, the significance level for the final analysis 
is 0.0498 with respect to the second primary hypothesis. 
For the comparison of DFS, three interim analyses will be carried out when 126, 166, and 
209 events are observed and the final definitive analysis will be conducted when 252 
events are observed.  Two-sided p-values 0.0005, 0.0005, and 0.001 will be used for the 
three interim looks, respectively.  Based on current assumptions, the first interim analysis 
is expected at about 4.5 years after the initiation of the trial.  After adjusting for these 
interim analyses, the significance level for the final analysis is about 0.0499. 
02/15/08 
02/15/08 
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18.9 Issues relating to racial and ethnic differences 
Possible racial and ethnic variation in response to the treatment under consideration is of 
great concern in African-Americans.  Researchers have noted poorer survival rates for 
black breast cancer patients as compared to Caucasians.175,176  This difference has been 
attributed to many factors including more advanced disease at the time of diagnosis,177 
social and economic factors178 or specific tumor characteristics such as ER 
positivity.179,180  Although outcomes tend to be less favorable in blacks, significant race-
by-treatment interactions have not been previously reported, suggesting that, where 
treatment efficacy exists, both groups appear to benefit.  Previous NSABP investigations 
of the relationship between race and prognosis support these conclusions.181,182 
Potential for the enrollment of minority patients in this protocol is enhanced by the 
NSABP’s recognition of the importance of increasing minority accrual.  To this end, we 
provide opportunities for greater participation by under-represented racial and ethnic 
groups.  In the NSABP protocol used for the projected sample size calculations (B-27), 
the study populations consisted of 73% white; 12% black, not of Hispanic origin; 8% of 
Hispanic origin; 3% other; and 4% unreported.  Other studies indicate 3% of the 
population are Hispanic; 2% are of Asian or Pacific Islander descent; < 1% are American 
Indian or Alaskan native; and < 1% are classified as other.  It is anticipated that this 
distribution will be maintained for the proposed protocol.  The prognostic effect of 
race/ethnicity will be evaluated using statistical models.  Unfortunately, because of power 
limitations, we will not be able to compare effects separately for the different cultural or 
racial groups.   
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TABLE 33. Expected racial and ethnic composition of NSABP B-40 
 
Ethnic Category 
 
 
Total 
Hispanic or Latino     99 
Not Hispanic or Latino 1,101 
Ethnic Category: Total of all subjects 1,200 
Racial Category  
American Indian or Alaskan Native     12 
Asian     57 
Black or African American    181 
Native Hawaiian or other Pacific Islander       4 
White     946 
Racial Category: Total of all subjects  1,200 
Ethnic Hispanic or Latino – a person of Cuban, Mexican, Puerto Rican, South or Central  
Categories: American, or other Spanish culture or origin, regardless of race. 
 Not Hispanic or Latino 
Racial American Indian or Alaskan Native – a person having origins in any of the original 
Categories: peoples of North, Central or South America, and who maintains tribal affiliations or 
 community attachment. 
 Asian – a person having origins in any of the original peoples of the Far East, 
 Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, 
 India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and  
 Vietnam. 
 Black or African American – a person having origins in any of the black racial 
 Groups of Africa. 
 Native Hawaiian or other Pacific Islander – a person having origins in any of the 
 original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. 
 White – a person having origins in any of the original peoples of Europe, the Middle 
                      East, or North Africa 
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19.0 PUBLICATION INFORMATION AND ADMINISTRATIVE AGREEMENTS 
The publication or citation of study results will be made in accordance with the publication policy 
of the NSABP that is in effect at the time the information is to be made publicly available. 
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DETERMINATION OF PERFORMANCE STATUS 
 
 
Performance status key 
 
ECOG or Zubrod Scale  Karnofsky Score 
0 
Fully active; able to carry on all pre-
disease performance without 
restriction 
90-100% 
1 Restricted in physically strenuous activity but ambulatory 70-80% 
2 
Ambulatory and capable of self-care; 
but unable to carry out any work 
activities 
50-60% 
3 
Capable of only limited self-care; 
confined to bed or chair more than 
50% of waking hours 
30-40% 
4 Completely disabled 10-20% 
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URINE PROTEIN/URINE CREATININE (UPC) RATIO INSTRUCTIONS 
NSABP B-40 requires screening for proteinuria prior to study entry and at scheduled time points during 
the study.  Because collection of a 24-hour urine specimen to screen for protein is inconvenient, urine 
protein/creatinine (UPC) ratio will be used to check for proteinuria. 
A. Procedure for calculating the UPC ratio 
1. The patient provides at least 4 ml of a random urine sample (24-hour urine collection is not 
required for this study).   
2. The lab determines urine protein (or urine albumin) concentration (result should be mg/dL). 
3. The lab determines urine creatinine concentration (result should be mg/dL). 
4. The coordinator (or lab) calculates the UPC ratio by dividing the urine protein (#2 above) by 
the urine creatinine (#3 above). 
Total urine protein (or urine albumin) ÷ urine creatinine = UPC ratio 
Example of UPC calculation: 
 46.5 mg/dL (urine protein) ÷ 1501.1 mg/dL (urine creatinine) = 0.0309 (UPC ratio) 
5. The coordinator documents the UPC ratio to the nearest tenth or to one decimal point.  
 Rounding the value is permitted.  If the number being rounded has a 5, 6, 7, 8, or 9 in the 
 hundredth position, round the number up.  If the number in the hundredth position is  
 0, 1, 2, 3, or 4, round the number down.  In the above example, the UPC ratio of 0.0309 
 would be rounded down to 0.0.  Other examples of rounding the UPC ratio: 
0.167 is rounded up to 0.2 
0.132 is rounded down to 0.1 
0.941 is rounded down to 0.9 
0.951 is rounded up to 1.0 
Important reminders: 
 Do NOT use serum protein or serum creatinine results for this calculation. 
 Do NOT use a dipstick to screen for proteinuria in B-40. 
 Do NOT use microalbumin values to calculate the UPC ratio. 
 
B. Using the UPC ratio for bevacizumab dose modifications and AE reporting 
The UPC ratio directly correlates with the amount of protein excreted in the urine per 24 hours.  
A UPC of 1.0 is roughly equivalent to 1 gram of protein in a 24-hour urine collection.  If the 
UPC ratio is  1, then the amount of protein in a 24-hour urine specimen can be assumed to be  
 1 gram per 24 hours. 
For the purposes of B-40, proteinuria will be graded based on the UPC ratio applied to the 
CTCAE v3.0 criteria for grading proteinuria (measured in grams/24 hours).    
Example of using the UPC ratio for AE grading:  
UPC ratio of 2.5 approximates 2.5 g/24 hrs = grade 2 proteinuria ( 1.0 - 3.5 g/24 hours) 
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FORMULA TO BE USED FOR 
CALCULATED CREATININE CLEARANCE 
 
 
For females, creatinine clearance (mL/min) = (140 – age) x weight (kg) x 0.85 
 72 x serum creatinine (mg/dL) 
 
OR (140 – age) x weight (kg) x 0.85 
 0.81 x serum creatinine (mmol/L) 
 
 
 
For males, creatinine clearance (mL/min) = (140 – age) x weight (kg) 
 72 x serum creatinine (mg/dL) 
 
OR (140 – age) x weight (kg) 
 0.81 x serum creatinine (mmol/L) 
 
 
 
Renal function is classified as normal ( > 80 mL/min), mildly impaired (50 – 80 mL/min), moderately 
impaired (30 – 50 mL/min), or severely impaired ( < 30 mL/min). 
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CAPECITABINE DOSE ACCORDING TO BODY SURFACE AREA 
 
Dose Level 0 = 825 mg/m2 
twice daily 
Number of tablets 
administered in the morning* 
Number of tablets 
administered in the evening* 
Body Surface 
Area (m2) 
Dose per 
administration 
(mg) 
 
150 mg 
 
500 mg 
 
150 mg 
 
500 mg 
< 1.31 1000 - 2 - 2 
1.31 – 1.48 1150 1 2 1 2 
1.49 – 1.67 1300 2 2 2 2 
1.68 – 1.90 1500 - 3 - 3 
1.91 – 2.09 1650 1 3 1 3 
2.10 – 2.27 1800 2 3 2 3 
> 2.27 2000 - 4 - 4 
Dose Level -1 = 650 mg/m2 
twice daily 
Number of tablets 
administered in the morning* 
Number of tablets 
administered in the evening* 
Body Surface 
Area (m2) 
Dose per 
administration 
(mg) 
 
150 mg 
 
500 mg 
 
150 mg 
 
500 mg 
< 1.31 800 2 1 2 1 
1.31 – 1.48 950 3 1 3 1 
1.49 – 1.67 1000 - 2 - 2 
1.68 – 1.90 1150 1 2 1 2 
1.91 – 2.09 1300 2 2 2 2 
2.10 – 2.27 1500 - 3 - 3 
> 2.27 1650 1 3 1 3 
Dose Level -2 = 500 mg/m2 
twice daily 
Number of tablets 
administered in the morning* 
Number of tablets 
administered in the evening* 
Body Surface 
Area (m2) 
Dose per 
administration 
(mg) 
 
150 mg 
 
500 mg 
 
150 mg 
 
500 mg 
< 1.31 650 1 1 1 1 
1.31 – 1.48 800 2 1 2 1 
1.49 – 1.67 800 2 1 2 1 
1.68 – 1.90 950 3 1 3 1 
1.91 – 2.09 1000 - 2 - 2 
2.10 – 2.27 1150 1 2 1 2 
> 2.27 1300 2 2 2 2 
*Please note: It is important to monitor patients' compliance in taking capecitabine.  Investigators are 
strongly encouraged to provide a patient diary or calendar to record capecitabine dosing information.  
Pill counts can also be used to supplement the diary or calendar. 
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SUGGESTED PROCEDURE FOR EVALUATION OF SURGICAL SPECIMENS 
FOLLOWING NEOADJUVANT THERAPY ON B-40 
The following procedures used for processing breast specimens following neoadjuvant chemotherapy at 
MD Anderson Cancer Center are provided as guidelines for NSABP institutions and investigators.  They 
are provided as suggestions, and may be modified as needed to make them functional in participating 
institutions. 
Specimens should be oriented with sutures by the surgeon following removal.  The surgeon and breast 
pathologist should confer to ensure optimal evaluation of the primary tumor site for possible pCR. 
Note: Refer to Section 8.4 for histopathology findings required for ALL B-40 patients for use by the 
NSABP Biostatistical Center in calculating the RCB index. 
 In cases showing significant clinical response: 
 The breast resection specimen is radiographed to identify metallic markers which were placed 
during or prior to chemotherapy. 
 Each specimen is inked using multiple colors to identify each face of the specimen, and then 
sectioned into 3-5 mm slices. 
 The sliced specimen is radiographed and a radiologist reviews the films to determine the presence 
and extent of residual tumor. 
 The pathologist examines the sliced specimen grossly to identify suspicious areas and notes their 
proximity to margins. 
 The radiographic and pathological evaluation is discussed with the surgeon who decides whether 
additional margins should be obtained. 
 Permanent paraffin sections of the suspicious areas and margins are obtained.  The number of 
sections taken is based on the gross inspection, radiologic features, and size of the resection 
specimen. 
 The entire radiographic abnormality as well as firm and suspicious appearing breast tissue is 
submitted for histologic evaluation. 
 In general, for non-palpable (clinical complete response) cases, at least 10-15 blocks are 
examined to assess the presence of residual microscopic disease. 
 In cases with residual palpable mass (partial clinical response or no response in the breast): 
 The resection specimen is inked and sectioned into 3-5 mm slices. 
 The pathologist examines the slices and determines the tumor size on gross evaluation and 
confirms the tumor size by microscopic evaluation. 
 Evaluation of axillary lymph nodes regardless of response: 
All axillary lymph nodes are also carefully evaluated by serial gross sectioning. 
 One or two representative histologic sections are evaluated for lymph nodes that contain grossly 
identifiable metastatic carcinoma. 
 The lymph nodes that do not show grossly identifiable tumor are submitted for histologic 
evaluation in their entirety.  One representative histologic section is evaluated per paraffin block.  
Immunohistochemical staining for cytokeratin is not routinely performed on negative nodes. 
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CANCER TRIALS SUPPORT UNIT (CTSU) INSTRUCTIONS 
 
These instructions supplement the protocol for CTSU participants.  The protocol is to be followed in areas 
not described in this appendix. 
1.0 SITE REGISTRATION AND PATIENT ENTRY FOR CTSU INVESTIGATORS 
Prior to the recruitment of a patient for this study, investigators must be registered members of 
the CTSU.  Each investigator must have an NCI investigator number and must maintain an 
“active” investigator registration status through the annual submission of a complete investigator 
registration packet (FDA Form 1572 with original signature, current CV, Supplemental 
Investigator Data Form with signature, and Financial Disclosure Form with original signature) to 
the Pharmaceutical Management Branch, CTEP, DCTD, NCI.  These forms are available on the 
CTSU registered member Web site (http://members.ctsu.org) or by calling the PMB at 301-496-
5725 Monday through Friday between 8:30 am and 4:30 pm Eastern Time.  Each CTSU 
investigator or group of investigators at a clinical site must obtain IRB approval for this protocol 
and submit IRB approval and supporting documentation to the CTSU Regulatory Office before 
they can enroll patients.  All forms and documents associated with this study can be downloaded 
from the NSABP B-40 Web page on the CTSU Member Web site (http://members.ctsu.org).  
Patients can be registered only after pre-treatment evaluation is complete, all eligibility criteria 
have been met, and the study site is listed as approved in the CTSU RSS. 
Requirements for NSABP B-40 site registration: 
 CTSU IRB Certification 
 IRB/Regulatory Approval Transmittal Sheet 
 
Requirements for patient enrollment on NSABP B-40: 
 Patient must meet all inclusion criteria and no exclusion criteria should apply 
 Patient has signed and dated the consent 
 All baseline laboratory tests and pre-study evaluations performed 
 Fresh tumor tissue (four cores) has been collected for submission to Precision Therapeutics, 
Inc. 
 
CTSU Procedures for Patient Enrollment: Contact the CTSU Patient Registration Office by 
calling 1-888-462-3009 and leave a voice mail to alert the CTSU Patient Registrar that an 
enrollment is forthcoming.  For immediate registration needs, i.e., within one hour, call the 
Registrar cell phone at 1-301-704-2376.  Complete the following forms: 
 CTSU Patient Enrollment Transmittal Form 
 Form A (Registration Form) with necessary attachments 
 Properly signed and dated B-40 consent form 
 
Fax these forms to the CTSU Patient Registrar at 1-888-691-8039 between the hours of 9:00 a.m. 
and 5:30 p.m. Monday-Friday, Eastern Time (excluding holidays).  Registrations received after 
5:00 p.m. will be processed the next business day.  The CTSU registrar will check the 
investigator and site information provided to ensure that all regulatory requirements have been 
met.  The registrar will also check that forms are complete and follow-up with the site to resolve 
any discrepancies. 
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Once investigator eligibility is confirmed and enrollment documents are reviewed for compliance, 
the CTSU registrar will access the NSABP on-line registration system to obtain assignment of a 
treatment arm and assignment of a unique NSABP Patient ID (to be used on all future forms and 
correspondence).  The CTSU registrar will confirm registration by fax. 
2.0 DRUG ORDERS FOR CTSU INVESTIGATORS 
Investigational IND agents 
 bevacizumab – request drug through the NSABP Biostatistical Center 
 capecitabine – request drug through the NSABP Biostatistical Center 
 gemcitabine – request drug through the NSABP Biostatistical Center 
 
Other commercial agents 
 doxorubicin, cyclophosphamide, and docetaxel – obtain commercially 
 
3.0 SPECIAL MATERIALS 
All tissue, blood, serum specimen requirements, and information regarding ordering kits for core 
biopsies are outlined in Section 8.1 (Table 7) and the B-40 Pathology Instructions located on the 
B-40 Web page on the CTSU Registered Member Web site. 
3.1 Submission of tissue by CTSU investigators 
Tumor tissue procured in RNAlater, formalin, and shipping medium for PTI will be 
collected prior to randomization (for all patients).  Tumor blocks are required from gross 
residual tumor  1 cm.  (If gross residual tumor  1 cm or no gross tumor, no tissue 
submission is required.)  CTSU investigators should follow protocol directions for tissue 
procurement and submission to the NSABP Biostatistical Center (blocks) and Precision 
Therapeutics, Inc. (core biopsy samples - see Section 8.1).  Do not submit specimens to 
the CTSU.  A completed NSABP Form PTI must accompany the pre-entry core biopsy 
specimens.  NSABP Form BLK must accompany the paraffin blocks. 
3.2 Submission of blood/serum by CTSU investigators 
CTSU will ship supplies for blood/serum collection to the CTSU site at the time of 
patient registration.  Subsequent blood/serum collection kits will be sent to the CTSU site 
by the NSABP Serum Bank.  CTSU investigators should follow protocol directions for 
collection of blood and serum (see Section 8.8).  Specimens should be shipped the same 
day as collected to the NSABP Serum Bank at the Baylor College of Medicine.  
Clinics should schedule specimen shipments to occur on Monday – Thursday so as not to 
be received on the weekend.  A completed NSABP Form BNK transmittal must 
accompany all shipments. 
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4.0 DATA SUBMISSION FOR CTSU INVESTIGATORS 
All case report forms (CRFs) associated with this study must be downloaded from the NSABP  
B-40 Web page located on the CTSU Registered Member Web site (http://members.ctsu.org).  
Sites must use the current form versions and adhere to the instructions and submission schedule 
outlined in the protocol. 
Submit all completed CRFs (with the exception of patient enrollment forms), clinical reports, and 
other documents directly to the NSABP Biostatistical Center.  The preferred method of sending 
data is via fax at 412-622-2111.  Do not include a cover sheet for faxed data. 
The NSABP Biostatistical Center will send query notices and delinquency reports directly to the 
site for reconciliation.  Please send query responses and delinquent data to the NSABP 
Biostatistical Center and do not copy the CTSU Data Operations.  If the query is sent with a fax 
transmittal form, return the data to the fax number on the transmittal form, otherwise fax to  
412-624-1082. 
Each site should have a designated CTSU Administrator and Data Administrator and must keep 
their CTEP AMS account contact information current.  This will ensure timely 
communication between the clinical site and the NSABP Biostatistical Center. 
5.0 ADVERSE EVENT (AE) REPORTING BY CTSU INVESTIGATORS 
Specific reporting requirements for NSABP B-40 are found in protocol Section 14.0.  The 
Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 is required for reporting 
adverse events for protocol B-40.  A link to the CTCAE version 3.0 is available on the CTSU 
Member Web site.  CTSU investigators should employ definitions of adverse events as described 
in Section 14.0 of the protocol.  All reporting must be conducted within the time frames specified 
in Section 14.0, and all completed forms should be submitted as outlined in Section 14.0. 
Adverse events determined to be reportable must also be reported according to the local policy 
and procedures to the Institutional Review Board responsible for the oversight of the patient. 
5.1 Routine reporting 
CTSU institutions: please refer to Section 14.3 for instructions regarding routine adverse 
event reporting requirements.  When indicated, supporting documentation must be 
included.  The B-40 Adverse Event Form is to be completed by the CTSU institution and 
sent to the NSABP Biostatistical Center. 
5.1 Expedited reporting 
 Refer to Section 14.2 and Tables 31 and 32 for instructions regarding expedited 
adverse event reporting requirements. 
 
 Contact the NSABP B-40 Research Nurse Specialist at the NSABP Biostatistical 
Center (refer to Information Resources, page v) for questions regarding completion 
of reports, the need for supporting documentation, and submission time constraints. 
 
 Follow the instructions in Section 14.0 of the protocol when AdEERS reporting is 
required.  Access the AdEERS electronic Web based application and complete it 
fully and accurately.  AdEERS reports are submitted electronically to the NSABP 
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Lead Group, and available supporting documentation is faxed to the NSABP 
Biostatistical Center (412-622-2113) at the time of the AdEERS submission.  Include 
the NSABP Patient ID number and the AdEERS ticket number on all supporting 
documentation. 
 
5.3  Secondary AML/MDS/ALL reporting 
Refer to protocol Section 14.2.4.  CTSU investigators will submit the NCI Secondary 
AML/MDS Report Form and supporting documentation to the NSABP Biostatistical 
Center.  The NSABP Research Nurse Specialist will review and forward the report form 
and supporting documentation to the NCI. 
5.4  Pregnancy occurring while the patient is on protocol therapy 
If a patient becomes pregnant while receiving protocol therapy, notify the NSABP 
Clinical Coordinating Division. 
6.0 REGULATORY AND MONITORING 
 6.1 Study audit 
To assure compliance with Federal regulatory requirements [CFR 21 parts 50, 54, 56, 
312, 314 and HHS 45 CFR 46] and National Cancer Institute (NCI)/Cancer Therapy 
Evaluation Program (CTEP) Clinical Trials Monitoring Branch (CTMB) guidelines for 
the conduct of clinical trials and study data validity, all protocols approved by NCI/CTEP 
that have patient enrollment through the CTSU are subject to audit. 
Responsibility for assignment of the audit will be determined by the site's primary 
affiliation with a Cooperative Group or CTSU.  For Group-aligned sites, the audit of a 
patient registered through CTSU will become the responsibility of the Group receiving 
credit for the enrollment.  For CTSU Independent Clinical Research Sites (CICRS), the 
CTSU will coordinate the entire audit process. 
For patients enrolled through the CTSU, you may request the accrual be credited to any 
Group for which you have an affiliation provided that Group has an active clinical trials 
program for the primary disease type being addressed by the protocol, (e.g., NSABP 
members may only request credit for protocols pertaining to breast or colorectal cancers).  
Registrations to protocols for other disease sites may still take place through CTSU 
without receiving credit for your NSABP activities.  Per capita reimbursement will be 
issued directly from CTSU. 
Details on audit evaluation components, site selection, patient case selection, materials to 
be reviewed, site preparation, on-site procedures for review and assessment, and results 
reporting and follow-up are available for download from the CTSU Operations Manual 
located on the CTSU Registered Member Web site. 
6.2. Health Insurance Portability and Accountability Act of 1996 (HIPAA) 
 
The HIPAA Privacy Rule establishes the conditions under which protected health 
information may be used or disclosed by covered entities for research purposes.  
Research is defined in the Privacy Rule referenced in HHS 45 CFR 164.501.  Templated 
language addressing NCI-US HIPAA guidelines are provided in the HIPAA 
Authorization Form located on the CTSU Web site. 
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The HIPAA Privacy Rule does not affect participants from outside the United States.  
Authorization to release Protected Health Information is NOT required from patients 
enrolled in clinical trials at non-US sites. 
6.3 Clinical Data Update System (CDUS) monitoring 
This study will monitored by the Clinical Data Update System (CDUS) Version 3.0.  
Cumulative CDUS data will be submitted quarterly to CTEP by electronic means.  The 
sponsoring Group fulfills this reporting obligation by electronically transmitting to CTEP 
the CDUS data collected from the study-specific case report forms. 
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NSABP B-40 Sample Consent Form 
 
NSABP PROTOCOL B-40 
 
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer 
Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to 
Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies 
Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens 
 
 
Study Consent Version: February 15, 2008 
Consent Addendum #1 Version: February 15, 2008 
Consent Addendum #2 Version: April 1, 2011 
To be attached to Protocol Version: April 1, 2011 
 
Instructions to Local Institutional Review Boards Regarding 
Local IRB Review of Multicenter Clinical Trials 
 
In order to conform to OHRP guidelines (effective November 9, 1992) regarding local IRB review of 
multicenter clinical trials, and to provide local IRBs with flexibility in conforming to local standards, the 
NSABP provides the following instructions regarding the IRB approval process of this multicenter 
clinical trial. 
The protocol and sample consent form provided by the NSABP have been reviewed and approved by the 
Division of Cancer Treatment and Diagnosis, National Cancer Institute.  Local IRBs and the investigator 
are permitted to make changes to the consent form; however, the editorial changes must not alter the 
overall content or the intent of the information in the sample consent form.  Should an investigator or 
local IRB delete or make a substantive modification of the information contained in the risks or 
alternative treatments sections of the consent form, this must be justified in writing by the investigator or 
the IRB and then approved by the IRB.  Also, the NSABP Operations Center requires that, similarly, the 
NSABP also be notified of substantive changes in the consent form section regarding consent to collect 
and store samples for possible future testing.  Of primary concern are text changes that could potentially 
affect the future usage of the banked samples.  The IRB is responsible for reflecting in the IRB minutes 
the justification for, and approval of, such deletions or modifications.  The investigator is responsible 
for forwarding copies of substantive IRB-approved changes with their justifications to the NSABP 
Operations Center Division of Regulatory Affairs immediately.  It is the responsibility of the principal 
investigator and the IRB to determine what constitutes a substantive change.  Any conflict between the 
two groups concerning this decision would be resolved at the NSABP Operations Center. 
Upon receipt of these documents at the NSABP Operations Center staff will review and approve the 
changes and their justifications with input (as needed) from the Quality Assurance staff and government 
agencies. 
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NSABP SAMPLE CONSENT Version as of 02/15/08 
IRB Approved: 00/00/00 
Consent Form 
For 
 
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with 
Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete 
Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered 
Before AC with or without Bevacizumab and Correlative Science Studies Attempting to 
Identify Predictors of High Likelihood for pCR with Each of the Regimens 
 
(Note: Centers outside of the U.S. and Canada must insert the applicable country and 
government oversight agencies in place of the FDA and Health Canada where appropriate 
throughout the consent form.) 
This is a clinical trial, a type of research study.  You are being asked to take part in this study 
because you have breast cancer and you have not yet had surgery to remove the tumor.  Your 
study doctor will explain the clinical trial to you.  Clinical trials include only people who choose 
to take part.  Please take your time to make your decision about taking part.  You may discuss 
your decision with your friends and family.  You can also discuss it with your health care team.  
If you have any questions, you can ask your study doctor for more explanation. 
Who is conducting the study? 
The National Surgical Adjuvant Breast and Bowel Project (NSABP) is conducting this study. 
(The NSABP institution must supply appropriate information as to who is conducting the trial 
locally.) 
Why is this research study being done? 
This study is being done for a number of reasons. 
 One of the main purposes of the study is to learn how breast cancer tumors such as yours 
respond to several different chemotherapy combinations.  Three of the chemotherapy drugs 
used in this study are docetaxel followed by the combination of doxorubicin and 
cyclophosphamide (AC), a standard treatment for breast cancer.  This study will add the drug 
capecitabine and the drug gemcitabine to docetaxel to see if either drug improves the 
effectiveness of the standard drugs at killing all of the tumor cells in the breast and nearby 
lymph nodes. 
Capecitabine and gemcitabine are both used to treat breast cancer that has spread beyond the 
breast and nearby lymph nodes, so we expect they will also be effective in treating patients 
with earlier stage cancer like yours.  Capecitabine and gemcitabine are considered 
investigational because they are still being researched and have not yet received approval 
from the Food and Drug Administration (FDA) for use in treating early stage breast cancer. 
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(Canadian Sites must insert the following paragraph in place of the last sentence above: 
Health Canada has not approved the use of gemcitabine and capecitabine for the treatment of 
early stage breast cancer.  Their use in this study is considered to be investigational.) 
 A second main purpose of the study is to learn how breast cancer tumors like yours respond 
when the drug bevacizumab is added to the combinations of chemotherapy in this study.  
Bevacizumab is considered investigational because it is still being researched and has not yet 
received approval from the FDA for use in treating breast cancer. 
(Canadian Sites must insert the following paragraph in place of the last sentence above: 
Bevacizumab is not commercially available in Canada.  Health Canada considers the use of 
this agent for treating breast cancer to be investigational.) 
Bevacizumab is an “angiogenesis inhibitor.”  Angiogenesis inhibitors and chemotherapy 
work in different ways.  Bevacizumab keeps the tumor from being able to make new blood 
vessels.  Without new blood vessels, the growth of the tumor is slowed.  Chemotherapy drugs 
kill cancer cells more directly. 
 Another purpose of the study is to learn more about the side effects of the combinations of 
drugs used in this study.  Included in what we will learn about side effects will be whether or 
not adding bevacizumab to chemotherapy for breast cancer will affect the heart.  We will also 
learn if receiving bevacizumab has any effect on how patients recover from breast surgery. 
 Another reason for doing this study is that tumor tissue collected before treatment starts will 
make it possible to do special tests, which should provide researchers at the NSABP with 
information about how tumors like yours respond to chemotherapy.  Researchers hope to 
determine if results of specialized tests on tumor tissue can predict which tumors will be 
completely killed by the drug combinations used in this study. 
How many people will take part in the study? 
About 1200 women will take part in the study. 
What will happen if I take part in this research study? 
Before you begin the study: You will need to have the following exams, tests, and procedures to 
find out if you can be in the study.  These exams, tests, and procedures are part of regular cancer 
care and may be done even if you do not join this study.  If you have had some of them recently, 
they may not need to be repeated.  This will be up to your study doctor. 
 medical history and physical exam 
 blood tests, including a pregnancy test for women of childbearing potential 
 chest x-ray or chest CT scan 
 breast examination to measure the tumor  
 mammogram  
 MUGA or echocardiogram (to see how well your heart pumps blood) 
 EKG (electrocardiogram) 
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 bone scan, bone x-rays, or bone tests (only if you have bone pain or your blood tests 
show an increase in a bone-related protein) 
 CT scan of the liver (only if your blood tests show abnormal liver function) 
 ultrasound of the breast and underarm area, if your doctor thinks you need this 
You will also need the following tests and procedure that are not part of regular cancer care and 
are being done for the purpose of this study. 
 additional breast tumor biopsy to collect tissue for research purposes 
 urine test (Because bevacizumab may cause some patients to have abnormal 
amounts of protein in the urine, a urine sample will be collected before you join the 
study.) 
 
During the study: If the exams, tests and procedures show that you can be in the study and you 
choose to take part, then you will be “randomized” into one of the six treatment groups.  
Randomization means that you are put into a group by chance.  A computer program will place 
you in one of the groups.  Neither you nor your doctor can choose the group you will be in.  You 
will have an equal chance of being placed in one of the six groups. 
 
After you have joined the study, you will begin your study therapy.  You will receive your drugs 
on a schedule specific to your group.  This schedule will be repeated every 21 days.  This 21-day 
period is known as a cycle.  The treatment drugs and schedules are as follows: 
 
Study therapy before surgery for patients randomized to Groups 1A, 2A, or 3A: 
Group 1A 
Part 1: You will receive docetaxel through a vein once every 21 days for 4 cycles.  Each 
treatment will take about 1½ hours.  The day before and in the morning on the day you receive 
docetaxel you will take another drug called dexamethasone.  Dexamethasone is a drug you take 
by mouth to help prevent some of the side effects of docetaxel.  Also, starting the day after you 
receive docetaxel, you will need to receive another drug, either pegfilgrastim (Neulasta®) or 
filgrastim (Neupogen®).  These drugs help to prevent low white blood cell counts that may lead 
to infection.  These drugs are given as a shot under your skin.  Your doctor or his/her staff may 
give you this shot or may teach you to give yourself this shot, or they can teach a friend or 
relative to give the shot to you.  The shot may be given on 1 or more days, depending on which 
drug your doctor decides is best for you.  Some patients experience bone pain with these drugs.  
If this happens, let your doctor know about it.   
Part 2: After you have received docetaxel for 4 cycles, you will then receive doxorubicin and 
cyclophosphamide (AC) through a vein once every 21 days for 4 cycles.  Each treatment will 
take about 1 hour. 
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Group 2A 
Part 1: You will receive docetaxel through a vein once every 21 days for 4 cycles.  Each 
treatment will take about 1½ hours.  The day before and in the morning on the day you receive 
docetaxel you will take another drug called dexamethasone.  Dexamethasone is a drug you take 
by mouth to help prevent some of the side effects of docetaxel.  You will also take capecitabine 
pills, twice a day, for 14 days starting on the day you receive docetaxel.  Your doctor may ask 
you to write in a diary or on a calendar each dose of capecitabine that you take.  You will then 
have 7 days without capecitabine before starting the next cycle.   
Part 2: After you have received docetaxel and capecitabine for 4 cycles, you will then receive 
doxorubicin and cyclophosphamide (AC) through a vein once every 21 days for 4 cycles.  Each 
treatment will take about 1 hour. 
Group 3A 
Part 1: On the first day of each cycle, you will receive docetaxel and gemcitabine through a 
vein.  You will also receive gemcitabine a week after the first dose of each cycle.  You will 
receive this therapy once every 21 days for 4 cycles.  The day before and in the morning on the 
day you receive docetaxel, you will take another drug called dexamethasone.  Dexamethasone is 
a drug you take by mouth to help prevent some of the side effects of docetaxel.  Each treatment 
will take about 2 hours on Day 1.  Treatment will take about ½ hour when you receive 
gemcitabine alone. 
Part 2: After you have received docetaxel and gemcitabine for 4 cycles, you will then receive 
doxorubicin and cyclophosphamide (AC) through a vein once every 21 days for 4 cycles.  Each 
treatment will take about 1 hour. 
Summary of study therapy for patients in Groups 1A, 2A, and 3A 
PART 1 
Group 1A 
 
 
Docetaxel 
by vein every 3 weeks  
for 4 cycles 
Group 2A 
Docetaxel  
by vein every 3 weeks 
for 4 cycles 
+ 
Capecitabine  
by mouth Days 1-14 
every 3 weeks 
for 4 cycles 
Group 3A 
Docetaxel 
by vein every 3 weeks 
for 4 cycles 
+ 
Gemcitabine 
by vein Days 1 and 8 
every 3 weeks 
for 4 cycles 
PART 2 
AC 
by vein every 3 weeks 
for 4 cycles 
AC 
by vein every 3 weeks 
for 4 cycles 
AC 
by vein every 3 weeks  
for 4 cycles 
You will have breast surgery after completion of study therapy. 
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Study therapy before and after surgery for patients randomized to Groups 1B, 2B, or 3B: 
Group 1B 
Part 1: On the first day of each cycle you will receive bevacizumab and the chemotherapy drug 
docetaxel through a vein.  You will receive this therapy for a total of 4 cycles.  It will take about 
3 hours to receive your first dose of therapy.  After that, if you have no problems receiving 
bevacizumab, it will take about 2 hours to receive your therapy. 
The day before and in the morning on the day you receive docetaxel you will take another drug 
called dexamethasone.  Dexamethasone is a drug you take by mouth to help prevent some of the 
side effects of docetaxel.  Also, starting the day after you receive docetaxel, you will also need to 
receive another drug, either pegfilgrastim (Neulasta®) or filgrastim (Neupogen®).  These drugs 
help to prevent low white blood cell counts that may lead to infection.  These drugs are given as 
a shot under your skin.  Your doctor or his/her staff may give you this shot or may teach you to 
give yourself this shot, or they can teach a friend or relative to give the shot to you.  The shot 
may be given on 1 or more days, depending on which drug your doctor decides is best for you.  
Some patients experience bone pain with these drugs.  If this happens, let your doctor know 
about it. 
Part 2: After you have received bevacizumab and docetaxel for 4 cycles, you will receive 
doxorubicin and cyclophosphamide (AC) through a vein once every 21 days for 4 cycles.  You 
will continue to receive bevacizumab.  However, during Part 2, you will receive bevacizumab 
every 21 days for only the first 2 cycles.  You are given bevacizumab only during the first  
2 cycles of AC so that you have at least one month without bevacizumab before your breast 
surgery.  This will reduce the chance of having wound healing problems after your breast 
surgery.  Each treatment will take about 1½ hours. 
After surgery: After you have recovered from surgery but no sooner than 28 days after your 
surgery, you will receive bevacizumab through a vein once every 21 days for 10 doses.  Each 
treatment will take about 1 hour. 
Group 2B 
Part 1: On the first day of each cycle you will receive bevacizumab and the chemotherapy drug 
docetaxel through a vein.  You will receive this therapy for a total of 4 cycles.  It will take about 
3 hours to receive your first dose of therapy.  After that, if you have no problems receiving 
bevacizumab, it will take about 2 hours to receive your therapy.  The day before and in the 
morning on the day you receive docetaxel, you will take another drug called dexamethasone.  
Dexamethasone is a drug you take by mouth to help prevent some of the side effects of 
docetaxel.  You will also take capecitabine pills, twice a day, for 14 days starting on the day you 
receive docetaxel and bevacizumab.  Your doctor may ask you to write in a diary or on a 
calendar each dose of capecitabine that you take.  You will then have 7 days without 
capecitabine before starting the next cycle. 
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Part 2: After you have received bevacizumab, docetaxel, and capecitabine for 4 cycles, you will 
receive doxorubicin and cyclophosphamide (AC) through a vein once every 21 days for 4 cycles.  
You will continue to receive bevacizumab.  However, during Part 2, you will receive 
bevacizumab every 21 days for only the first 2 cycles.  You are given bevacizumab only during 
the first 2 cycles of AC so that you have at least one month without bevacizumab before your 
breast surgery.  This will reduce the chance of having wound healing problems after your breast 
surgery.  Each treatment will take about 1½ hours. 
After surgery: After you have recovered from surgery but no sooner than 28 days after your 
surgery, you will receive bevacizumab through a vein once every 21 days for 10 doses.  Each 
treatment will take about 1 hour. 
Group 3B 
Part 1: On the first day of each cycle, you will receive bevacizumab and the chemotherapy drugs 
docetaxel and gemcitabine through a vein.  You will also receive gemcitabine a week after the 
first dose of each cycle.  You will receive this therapy once every 21 days for 4 cycles.  It will 
take about 3½ hours to receive your first dose of study therapy.  After that, if you have no 
problems receiving bevacizumab, it will take about 2½ hours to receive your therapy when you 
receive all 3 drugs and about ½ hour when you receive gemcitabine alone.  The day before and in 
the morning on the day you receive docetaxel you will take another drug called dexamethasone.  
Dexamethasone is a drug you take by mouth to help prevent some of the side effects of 
docetaxel. 
Part 2: After you have received bevacizumab, docetaxel, and gemcitabine for 4 cycles, you will 
receive doxorubicin and cyclophosphamide (AC) through a vein once every 21 days for 4 cycles.  
You will continue to receive bevacizumab.  However, during Part 2, you will receive 
bevacizumab every 21 days for only the first 2 cycles.  You are given bevacizumab only during 
the first 2 cycles of AC so that you have at least one month without bevacizumab before your 
breast surgery.  This will reduce the chance of having wound healing problems after your breast 
surgery.  Each treatment will take about 1½ hours. 
After surgery: After you have recovered from surgery but no sooner than 28 days after your 
surgery, you will receive bevacizumab through a vein once every 21 days for 10 doses.  Each 
treatment will take about 1 hour. 
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Summary of study therapy for patients in Groups 1B, 2B, and 3B 
PART 1 
Group 1B 
 
 
Docetaxel 
by vein every 3 weeks 
for 4 cycles 
+ 
Bevacizumab  
by vein every 3 weeks 
for 4 cycles 
Group 2B 
Docetaxel 
by vein every 3 weeks 
for 4 cycles 
+ 
Capecitabine 
by mouth days 1-14 
every 3 weeks  
for 4 cycles 
+ 
Bevacizumab  
by vein every 3 weeks 
for 4 cycles 
Group 3B 
Docetaxel 
by vein every 3 weeks 
for 4 cycles 
+ 
Gemcitabine  
by vein Days 1 and 8 
every 3 weeks 
for 4 cycles 
+ 
Bevacizumab  
by vein every 3 weeks 
for 4 cycles 
PART 2 
AC 
by vein every 3 weeks 
for 4 cycles 
+ 
Bevacizumab  
by vein every 3 weeks 
for 2 cycles 
AC 
by vein every 3 weeks 
for 4 cycles 
+ 
Bevacizumab  
by vein every 3 weeks 
for 2 cycles 
AC 
by vein every 3 weeks  
for 4 cycles 
+ 
Bevacizumab  
by vein every 3 weeks 
for 2 cycles 
You will have breast surgery after completion of the study therapy summarized above. 
Study therapy after surgery for Groups 1B, 2B, and 3B 
Bevacizumab by vein every 3 weeks for 10 cycles. 
During study therapy for all groups: 
All patients will have the following exams and tests during study therapy.  They are part of 
regular cancer care. 
 a physical exam before each cycle of therapy  (During some exams, you will have a breast 
examination to check your tumor.) 
 blood tests to check your blood counts before each cycle of therapy 
 blood tests to check how well your kidneys and liver are working before every other cycle of 
study therapy 
 breast exam to measure the tumor after completing Part 1 of study therapy, before 
beginning AC 
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The following tests are not part of regular cancer care and are being done for the purpose of this 
study: 
 
 urine test to check for protein in your urine before the 3rd and 5th cycles of study therapy  
(Groups 1B, 2B, and 3B patients only) 
 optional blood collection for research before beginning study therapy and before the 3rd 
cycle of chemotherapy that includes docetaxel (only if you answered "yes" to the optional 
blood collection question at the end of this consent) 
Before breast surgery for all groups:  After you have recovered from preoperative study therapy, 
you will see your doctor and have the following exams and tests.  They are part of regular cancer 
care. 
 routine blood tests 
 a physical exam 
 breast examination to measure the tumor  
 mammogram 
 
The following tests are not part of regular cancer care and are being done for the purpose of this 
study: 
 
 MUGA scan or echocardiogram 
 optional blood collection for research (only if you answered "yes" to the optional blood 
collection question at the end of this consent) 
 
You will then have either a lumpectomy or mastectomy to remove the remaining tumor and nearby 
lymph nodes.  Surgery usually takes place 3-6 weeks after you finish study therapy.  (If you are a 
patient in Group 1B, 2B, or 3B, your breast cancer surgery may not take place until at least one 
month after your last dose of bevacizumab before surgery.) 
 
Note: If you have a mastectomy (removal of the entire breast), you may decide to have breast 
reconstruction (plastic surgery to restore the shape and appearance of your breast) at the same 
time as the mastectomy.  If you are randomized to Group 1B, 2B, or 3B and your breast 
reconstruction plan includes the use of a tissue expander, the expander may be placed at the time 
of the mastectomy and expanded slightly up until 2 weeks before you resume bevacizumab.  No 
further expansion will be performed until after you complete your bevacizumab therapy.  This is 
to avoid possible problems with wound healing related to bevacizumab.  About 6 weeks 
following your last dose of bevacizumab, expansion of the expander will resume and your breast 
reconstruction will continue.  Your doctor will explain all of your breast reconstruction options 
to you in more detail. 
After surgery for all groups: All patients will have a physical exam or contact from the study 
doctor at 3 to 5 weeks after surgery and at 9 and 12 months from the time you joined the study. 
02/15/08 
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During study therapy after surgery for Groups 1B, 2B, and 3B only: 
You will have a history and physical exam before you begin bevacizumab after your surgery.  
This is part of regular cancer care. 
The following tests will also be performed before you begin bevacizumab after surgery.  These 
tests are not part of regular cancer care and are being done for the purpose of this study. 
 blood tests to check blood counts and how well your kidneys and liver are working 
 urine test to check for protein 
 MUGA or echocardiogram (This will be repeated after surgery, before the start of 
bevacizumab, only if your test result before surgery was below normal. 
 If this repeat MUGA (or echocardiogram) result has improved to within normal range, 
bevacizumab will resume after surgery.  A MUGA or echocardiogram will be repeated 
after you have received 4 doses of bevacizumab following surgery. 
 If this result has not improved to within normal range, you will not receive bevacizumab 
after surgery. 
Before every other cycle of bevacizumab, you will have a history and physical exam which is 
part of regular cancer care. 
You will also have the following tests which are not part of regular cancer care and are being 
done for the purpose of this study. 
 urine test to check for protein before every other cycle of bevacizumab 
 MUGA or echocardiogram at 18 months from when you joined the study, if you have 
received at least one dose of bevacizumab. 
After completion of all study therapy and surgery for all groups: 
 a physical exam about every 6 months for years 2 through 5 and about every 12 months years 
6 through 10. 
 mammogram about every 12 months 
 
Other therapy for all patients: 
Hormonal therapy: If your breast cancer is affected by hormones (estrogen or progesterone), 
your doctor will also give you at least 5 years of hormonal therapy after you complete your study 
therapy and surgery. 
Radiation therapy: After you complete your study therapy, your doctor may advise you to have 
radiation therapy after your surgery. 
How long will I be on the study? 
You will be in this study for about 10 years.  Your study therapy will last about 6 months if you 
are randomized to Groups 1A, 2A, or 3A or about 13 months if you are randomized to Groups 
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1B, 2B, or 3B.  You will have your breast cancer surgery about 3-6 weeks after the last dose of 
study therapy given before surgery.  (If you are a patient in Group 1B, 2B, or 3B, your breast 
cancer surgery may not take place until at least one month after your last dose of bevacizumab 
before surgery.)  We would like to keep track of your health the entire 10 years you are on the 
study. 
Can I stop being in the study? 
Yes, you can decide to stop at any time.  Tell the study doctor if you are thinking about stopping 
or decide to stop.  He or she will tell you how to stop safely.   
It is important to tell the study doctor if you are thinking about stopping so any risks from the 
study drugs can be evaluated by your doctor.  Another reason to tell your doctor that you are 
thinking about stopping is to discuss what follow-up care and tests will be most helpful for you.   
You can choose to withdraw in one of two ways.  In the first, you can stop your study treatment, 
but still allow the study doctor to report your health status to the NSABP until 10 years after you 
join the study.  In the second, you can stop your study treatment and request that no new 
information be reported to the NSABP. 
Can anyone else stop me from being in the study? 
The study doctor may stop you from taking part in this study at any time if he or she believes it is 
in the best interest for your health, if you do not follow the study rules, or if the study is stopped 
by the NSABP. 
What side effects or risks can I expect from being in the study? 
You may have side effects while on this study.  Most of these are listed here, but there may be 
other side effects that we cannot predict.  Side effects will vary from person to person.  Everyone 
taking part in the study will be carefully watched for any side effects.  However, doctors do not 
know all the side effects that may happen.  Side effects may be mild or very serious.  Your health 
care team may give you medications to help lessen some of the side effects.  Many side effects 
go away soon after you stop taking your study drugs.  In some cases, side effects may be very 
serious, long-lasting, or may never go away.  There is also a risk of death.   
You should talk with your study doctor about any side effects that you may have while taking 
part in the study.   
During the study, we will do blood tests to see if the dose of the drugs you are receiving during 
your therapy should be changed or delayed.  The tests will also help monitor any side effects you 
may have.  You will not need to be hospitalized unless you have serious side effects. 
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Risks and side effects related to docetaxel (Taxotere) (Groups 1A and 1B): 
Likely effects 
These side effects occur in 25% or more of patients receiving docetaxel: 
 Hair loss 
 Nausea 
 Vomiting 
 Taste changes 
 Weakness/loss of strength 
 Fatigue 
 Hot flashes (in premenopausal women) 
 Irregular or permanent stoppage of 
menstrual cycles (periods) 
 Inability to become pregnant 
 Skin and nail changes, including 
discoloration and peeling 
 Lowered white blood cell count  
(may lead to infection) 
 Lowered red blood cell count  
(may lead to anemia, tiredness, shortness of 
breath) 
 Time away from work 
These side effects occur in 10-24% of patients receiving docetaxel: 
 Diarrhea 
 Constipation 
 Loss of appetite 
 Mouth sores 
 Infection 
 Pain in muscles, bones, or joints 
 Headache 
 Fluid retention (bloating or swelling) 
 Numbness, tingling, prickling, and burning 
in the hands and feet 
Less likely effects 
These side effects occur in 3-9% of patients receiving docetaxel: 
 Ulcers in the stomach or bowels 
 Darkening of the soles of the feet or palms 
of the hands 
 Peeling of the skin  
(including hands and feet) 
 Lowered number of platelets (which may 
lead to increased bruising or bleeding) 
 Eye irritation 
 Blurred vision 
 Dizziness 
 Changes (high or low) in blood pressure 
 Hardening of the walls of the veins used 
for chemotherapy 
 Reversible changes in blood test results 
that show possible liver injury 
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Rare but serious effects 
These side effects occur in less than 3% of patients receiving docetaxel: 
 Liver failure 
 Gastrointestinal problems (such as bleeding, 
blockage, or perforation [opening of a hole] 
in the stomach or bowel) 
 Lowered red blood cell count severe 
enough to require red blood cell transfusion 
 Skin and tissue damage in the area 
surrounding the catheter where the 
chemotherapy drugs are injected 
 Acute leukemia (cancer of the blood cells) 
 Blood clots that may be life-threatening 
 Heart damage 
 Lung damage 
 Severe infection 
 Inflammation of the pancreas causing 
abdominal pain 
 Allergic reaction including itching, hives, 
skin rash, flushing, shortness of breath, 
wheezing, chest tightness, fever, chills, 
severe shivering, sinus congestion, or 
swelling of face, especially eyelids 
 A group of symptoms which may include 
a blister-like rash that may be severe; 
fever; inflamed eyes; redness, swelling, 
and painful sores on lips and in mouth.  
(If this occurs, you may need to be 
hospitalized and have IV fluids and 
medicines.) 
Risks and side effects related to capecitabine (Xeloda) and docetaxel (Taxotere)  
(Groups 2A and 2B): 
Likely effects 
 
These side effects occur in 25% or more of patients receiving capecitabine and docetaxel: 
 
 Hair loss 
 Nausea 
 Vomiting 
 Diarrhea 
 Taste changes 
 Weakness/loss of strength 
 Fatigue 
 Hot flashes (in premenopausal women) 
 Irregular or permanent stoppage of 
menstrual cycles (periods) 
 Inability to become pregnant 
 Skin and nail changes, including 
discoloration and peeling 
 Redness and tingling of palms and soles 
of feet 
 Lowered white blood cell count  
(may lead to infection) 
 Lowered red blood cell count  
(may lead to anemia, tiredness, shortness 
of breath) 
 Time away from work 
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These side effects occur in 10-24% of patients receiving capecitabine and docetaxel: 
 
 Constipation 
 Loss of appetite 
 Sores/inflammation in mouth and/or throat 
 Abdominal pain 
 Numbness, tingling, prickling, and burning 
in the hands and feet 
 Pain in muscles, bones, or joints 
 Headache 
 Fluid retention (bloating or swelling) 
 Infections 
 Eye irritation (tearing) 
Less likely effects 
 
These side effects occur in 3-9% of patients receiving capecitabine and docetaxel: 
 
 Ulcers in the stomach or bowels 
 Darkening of the soles of the feet or palms 
of the hands 
 Peeling of the skin  
(including hands and feet) 
 Lowered number of platelets (which may 
lead to increased bruising or bleeding) 
 Rash or hives 
 Flu-like symptoms 
 Blurred vision 
 Dizziness 
 Changes (high or low) blood pressure 
 Hardening of the walls of the veins 
used for chemotherapy 
 Reversible changes in blood test results 
that show possible liver injury 
Rare but serious effects 
 
These side effects occur in less than 3% of patients receiving capecitabine and docetaxel: 
 
 Liver failure 
 Gastrointestinal problems (such as bleeding, 
blockage, or perforation [opening of a hole] 
in the stomach or bowel) 
 Lowered red blood cell count severe 
enough to require red blood cell transfusion 
 Skin and tissue damage in the area 
surrounding the catheter where the 
chemotherapy drugs are injected 
 Acute leukemia (cancer of the blood cells) 
 Blood clots that may be life-threatening 
 Heart damage 
 Lung damage 
 Severe infection 
 Inflammation of the pancreas causing 
abdominal pain 
 Allergic reaction including itching, hives, 
skin rash, flushing, shortness of breath, 
wheezing, chest tightness, fever, chills, 
severe shivering, sinus congestion, or 
swelling of face, especially eyelids 
 A group of symptoms that may be severe 
enough to require hospitalization and 
includes a blister-like rash; fever; inflamed 
eyes; redness, swelling, and painful sores on 
lips and in mouth (Stevens-Johnson 
Syndrome) 
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Risks and side effects related to gemcitabine (Gemzar) and docetaxel (Taxotere)  
(Groups 3A and 3B): 
 
Likely effects 
 
These side effects occur in 25% or more of patients receiving gemcitabine and docetaxel: 
 Hair loss 
 Nausea 
 Vomiting 
 Taste changes 
 Weakness/loss of strength 
 Fatigue 
 Irregular or permanent stoppage of 
menstrual cycle (periods) 
 Hot flashes (in premenopausal women) 
 Inability to become pregnant 
 Skin rash 
 Skin and nail changes, including 
discoloration and peeling 
 Lowered white blood cell count  
(may lead to infection) 
 Lowered red blood cell count (may lead 
to anemia, tiredness, shortness of breath) 
 Time away from work 
These side effects occur in 10-24% of patients receiving gemcitabine and docetaxel: 
 Constipation 
 Pain in muscles, bones, or joints 
 Fluid retention (bloating or swelling) 
 Loss of appetite 
 Weight loss/gain 
 Headache 
 Fever 
 Diarrhea 
 Mouth sores 
 Blood test results that show changes in 
liver function (usually mild and 
temporary) 
 Numbness, tingling, prickling, and 
burning in hands and feet 
 Flu-like symptoms (headache, fever, 
chills, cough, muscle pain, weak feeling, 
sleeplessness) 
 Infection 
Less likely 
These side effects occur in 3-9% of patients receiving gemcitabine and docetaxel: 
 Darkening of the soles of the feet or palms 
of the hands 
 Peeling of the skin (including hands and 
feet) 
 Lowered number of platelets (may lead to 
increased bruising or bleeding) 
 Ulcers in stomach or bowels 
 Changes in blood pressure  
(high or low) 
 Dizziness 
 Hardening of the walls of the veins 
used for chemotherapy 
 Blurred vision 
 Eye irritation 
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Rare but serious effects 
 
These side effects occur in less than 3% of patients receiving gemcitabine and docetaxel: 
 
 Lowered red blood cell count severe 
enough to require red blood cell 
transfusions 
 Lowered number of platelets severe 
enough to require a transfusion 
 Liver failure 
 Acute leukemia (cancer of the blood cells) 
 Heart damage 
 Blood clots that may be life-threatening 
 Skin and tissue damage in the area 
surrounding the catheter where the 
chemotherapy drugs are injected 
 Protein or blood in the urine that could 
mean kidney damage 
 A breakdown of red blood cells and kidney 
failure known as hemolytic uremic 
syndrome 
 Gastrointestinal problems (such as 
bleeding, blockage, or perforation [opening 
of a hole] in the stomach or bowel) 
 A group of symptoms including a 
blister-like rash that may be severe; 
fever; inflamed eyes; redness, swelling, 
and painful sores on lips and in mouth.   
 Severe infection 
 Severe lung problems (including 
shortness of breath, inflammation, and 
damage that could be permanent) 
 Inflammation of the pancreas causing 
abdominal pain 
 Decreased blood flow to the hands and 
feet that may cause tissue damage that 
may result in the loss of tissue. 
 Allergic reaction including itching, 
hives, skin rash, flushing, shortness of 
breath, wheezing, chest tightness, fever, 
chills, severe shivering, sinus 
congestion, or swelling of the face, 
especially eyelids 
Risks and side effects related to doxorubicin (Adriamycin) and cyclophosphamide  
(All Groups): 
Likely effects 
These side effects occur in 25% or more of patients receiving doxorubicin and cyclophosphamide: 
 Hair loss 
 Nausea 
 Vomiting 
 Low white blood cell count  
(may lead to infection) 
 Fatigue 
 Hot flashes (in premenopausal women) 
 Inability to become pregnant 
 Irregular or permanent stoppage of 
menstrual cycles (periods) 
 Low red blood cell count (may lead to 
anemia, tiredness, shortness of breath) 
 Temporary red discoloration of urine  
(not blood) 
 Time away from work 
These side effects occur in 10-24% of patients receiving doxorubicin and cyclophosphamide: 
 Mouth sores 
 Infection 
 Taste changes 
 Skin and nail changes, including 
discoloration and peeling 
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Less likely effects 
 
These side effects may occur in 3-9% of patients receiving doxorubicin and cyclophosphamide: 
 Diarrhea 
 Constipation 
 Loss of appetite 
 Darkening of the soles of the feet or 
palms of the hands 
 Low platelet count  
(may lead to bleeding) 
 Irregular heartbeat 
 Eye irritation 
 Hardening of the walls of the veins used for 
chemotherapy 
 Temporary changes in liver function blood 
tests  
 Headache 
 Pain in muscles, bones, or joints 
Rare but serious effects 
 
These side effects occur in less than 3% of patients receiving doxorubicin and cyclophosphamide: 
 Skin damage (due to leakage of drugs 
during treatment) 
 Acute leukemia (cancer of the blood cells) 
 Blood clots that may be life-threatening 
 Decreased ability of the heart to pump 
blood.  If severe, you could have shortness 
of breath and other symptoms of heart 
failure.  (If mild, you may not have any 
symptoms.) 
 Lung damage 
 Severe infection 
 Severe bladder irritation 
 Lowered red blood cell count severe enough 
to require red blood cell transfusion 
 Allergic reaction including itching, hives, 
rash, flushing, shortness of breath, wheezing, 
chest tightness, fever, chills, swelling of face, 
severe breathing problems 
Risks and side effects related to bevacizumab (Groups 1B, 2B, and 3B): 
Likely 
These side effects occur in 25% or more of patients receiving bevacizumab: 
 Nose bleeds 
 High blood pressure 
 Protein in the urine 
These side effects occur in 10-24% of patients receiving bevacizumab: 
 Shortness of breath 
 Watery eyes 
 Skin and nail changes (including dryness, 
itching, rash, discoloration, ulcers, or 
peeling) 
 Sores in mouth and/or throat 
 Taste changes 
 Mild to moderate bleeding in the 
gastrointestinal tract (serious and life-
threatening bleeding events were rare) 
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Less likely 
These side effects occur in 3-9% of patients receiving bevacizumab: 
 Gastrointestinal upset (which may include 
heartburn, gas, constipation, diarrhea, 
nausea, vomiting, or loss of appetite) 
 Abdominal pain 
 Abnormally slow bowel contraction 
 Headache 
 Pain in the chest area 
 Flu-like symptoms, such as fevers, chills, 
muscle aches, joint pain, and stiffness 
 Low red blood cell count (may lead to 
anemia, tiredness, shortness of breath) 
 Low platelet count that might interfere with 
clotting 
 Low white blood cell count (may make you 
more likely to get infections) 
 Allergy type symptoms like stuffy nose and 
sneezing 
 Tiredness/weakness 
 Weight loss 
 Confusion 
 Unsteady walk or loss of balance 
 Low sodium and/or potassium levels that 
might make you feel weak or dizzy 
 Cough 
 Frequent urination 
 Bleeding from the lining of the vagina 
 Voice changes (hoarseness) 
 Blood clots in a vein 
 Changes in blood tests that indicate 
possible kidney damage 
 Blood clots in your arteries which may cause stroke or heart attack or other problems.  
Several studies comparing chemotherapy with bevacizumab to chemotherapy alone have 
been done in patients with advanced cancers.  Side effects of each study were looked at 
together.  Problems due to blood clots in arteries were seen in about 2% of patients receiving 
chemotherapy alone and about 4.5% of patients receiving bevacizumab with chemotherapy.  
Patients who were 65 or older and those with past problems with blood clots in their arteries 
appeared to be at greatest risk.  Problems due to blood clots in the arteries were seen in about 
2.9% of patients 65 or older receiving chemotherapy alone and about 8.5% of patients 65 or 
older receiving bevacizumab with chemotherapy.  Patients who were both 65 or older and 
reported a history of past problems with blood clots in their arteries appeared to be at even 
higher risk, although further study is required before an estimate of the risk can be provided.  
These conditions can be life-threatening or fatal. 
Rare but serious 
These side effects occur in less than 3% of patients receiving bevacizumab: 
 Bleeding in various parts of the body leading to disability (including stroke) or death 
(especially in lung cancer patients). 
 Allergic reaction including: fever, chills, rash, hives, flushing, low blood pressure, swelling, 
and shortness of breath 
 Reaction to the infusion including: fever, chills, hives, rash, joint pain, shortness of breath, 
low or high blood pressure, muscle stiffening, and sweating may occur during the infusion 
and last about 24 hours 
 Kidney damage 
 Coughing up blood 
 Heart problems (including irregular heartbeats, changes in blood pressure, fluid collections 
surrounding the heart, chest pain, and possibly heart attack or heart failure) 
 Infection 
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 Lung problems 
 Reversible changes in liver function tests that may indicate liver damage 
 Bowel perforation, which is an abnormal opening in the bowel wall allowing bowel contents 
to spill into the abdomen.  This problem can lead to a life-threatening infection and usually 
requires surgery to repair. 
In a small study for patients with advanced lung cancer, 3 out of 17 patients who were 
receiving the combination of docetaxel, gemcitabine, and bevacizumab developed bowel 
perforations that resulted in death.  Because of these deaths, the study was stopped.  Bowel 
perforations have not been reported in patients receiving this same drug combination in 2 
other studies, so it is not clear whether the bowel perforations that occurred in the lung cancer 
patients were related to this combination of drugs or to other medical conditions. 
 In addition to bowel perforation, perforation of other organs or tissues. 
 Fistula (an abnormal tube-like connection between internal organs and skin or other tissues 
that are not normally connected) may occur, for example, between the gastrointestinal tract 
and the skin or between the gastrointestinal tract and the vagina.  A rare type of fistula, 
tracheo-esophageal fistula, which is an abnormal connection between the windpipe (trachea) 
and the esophagus (the tube that connects the mouth to the stomach) has been reported. 
 Risk related to wound healing: There have been reports of patients receiving bevacizumab 
who developed problems with healing of their surgical wounds.  This problem can lead to a 
life-threatening infection and could require surgery to repair.  While you are receiving 
bevacizumab, your doctor will temporarily stop your bevacizumab therapy prior to any 
surgery to avoid possible problems with wound healing.  If you need surgery for any reason 
while on bevacizumab, tell your doctor. 
There have also been a few reports of patients receiving bevacizumab in other trials who 
developed complications with wound healing due to skin problems such as leg ulcers.  These 
wound healing problems have been associated with infections that can take a long time to 
heal. 
 Reversible Posterior Leukoencephalopathy Syndrome (RPLS) is a medical condition related 
to leakiness of blood vessels in the brain.  RPLS can cause headaches, confusion, vision 
changes or blindness, and seizure, as well as changes in brain scans.  This condition is 
usually temporary but in very rare cases, it is potentially life-threatening and may have  
long-term effects on brain function. 
 Severe high blood pressure that can have an effect on brain function and can be  
life-threatening. 
 High blood pressure of the blood vessels in the lungs 
Risks related to fertility and pregnancy: 
The drugs in this study can affect an unborn baby.  Therefore, you should not become pregnant 
while on this study, or if you received bevacizumab, at least 3 months after your last dose.  You 
should ask about counseling and more information about preventing pregnancy.  If you feel you 
might be pregnant, even though you practiced birth control, notify the study doctor immediately.  
A pregnancy test may be performed.  Women should not breastfeed a baby while on this study, 
or if you received bevacizumab, at least 3 months after your last dose. 
Some of the drugs used in this study may make you unable to have children in the future. 
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For more information about risks and side effects, ask your study doctor. 
Are there benefits to taking part in this study? 
Taking part in this study may or may not make your health better.  While doctors hope that 
adding capecitabine, gemcitabine, or bevacizumab to standard chemotherapy will be more useful 
in treating your breast cancer compared to standard chemotherapy alone, there is no proof of this 
yet.  We do know that the information from this study will help doctors learn more about 
capecitabine and gemcitabine as treatments for breast cancer.  This information could help future 
cancer patients. 
What other choices do I have if I do not take part in this study? 
Your other choices may include: 
 Getting treatment or care for your cancer without being in this study 
 Taking part in another study 
 Having surgery first and then deciding about other treatments after surgery 
 Getting no treatment 
Please talk with your doctor about your choices before you decide if you will take part in this 
study. 
Will my medical information be kept private? 
We will do our best to make sure that the personal information in your medical record will be 
kept private.  However, we cannot guarantee total privacy.  Your personal information may be 
given out if required by law.  If information from this study is published or presented at scientific 
meetings, your name and other personal information will not be used.  Organizations that may 
look at and/or copy your medical records for research, for quality assurance, and data analysis 
include: 
 the National Surgical Adjuvant Breast and Bowel Project (NSABP); 
 Eli Lilly and Company (the company that makes gemcitabine); 
 Roche Laboratories, Inc. (the company that makes capecitabine); 
 Genentech, Inc. (the company that makes bevacizumab); 
 Precision Therapeutics, Inc. (a company involved with the tissue research); 
 your local Institutional Review Board (IRB), a group of people who review the research 
study to protect your rights; 
 the Cancer Trials Support Unit (CTSU), a research group sponsored by the National Cancer 
Institute (NCI) to provide greater access to cancer trials; and 
 government agencies, including the NCI or its authorized representatives, the FDA, the 
Office for Human Research Protections (OHRP), and Health Canada.  These agencies may 
review the research to see that it is being done safely and correctly. 
What are the costs of taking part in this study? 
You and/or your health plan/insurance company will need to pay for some or all of the costs of 
treating your cancer in this study except for those described below in this section.  Some health 
plans will not pay these costs for people taking part in studies.  Check with your health plan or 
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insurance company to find out what they will pay for.  Taking part in this study may or may not 
cost your insurance company more than the cost of getting regular cancer treatment. 
Tests, procedures, or drugs for which there is no charge in this study: 
 MUGA scans (or echocardiograms) performed during the first 2 years after you join the 
study. 
 All urine tests to check for protein.  These tests will be done before you join the study and at 
the scheduled time points described earlier in this consent form. 
 Costs of the blood test to check your blood counts just before beginning postoperative 
bevacizumab (Groups 1B, 2B, and 3B only). 
 Costs of blood tests to check how well your kidneys and liver are working just before 
beginning postoperative bevacizumab (Groups 1B, 2B, and 3B only). 
 Costs of the required additional breast tumor biopsy to collect tissue for research purposes and 
the required tissue collection at the time of surgery as described at the end of this consent. 
 Costs of the three optional blood collections done solely for the purpose of the B-40 study as 
described at the end of this consent. 
 Gemcitabine will be provided for this study at no cost to you by Eli Lilly and Company.  
Roche Laboratories, Inc. will provide the capecitabine for this study at no cost to you.  
Genentech, Inc. will provide the bevacizumab for this study at no cost to you.  However, you 
or your health plan will need to pay for costs of the supplies and personnel who give you the 
drugs.  Every effort will be made to ensure adequate supply of gemcitabine, capecitabine, and 
bevacizumab, free-of-charge, for all patients assigned to these drugs.  Gemcitabine, 
capecitabine, and bevacizumab may become commercially available for your stage of breast 
cancer during this study.  If this happens, there is a possibility that you and/or your health 
plan may have to pay for the drug needed to complete the study.  Your study doctor will 
discuss this with you if this occurs. 
(Canadian Sites must use the following information in place of the text above regarding costs 
of the investigational drugs in the study: 
Eli Lilly and Company will provide the gemcitabine free-of-charge for this study.  Roche 
Laboratories, Inc. will provide the capecitabine free-of-charge for this study.  Genentech, Inc. 
will provide the bevacizumab free-of-charge for this study.  Every effort will be made to ensure 
an adequate supply of gemcitabine, capecitabine, and bevacizumab, free-of-charge, for all 
patients assigned to these drugs.  If, however, gemcitabine, capecitabine, or bevacizumab 
becomes commercially available for your stage of breast cancer during this study, there is a 
remote possibility that alternative arrangements may have to be made to pay for these drugs.  
Your physician will discuss this with you should this situation arise.) 
Bevacizumab is the common name for the commercial drug Avastin.  The bevacizumab used in 
this trial, however, is for use in research studies only and may be made at locations different 
from those where Avastin is made.  Although some differences may exist, bevacizumab for 
research use and the commercial drug Avastin are manufactured by a similar process, meet 
similar standards for final product testing, and are expected to be very similar in safety and 
effectiveness. 
 APPENDIX G (continued) 
  NSABP B-40 
  Page 21 of 25 
Doxorubicin, cyclophosphamide, docetaxel, pegfilgrastim, and filgrastim are commercially 
available and will not be provided for free with this study.  You and/or your health 
plan/insurance company will be responsible for the costs of doxorubicin, cyclophosphamide, 
docetaxel, and, if given, pegfilgrastim and filgrastim. 
 
You will not be paid for taking part in this study.  Taking part in this study may result in added 
costs to you. 
For more information on clinical trials and insurance coverage, you can visit the National Cancer 
Institute’s Web site at http://cancer.gov/clinicaltrials/understanding/insurance-coverage.  You 
can print a copy of the “Clinical Trials and Insurance Coverage” information from this Web site.  
Another way to get the information is to call 1-800-4-CANCER (1-800-422-6237) and ask them 
to send you a free copy. 
What happens if I am injured because I took part in this study? 
It is important that you tell your study doctor, __________________________(insert doctor’s 
name), if you feel that you have been injured because of taking part in this study.  You can tell 
the doctor in person or call him or her at _________________________(insert doctor’s phone 
number). 
You will get medical treatment if you are injured as a result of taking part in this study.  You 
and/or your health plan will be charged for this treatment.  The study will not pay for medical 
treatment. 
(Canadian Sites must insert the following paragraph in place of the one above: 
In the case of research-related side effects or injury, medical care will be provided by your 
doctor or you will be referred for appropriate medical care.  Although no funds have been set 
aside to compensate you in the event of injury or illness related to the study treatment or 
procedures, you do not waive any of your legal rights for compensation by signing this form.) 
What are my rights if I take part in this study? 
Taking part in this study is your choice.  You may choose either to take part or not to take part in 
the study.  If you decide to take part in this study, you may leave the study at any time.  No 
matter what decision you make, there will be no penalty to you and you will not lose any of your 
regular benefits.  Leaving the study will not affect your medical care.  You can still get your 
medical care from our institution. 
The Data Monitoring Committee (DMC), an independent group of experts, will be reviewing the 
data from this research throughout the study.  We will tell you about new information or changes 
in the study that may affect your health or your willingness to continue in the study.  You may be 
asked to sign another consent form in response to new information. 
In the case of injury resulting from this study, you do not lose any of your legal rights to seek 
payment by signing this form. 
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Who can answer my questions about the study?  
You can talk to your study doctor about any questions or concerns you have about this study.  
Contact your study doctor ____________________________________(insert doctor’s name 
and phone number). 
For questions about your rights while taking part in this study, call the __________________ 
(insert the institution’s name) Institutional Review Board (IRB) (a group of people who review 
the research to protect your rights) at __________________ (insert IRB phone number). 
 
(If your institution is using the NCI Central IRB, insert the following sentence:  You may also 
call the Operations Office of the NCI Central Institutional Review Board [CIRB] at  
1-888-657-3711 [from the continental U.S. only].) 
Additional Tests for the NSABP B-40 Study 
What about the use of my blood and tissue for research? 
About using blood and tissue for research: One of the main reasons for doing this study is to test 
blood and tissue samples to find out if doctors in the future will be able to predict which patients 
will benefit from specific drugs or combinations of drugs.  Not all patients will respond the same 
way to chemotherapy.  We hope the samples collected in this study will help doctors be able to 
select the best drugs for patients in the future. 
 
The research that will be done with your blood and tissue samples is not designed to specifically 
help you.  It might help people who have cancer in the future.  Reports about research done with 
your samples will not be given to you or your doctor.  These reports will not be put in your 
health records.  The research using your blood and tissue samples will not affect your care.  
These blood and tissue samples will not be used for genetic research about diseases that are 
passed on in families. 
 
The blood and tissue samples will be stored at the NSABP and will be used for the purpose of 
the B-40 study.  Some of the research tests will be done soon, but others will be done in the 
future when the best methods are ready to test the samples.  The NSABP will study the samples 
and may give them to other researchers approved by the NSABP.  Any research using your 
samples must also be approved by an Institutional Review Board (IRB).  An IRB is a group of 
people who review the research to determine if it is being done correctly and safely.   
 
People who do research with your blood and tissue samples may need to know more about your 
health.  While the NSABP may give them reports about your health, they will not give them your 
name, address, phone number, or any other information that will let the researchers know who 
you are. 
 
Your blood and tissue samples will be used only for research and will not be sold.  The research 
done with your samples may help to develop new products in the future, but you will not be paid. 
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Collection of tissue samples is required if you take part in this study.  Collection of blood 
samples is optional.  All of the samples are important to answer questions about how breast 
cancer responds to different combinations of chemotherapy.  Each of these tissue and blood 
collections is described in more detail on the following pages. 
Required collection of tissue before chemotherapy begins:  These samples must be collected 
before you join the study. 
 
By signing this consent form, you are agreeing to have an additional biopsy before you join the 
study.  You will have small samples of your tumor removed and sent to the NSABP.  This is 
required for you to participate in this study because it is a very important part of this study.  You 
or your insurance company will not be charged for the tissue sample procedure. 
 
You are also agreeing to allow the NSABP to use the samples for this research study.  Since 
these samples are required for this study, if you do not agree, you cannot be in the study. 
 
Required collection of tissue following your surgery: Tissue removed during your surgery will 
be examined in the hospital’s standard manner.  If any tumor 1 cm (about half an inch) or larger 
is remaining, small samples of the tumor will then be sent to the NSABP.  Researchers will 
compare the results of these samples to the samples collected before you joined the study.  This 
will help answer the question of how tumors respond to chemotherapy. 
 
Optional collection of blood: The NSABP would also like to have samples of your blood 
collected at three times during the study.  If you agree, these collections will usually be taken  
at the same times that other blood tests that are done for your cancer treatment.  They will not 
usually require a separate collection.  The blood samples will be collected: 
 before you start your chemotherapy, 
 before your third cycle of chemotherapy that includes docetaxel, and 
 after you have finished all of your chemotherapy (before your surgery). 
 
Researchers will look at markers in the blood that may give them information about how the 
chemotherapy regimens work for different patients. 
If you decide now that your blood and tissue samples can be kept for this research, you can 
change your mind at any time.  Just contact your study doctor and let him or her know that you 
do not want the NSABP to use your blood and tissue samples and they will no longer be used for 
research.  Otherwise, they may be kept until they are used up, or until the NSABP decides to 
destroy them. 
Benefits and risks: The possible benefits of research from your blood and tissue include learning 
more about what causes cancer and how to treat it.   
There are risks to having a biopsy performed.  These include discomfort during the biopsy, 
bleeding at the site of the biopsy, and infection.  In addition, there is a risk of the release of 
information from your health records.  The NSABP will protect your records so that your name, 
address, and phone number will be kept private.  The chance that this information will be given 
to someone else is very small.   
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Costs of the sample collections:  You and/or your health plan/insurance company will need to 
pay for all of the costs of your first breast biopsy which was done to diagnose your cancer.  
Check with your health plan or insurance company to find out what they will pay for.  There will 
be no cost to you for the additional breast tumor biopsy required for this study, the required 
tissue collection at the time of surgery, or for the collection and storage of the optional blood 
collections in this study. 
Making your choices 
Please read each question below and think about your choice.  After reading each question, circle 
“yes” or “no.”  If you have questions, please talk to your doctor or health care team member. 
Participation in the optional blood collection: Remember, no matter what you decide about the 
optional collection and use of the blood samples in this research study, you may still take part in 
the B-40 study. 
1. I agree to have blood samples collected three times during this study.  These samples will be 
sent to the NSABP for the research purposes of the B-40 study. 
   YES   NO 
 
Contact in the future for other research: Remember, no matter what you decide, you may still 
take part in the B-40 study. 
2. My study doctor (or someone he or she chooses) may contact me in the future to ask me to 
take part in more research. 
   YES   NO 
Where can I get more information about cancer and its treatment? 
 You may call the National Cancer Institute’s (NCI’s) Cancer Information Service at: 
1-800-4-CANCER (1-800-422-6237) or TTY: 1-800-332-8615 
 You may also visit the NCI Web site at http://cancer.gov 
 For the NCI’s clinical trials information, go to: http://cancer.gov/clinicaltrials 
 For the NCI’s general information about cancer, go to: http://cancer.gov/cancerinfo 
 You may also visit the NSABP Web site at http://www.nsabp.pitt.edu 
You will receive a copy of this form.  If you want more information about this study, ask your 
study doctor. 
(NSABP institutions may insert or attach a list of materials that they can provide locally to 
patients regarding clinical trials, drug information, the institution/investigator, and/or the 
NSABP.) 
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Signatures 
I have been given a copy of all twenty-five pages of this form.  I have read the consent form or it 
has been read to me.  This information was explained to me and my questions were answered. 
 
I agree to take part in this research study, including the collection of the required tissue samples. 
 
 
______________________________  ______________________________ 
 Date Patient's signature 
 
______________________________  ______________________________ 
 Date Signature of person conducting the 
  informed consent discussion
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NSABP SAMPLE CONSENT FORM ADDENDUM #1 
Consent Form Addendum #1 
for  
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with 
Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete 
Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered 
Before AC with or without Bevacizumab and Correlative Science Studies Attempting to 
Identify Predictors of High Likelihood for pCR with Each of the Regimens 
[This information was not provided in the original consent form that patients signed.  It is 
provided here as new information to be given to patients after local approval of Amendment #2.] 
When you joined the NSABP B-40 study, the NSABP promised to tell you about new 
information that might affect your participation in the trial.  The NSABP would like to inform 
you of some changes to the study and some additional side effects related to the drugs used in 
this study. 
New information about side effects related to bevacizumab: 
You were told in the original consent form you signed that the drug bevacizumab may cause 
wound healing problems for patients who undergo surgery while receiving the drug.  There have 
also been a few reports of patients receiving bevacizumab in other trials who developed 
complications with wound healing due to skin problems such as leg ulcers.  These wound healing 
problems have been associated with infections that may take a long time to heal.  Therefore, if 
you develop any skin problems, such as open sores or wounds, tell your study doctor. 
You were also told in the original consent form you signed that some patients with cancer in the 
abdomen or pelvis have developed bowel perforations while receiving bevacizumab.  (A bowel 
perforation is an abnormal opening in the bowel wall allowing bowel contents to spill into the 
abdomen.)  The company that makes bevacizumab recently reported that patients receiving 
bevacizumab for cancers that are not in the abdomen and pelvis have also had bowel 
perforations. 
In a small study for patients with advanced lung cancer, 3 out of 17 patients who were receiving 
the combination of docetaxel, gemcitabine, and bevacizumab developed bowel perforations that 
resulted in death.  Because of these deaths, the study was stopped.  Bowel perforations have not 
been reported in patients receiving this same drug combination in 2 other studies, so it is not 
clear whether the bowel perforations that occurred in the lung cancer patients were related to this 
combination of drugs or to other medical conditions. 
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Since you signed the original consent form, there have also been reports of patients receiving 
bevacizumab who experienced the following side effects: 
 In addition to bowel perforation, perforation of other organs or tissues (rare, occurring in 
less than 3% of patients receiving bevacizumab). 
 Fistula (an abnormal tube-like connection between internal organs and skin or other tissues 
that are not normally connected) may occur, for example, between the gastrointestinal tract 
and the skin or between the gastrointestinal tract and the vagina.  A rare type of fistula, 
tracheo-esophageal fistula, which is an abnormal connection between the windpipe (trachea) 
and the esophagus (the tube that connects the mouth to the stomach) has been reported. 
(rare, occurring in less than 3% of patients receiving bevacizumab) 
 High blood pressure of the blood vessels in the lungs (rare, occurring in less than 3% of 
patients receiving bevacizumab). 
 Low red blood cell count (may lead to anemia, tiredness, shortness of breath); (less likely, 
occurring in 3-9% of patients receiving bevacizumab). 
 Allergy type symptoms like stuffy nose and sneezing (less likely, occurring in 3-9% of 
patients receiving bevacizumab). 
 Abnormally slow bowel contraction (less likely, occurring in 3-9% of patients receiving 
bevacizumab) 
 Bleeding from the lining of the vagina (less likely, occurring in 3-9% of patients receiving 
bevacizumab) 
Information about side effects related to gemcitabine and docetaxel: 
You were told in the original consent form you signed that the drug docetaxel alone and the 
combination of capecitabine and docetaxel may cause the side effects listed below.  However, 
these risks were accidentally not included in the list of risks related to the combination of 
gemcitabine and docetaxel.  Thus, the NSABP would like to inform you that the risks listed 
below are also related to the combination of gemcitabine and docetaxel. 
 Peeling of the skin (including hands and feet); (less likely, occurring in 3-9% of patients 
receiving gemcitabine and docetaxel) 
 Blurred vision (less likely, occurring in 3-9% of patients receiving gemcitabine and 
docetaxel) 
 Heart damage (rare, occurring in less than 3% of patients receiving gemcitabine and 
docetaxel) 
 Gastrointestinal problems (such as bleeding, blockage, or perforation which is an abnormal 
opening in the stomach or bowel); (rare, occurring in less than 3% of patients receiving 
gemcitabine and docetaxel) 
Information about required tissue collection following your surgery: 
You were told in the original consent form you signed that small samples of the tissue removed 
during your surgery would be sent to the NSABP.  They now will only receive samples if any 
tumor remaining at the time of your surgery is 1 cm (about half an inch) or larger.
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Information about breast reconstruction: 
You were told in the original consent form you signed that if you were randomized to Group 1B, 
2B, or 3B and you have a mastectomy, that you would not be able to have breast reconstruction 
until at least 3 months after your bevacizumab is completed.  If you have not yet had your 
mastectomy, you may have breast reconstruction at the same time as your mastectomy.  
However, if tissue expanders are used, the expander may only be expanded slightly and only up 
until 2 weeks before you resume bevacizumab.  No further expansion will be performed until 
after you complete your bevacizumab therapy. 
If you have questions about any of this information, you should discuss them with your study 
doctor (insert name and phone number here). 
Signatures 
I have been given this new information that was not in the original consent form. 
 
 
________________________  _______________________________________ 
 Date  Patient’s Signature 
 
 
 
     
 Date Signature of person conducting  
  the informed consent discussion
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NSABP SAMPLE CONSENT FORM ADDENDUM #2 
Consent Form Addendum #2 
for  
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with 
Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete 
Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered 
Before AC with or without Bevacizumab and Correlative Science Studies Attempting to 
Identify Predictors of High Likelihood for pCR with Each of the Regimens 
[This information was not provided in the original consent form that patients signed.  It is 
provided here as new information to be given to patients enrolled on the study and randomized 
to receive bevacizumab.] 
When you joined the NSABP B-40 study, the NSABP promised to tell you about new 
information that might affect your participation in the trial.  
You are being provided with this information because you were assigned to receive bevacizumab 
as part of the B-40 study.  The purpose of this addendum is to inform you about recent 
information reported about the use of bevacizumab. 
 A review of studies using bevacizumab in patients with a variety of advanced cancers 
showed that more patients died from the side effects of treatment when they received 
bevacizumab along with chemotherapy than when they received chemotherapy without 
bevacizumab.  However, when only the studies in patients with advanced breast cancer were 
considered, this difference was not present.  We do not know how this information applies to 
patients like you with early stage breast cancer. 
 The FDA did an updated review of the results from four studies using bevacizumab with 
chemotherapy in patients with advanced (metastatic) breast cancer.  On the basis of this 
review, the FDA has stated that the benefit of adding bevacizumab to chemotherapy in 
patients with advanced breast cancer did not outweigh the risks of adding bevacizumab in 
terms of patients living longer and slowing the spread of their cancer.  We do not know what 
the results mean for patients like you with early stage breast cancer.  
 Two large studies (NSABP C-08 and AVANT) in which patients with colon (bowel) cancer 
received either standard chemotherapy alone or standard chemotherapy with bevacizumab 
following surgery have recently been reported.  The purpose of these studies was to 
determine if bevacizumab could improve results achieved with standard chemotherapy.  The 
NSABP C-08 study data showed that adding bevacizumab to chemotherapy did not change 
the activity of the chemotherapy alone.  The AVANT study showed that bevacizumab did not 
improve the results of chemotherapy, and some of the colon cancer patients appeared to be 
doing better with chemotherapy alone.  Side effects reported for the NSABP C-08 and the 
AVANT studies were in line with what is known for chemotherapy and bevacizumab.  The 
B-40 study should provide important information about adding bevacizumab to 
chemotherapy for patients like you with early stage breast cancer. 
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The Data Monitoring Committee (an independent group of scientific experts) monitors the data 
from B-40 and data from other trials as it becomes available.  These scientific experts carefully 
evaluate the well-being of all patients participating in B-40 on a regular basis.  These scientific 
experts have recommended that the B-40 study continue with no change to either treatment or 
follow-up visits.   
If you have any questions or concerns, you can discuss them with your doctor at any time (insert 
name and phone number here).  I understand that I may withdraw from this study at any time, 
and it will not affect my future care. 
Signatures 
I have been given this new information that was not in the original consent form.  I have been 
given a copy of this consent form. 
 
______________________________  ______________________________ 
 Date     Patient's signature 
 
 
       ______________________________ 
       Print patient’s name 
 
 
______________________________  ______________________________ 
 Date     Signature of person conducting the 
      informed consent discussion 
 
 
      ______________________________ 
      Print name of person conducting the 
       informed consent discussion 
 
 
[Additional signature lines may be added as required by local policies or regulations.] 
